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Abstract
The phosphatidylinositol transfer proteins (PITPs) are a family  of lipid carrier proteins 
that bind and transfer phosphatidylinositol (PI) and phosphatidylcholine (PC) between 
membranes. PITPs are commonly involved in phosphoinositide-requiring processes, 
including phospholipase C and PI 3-kinase signalling, and membrane trafficking. In this 
study I focus on the uncharacterised soluble PITP, RdgBβ (PITPNC1). The lipid binding 
and transfer properties of RdgBβ have scarcely been characterised, and the function of 
RdgBβ is completely unknown. I uncover that RdgBβ interacts with 14-3-3 through its 
long, disordered C-terminus. RdgBβ is ubiquitinated and subject to rapid degradation in 
cells, and binding of 14-3-3 via two phosphorylated residues may serve to protect the 
protein from protease digestion. Whereas RdgBβ binds 14-3-3 under basal conditions, I 
deduce that, upon stimulation of cells with phorbol ester, RdgBβ binds the Angiotensin 
II receptor (AT1R)-associated protein, ATRAP, via its N-terminal PITP domain. Others 
have shown that ATRAP suppresses Angiotensin II signalling by uncoupling AT1R from 
G proteins and promoting AT1R internalisation. I find that the RdgBβ-ATRAP 
interaction is blocked by  inhibition of protein kinase C or protein synthesis, and may 
function to re-localise RdgBβ to the membrane in stimulated cells. Unexpectedly, I find 
that RdgBβ binds PI and phosphatic acid (PA), rather than PI and PC, and that binding 
of PA is increased by stimulation of cells with GTPγS. Mass spectrometry is used to 
analyse the molecular species of PI and PA bound by RdgBβ, and reveals that  whereas 
RdgBβ is non-selective in its binding of PI, it selects short-chain monounsaturated or 
saturated PA species, likely derived from the hydrolysis of PC by phospholipase D.
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siRNA! ! Small interfering ribonucleic acid
SLO ! ! Streptolysin O
SM! ! Sphingomyelin
SRC! ! Subrhabdomeric cisternae
StAR! ! Steroidogenic acute regulatory protein
START! StAR-related lipid transfer
TAE! ! Tris-acetate-EDTA
TBS(-T)! Tris-buffered saline(-tween)
TEMED! N,N,Nʼ,Nʼ-tetramethylethylenediamine
TGN! ! Trans-Golgi network
TLC ! ! Thin layer chromatography
Tm! ! Melting temperature
TNP-PE! N-trinitrophenyl-phosphatidylethanolamine
TX-100! Triton X-100
VAP! ! (Vesicle-associated membrane protein) VAMP-associated protein
VSMC !! Vascular smooth muscle cells
VSV! ! Vesicular stomatitis virus
WB! ! Western blot
WT! ! Wild-type
WW! ! Two conserved tryptophan proline-rich peptide binding motif
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CHAPTER 1: Introduction
1.1: Phosphoinositides and phosphatidylinositol transfer proteins
Phosphoinositides are essential components of all eukaryotic cell membranes. They  are 
derived from the phosphorylation of the phospholipid, phosphatidylinositol (PI), at 
positions 3, 4 and 5 of its inositol head group  (Figure 1.1), to produce seven 
phosphorylated derivatives. Whereas PI itself only constitutes ~5-7% of the total 
cellular lipids, the phosphoinositides make up just over a tenth of this amount, the major 
bulk of which is PI(4)P and PI(4,5)P2. Phosphoinositides form docking sites for protein 
effectors containing membrane-interaction domains, such as PH, FYVE and ENTH 
domains, and act as precursors of many  second messengers. Different species of 
phosphoinositide have unique distributions across intracellular membranes, brought 
about partly by  the differential distribution of the enzymes that generate or modify 
them. Phosphoinositides form part of a dynamic protein-lipid interaction network 
capable of regulating a multitude of cellular processes, including cell growth and 
survival through signal transduction and ion channel modulation, cytoskeletal dynamics 
and membrane trafficking. Almost all of the structural lipids or their precursors are 
synthesised at the endoplasmic reticulum (ER), and so the phosphoinositides must reach 
their destination either via vesicular transport, or with the help of lipid carrier proteins 
(Figure 1.2). One such lipid carrier, a key regulator in the distribution of 
phosphoinositides, is the phosphatidylinositol transfer protein (PITP).
There are five members of the PITP family in humans (Figure 1.3 A, p. 49): three 
members of the family are small, soluble proteins (PITPα, PITPβ and RdgBβ), whereas 
the RdgBα I and II proteins are large, multi-domain, membrane-associated proteins. The 
PITPs are characterised by the presence of a PITP domain at their N-terminus; the class 
I proteins, PITPα and PITPβ, bind a single molecule of either PI or phosphatidylcholine 
(PC) in the lipid-binding cavity of this domain (Figure 1.3 B). It  is becoming clear that 
the PI-binding and transfer activity of distinct PITPs is vital in almost  all processes 
involving phosphoinositides. I begin this section by discussing the role of 
phosphoinositides in particular biological processes with respect to PITPs, and then 
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progress to an analysis of PITP function at the molecular level. An emerging theme is 
one in which PITP presents PI to PI kinases for phosphorylation to PI(3)P or PI(4)P.
Figure 1.1: The structure of key phospholipids: PC, PI and PA.
Molecular structures of PC, PI and phosphatidic acid (PA). The head groups of PC and 
PI are indicated beyond the phosphate group, which is in red; the glycerol backbone is 
indicated in green, and the fatty  acid/acyl chains indicated, attached to positions sn1 
and sn2 of the glycerol moiety. The numbering of the inositol head group hydroxyl 
groups is indicated in blue.
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1.1.1: PITP and Signal Transduction: PLC and PI3K
Reconstitution of PLC activity in permeabilised cell assays
Multiple studies report roles for PITP family  members in phospholipase C (PLC) 
signalling (Figure 1.2). The first mammalian PITP was purified from bovine brain 
cytosol in 1974 (Helmkamp et al., 1974). When the second PITP was cloned in 1994 
(Tanaka and Hosaka, 1994), the first PITP was renamed PITPα, and the second, PITPβ. 
Prior to this, in 1993, a requirement of PITP for PLC activity was established (Thomas 
et al., 1993). When HL60 cells were permeabilised by  streptolysin O (SLO), which 
forms large lesions in the cell membrane by sequestering cholesterol, cytosolic proteins 
were observed to leak out (Stutchfield and Cockcroft, 1988). By 10-15 mins, the ability 
of GTPγS to activate PLCβ was greatly diminished (Thomas et al., 1991). There are six 
families of PLC enzymes in mammalian cells (PLCβ, γ, δ, ε ζ and η), each with 
differing characteristics and activation requirements. The predominant PLC isoforms in 
HL60 cells washed of cytosol were found to be PLC-β2 and PLC-β3 (Thomas et al., 
1993). GTPγS is a poorly-hydrolysable analogue of GTP and therefore is a potent 
activator of G proteins. PLCβ isoforms are activated by α or βγ subunits of the Gq/11 
family of heterotrimeric G proteins (specificity  varies according to the PLCβ isoform), 
and therefore are activated downstream of GTPγS. It  was identified that bovine brain 
cytosol was able to reconstitute PLC activity, and the reconstituting factor was purified, 
sequence determined and protein identified as PITP (Thomas et al., 1993). Since PITP 
transfers PI between membranes in vitro, it was proposed that PITP delivers PI from its 
site of synthesis at the ER to the plasma membrane for phosphorylation by lipid kinases 
to PI(4,5)P2, the substrate of PLC (Figure 1.2). In these experiments, PITP was essential 
for the sustained activity  of PLCβ, and reconstitution increased linearly as more PITP 
was added.
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(Facing page) Figure 1.2: Phosphoinositide metabolism and the PI cycle.
PI is synthesised at the ER and transported to distal intracellular membranes by  PITPs 
or vesicular transport. PI is phosphorylated by  lipid kinases such as PI 4-kinase (PI4K) 
and PI4P 5-kinase (PI4P-5-K). PI(4,5)P2 has many  functions, including hydrolysis by 
PLC in response to an appropriate stimulus, to produce the second messengers, 
diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 promotes Ca2+ release from 
intracellular stores, and this Ca2+, together with DAG, activates protein kinase C (PKC). 
DAG may then be phosphorylated to PA by  DAG kinase (DGK). PA is also produced by 
the hydrolysis of PC by  phospholipase D (PLD). PI re-synthesis occurs at the ER, the 
location of the two key  enzymes in this process, cytidine diphosphate (CDP)-DAG 
synthase and PI synthase (PIS), and therefore either DAG or, more likely, PA, must be 
transferred back to the ER (mechanism unknown). PAP, PA phosphatase.
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PLCγ is activated downstream of tyrosine kinases, such as the receptor tyrosine kinase, 
epidermal growth factor (EGF) receptor, as well as non-receptor tyrosine kinases of the 
Src family, such as Lyn and Syk. PLCγ is a soluble protein, recruited to activated 
membrane proteins by binding to phospho-tyrosine residues via its SH2 domains. Since 
PLCγ would be lost  during permeabilisation with SLO, examination of the effect of 
PITP on PLCγ activity in permeabilised cells required that purified PLCγ be titrated 
back into the system, along with appropriate stimulus and recombinant PITP. As for 
GTPγS-stimulated PLCβ in HL60 cells, PITP was found to be required for the 
reconstitution of receptor tyrosine kinase (EGF)-stimulated PLC activity in SLO-
permeabilised A431 human epidermoid carcinoma cells; the addition of EGF and PLCγ 
alone was insufficient for restoration of the activity (Kauffmann-Zeh et al., 1995). A 
similar requirement for PITP was demonstrated in antigen-stimulated RBL-2H3 cells, 
where PLCγ is activated downstream of the Fc receptor via non-receptor tyrosine 
kinases (Cunningham et al., 1996). The ability of PITP to reconstitute the activity of 
both PLCβ and PLCγ indicates a PLC isoform-independent function for PITP.
It was initially assumed that PLC would use up all available PIP2 in the local 
membrane, and that PITP would only be required to deliver more PI from the ER once 
the signalling membrane PIP2 (and therefore PI and PIP) stocks had been exhausted. 
One study estimated that there was sufficient PI in the plasma membrane of 
permeabilised HL60 cells to maintain PLC activity  linearly  for 20 min when the cells 
were stimulated with GTPγS (Cunningham et  al., 1995). It was therefore expected that 
PITP addition would not affect the initial rate of inositol lipid hydrolysis (at  <20 min), 
only the ability of PLC to sustain this rate. However, upon addition of PITP, the initial 
rate of inositol phosphate production was greatly increased in response to 10 µM 
GTPγS, in contrast to GTPγS alone (Cunningham et  al., 1995). Another experiment 
monitored the decline in inositol lipid hydrolysis upon permeabilisation. The decline 
was observed to exactly match the exit of PITP from the cytosol (Cunningham et al., 
1995).
The amount of inositol trisphosphate (IP3) made upon stimulation with GTPγS in the 
presence of PITP is far greater than the amount of PIP2 present in cells, indicating that 
the lipid kinases, PI 4-kinase (PI4K), which phosphorylates PI at the 4’-OH position of 
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the inositol head group  to PI(4)P, and PI4-P 5-kinase (PI4P-5-K), which phosphorylates 
PI(4)P at the 5’-OH position to PI(4,5)P2, must  be able to carry  out their functions on 
demand. In cells permeabilised in the presence of 100 µM Mg-ATP and 10 µCi [γ-32P]-
ATP, stimulation with GTPγS increased the amount of radioactivity associated with PIP2 
more rapidly than in control cells (Cunningham et al., 1995), indicating the ability  of 
GTPγS to stimulate lipid kinase activity. Here the activity  of both kinases, PI4K and 
PI4P-5-K, was found to be associated with membranes and therefore not lost upon 
permeabilisation. Upon permeabilisation of the HL60 cells to remove endogenous PITP 
prior to the addition of GTPγS, synthesis of PIP2 was impaired, and was only regained 
upon addition of exogenous PITP (Cunningham et al., 1995). The authors interpret  this 
observation as PITP exerting a direct  effect on lipid kinase activity, which they say 
explains why reconstitution of PLC signalling by  PITP is absolutely  dependent on the 
presence of Mg-ATP (Thomas et al., 1993). These interpretations gave rise to the ‘Lipid 
Presentation’ model of PITP function (Figure 1.5 B, p. 61) (Cunningham et al., 1995).
As in HL60 cells, the PI4K regulated by EGF in A431 cells is membrane-associated and 
therefore not lost from cells during permeabilisation. The activity  of endogenous PI4K 
was measured in response to differing combinations of exogenously-added EGF, PITP 
and PLCγ. Addition of each component individually  did not increase PI4K activity, only 
the addition of EGF and PITP together increased the amount of phosphorylated PI (PIP 
and PIP2) present (Kauffmann-Zeh et al., 1995). The further addition of PLCγ resulted 
in the phosphorylated PI species being barely detectable, likely due to the rapid 
hydrolysis of PIP2 by PLCγ. That PITP is required for PI4K activity  as well as PLC 
activity, and that the dose response of PLCγ activity  to PITP is similar to that of PI 
phosphorylation by  PI4K, again indicates that the target of PITPs might be PI4K rather 
than the PLC itself.
RdgBα and PLC signalling in the fly eye
The rdgB mutant was one of the first Drosophila retinal degeneration mutants identified 
(Hotta and Benzer, 1969), characterised by an abnormal termination of the light 
response in the photoreceptor cells of the eye and a profound loss of the 
electroretinogram (ERG) amplitude shortly after initial light exposure. The mutant fly 
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also suffered light-enhanced retinal degeneration. The gene responsible was identified 
in 1991 (Vihtelic et al., 1991), and subsequent analysis of the protein product revealed a 
160 kDa membrane-associated protein with 281 N-terminal residues that shared >40% 
identity  to the rat brain PITP (Vihtelic et al., 1993). The identification of this protein 
founded the class II PITPs, and gave them their alternate name, Retinal degeneration 
type B (RdgB) (Figure 1.3 A, p. 49).
The Drosophila photoreceptor cell is a giant polarized cell whose apical domain forms 
the specialised light-sensing organelle, known as the rhabdomere. This organelle 
consists of closely  packed photoreceptive microvilli. In the rdgB mutant, the 
rhabdomeric membrane undergoes vesiculation and is internalised and lost, resulting in 
a reduction in the size of the apical membrane. Drosophila melanogaster (Dm)-RdgBα 
localises to the region immediately beneath the light-sensing rhabdomeric membrane, 
the subrhabdomeric cisternae (SRC), as well as to the adjacent plasma membrane 
(Vihtelic et  al., 1993). This subrhabdomeric region is continuous with the main ER 
system of the photoreceptor, the site where PI synthesis occurs. Visual transduction is 
mediated by the PLC-catalysed hydrolysis of PI(4,5)P2, and mutation of enzymes 
involved in PI re-synthesis all lead to retinal degeneration. This includes mutation of 
CDP-DAG synthase in the cds mutant, which is unable to sustain a light-activated 
current (Wu et al., 1995). Furthermore, neither the rdgB nor the cds mutant was able to 
promote recovery from inactivation for the trp (transient receptor potential) mutant 
phenotype, in which Ca2+ entry into the rhabdomere is prevented (Hardie et al., 2001). It 
is understood that Ca2+ inhibits PIP2 hydrolysis, and so a functioning PI re-synthesis 
pathway is required to overcome this defect.
Detection of light by  the G protein-coupled receptor (GPCR) rhodopsin leads to the 
activation of PLCβ (NorpA) via the heterotrimeric G protein, Gq. Since the SRC lies in 
such close proximity to the rhabdomeric membrane above (~10 nm), it is hypothesised 
that Dm-RdgBα remains associated with the SRC via hydrophobic regions of its 
sequence, whilst its N-terminal PITP domain ‘swings’ between the SRC and the 
rhabdomere to deliver PI. The membrane-anchoring domains are not essential for its 
function, however, as expression of the Dm-RdgBα PITP domain in rdgB mutant flies 
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was sufficient to restore the wild-type electrophysiological light response and prevent 
degeneration (Milligan et al., 1997).
PITPα, PLC and PI3K in axonal outgrowth
PITPα plays a crucial role in the developing nervous system: mutation of the gene 
encoding PITPα, PITPNA, was found to be responsible for the vibrator mouse mutant 
phenotype (Hamilton et al., 1997). This mouse had a rapid action tremor and died 
within 30 days of birth (<P30). Neurones of the spinal cord, dorsal root ganglia, 
brainstem and cerebellum showed progressive degeneration, with dilated ER in the 
neurone cell bodies, dendrites and axons, eventually  progressing to severe intracellular 
vacuolation and some cell death (Weimar et al., 1982).
Wiring of the nervous system is informed by  extracellular guidance factors, which 
attract or repel the growth cones at the tips of developing neurones. Attracting 
substances include growth factors, such as netrin-1 and brain-derived neurotrophic 
factor (BDNF), and components of the extracellular matrix, such as laminin. Cortical 
explants derived from E15 vibrator mice (PITPαvb mice), shown to have a 5-fold 
reduction in PITPα protein expression, extended only a few short processes under basal 
conditions, similar to wild-type neurones. However, the number and length of processes 
was significantly reduced relative to wild-type explants when growth was stimulated by 
netrin-1 (Xie et al., 2005). Process elongation induced by BDNF was also attenuated. 
Similarly, hippocampal neurones grown on poly-L-lysine (a non-stimulatory 
substratum) and treated with PITPNA siRNA, which reduced PITPα protein levels by 
~70%, exhibited a morphology  comparable to control neurones. When the same 
neurones were grown on laminin, however, a significant reduction in axonal length was 
observed for the PITPα-knockdown cells (Cosker et al., 2008).
PITPα expression is enriched in the brain. An analysis of developing rat E18 
hippocampal neurones indicated the specific presence of PITPα protein in the axonal 
processes, including growth cones, and its expression was found to increase during the 
first few days of development (Cosker et al., 2008). This localisation contrasts with that 
reported in COS-7 cells, in which PITPα was observed throughout the cytoplasm and 
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nucleus (Larijani et al., 2003), indicating that PITPα could have specific binding 
partners in axons which determine its discrete localisation.
DCC (‘Deleted in colorectal cancer’), and the closely-related protein, neogenin, are cell 
surface receptors that bind netrin-1 through their extracellular domains. They  are 
transmembrane proteins, yet lack any discernible catalytic activity, and so it was 
initially unclear how the netrin-1 signal is transmitted into the cell interior. A yeast two-
hybrid screen identified PITPα as a binding partner of DCC and neogenin, the 
interaction confirmed in neuronal lysates, and further experiments deduced that PITPα 
interacts with the P3 domain of both proteins (Xie et al., 2005). The amount of PITPα 
associated with DCC (or neogenin) increased 4-fold after stimulation of the neurones 
with netrin-1. This event was also observed in HEK-293 cells expressing DCC (or 
neogenin) and PITPα.
Growth cone guidance in response to netrin-1 or BDNF requires co-activation of the 
PLCγ and PI 3-kinase (PI3K) signalling pathways (Ming et al., 1999). In cultured wild-
type cortical neurones, netrin-1 stimulated PIP2 hydrolysis in a time-dependent manner. 
However, this agonist failed to induce PIP2 hydrolysis in neurones from homozygous 
PITPαvb mice (Xie et al., 2005). Like PLC, the substrate of PI3K is PI(4,5)P2, but rather 
than hydrolysing it, PI3K phosphorylates PIP2 at the 3’-OH position of its inositol ring 
to form PI(3,4,5)P3. PI3K activity  is specifically  activated at the tip  of the elongating 
axon in response to laminin stimulation. On this substratum, the effect of PITPα over-
expression on axonal extension was found to be blocked by treatment with the PI 3-
kinase inhibitor, LY294002 (Cosker et al., 2008). Similarly, the application of BDNF to 
hippocampal neurones resulted in an increase in axonal length; this effect was also 
attenuated by inhibition of PI3K or PITPα knockdown (Cosker et al., 2008).
The activity of PI3K activates the serine/threonine protein kinase, protein kinase B 
(PKB) through the local provision of PI(3,4,5)P3. Stimulation of hippocampal neurones 
with BDNF for 1 hr or 15 hrs was observed to promote activation of PKB, as did 
expression of GFP-PITPα. The quantity of phosphorylated (active) PKB was ~50% 
higher in whole cell lysates derived from cells over-expressing PITPα compared with 
control-transfected cells, and immunocytochemistry revealed that the quantity of 
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phospho-PKB was significantly  increased in the axonal growth cones (Cosker et al., 
2008). Co-expression of GFP-PITPα with a dominant-negative PKB mutant, K179M, in 
hippocampal cells grown on laminin suppressed PITPα-promoted axonal elongation.
Together, these studies indicate a requirement for PITPα in axonal outgrowth under 
stimulation from netrin-1, BDNF or laminin. PITPα is specifically involved in signal 
transduction upstream of PIP2 hydrolysis by PLC, and upstream of PI3K activity. Since 
both enzymes use the substrate PI(4,5)P2, this implies that PITPα functions in the 
delivery of PI to the signalling membrane.
The ability  of PITPα to enhance the activity of a receptor-stimulated PI3K is consistent 
with a previous report, where PITPα was found to be required for the reconstitution of 
PI3Kγ activity stimulated by fMetLeuPhe (a Gi-coupled receptor) or GTPγS in SLO-
permeabilised human neutrophils washed of cytosol (Kular et al., 1997).
RdgBα in C. elegans sensory systems
The nematode worm, Caenorhabditis elegans, has a compact nervous system consisting 
of 302 neurones. It detects chemicals with a limited number of sensory  neurones, 
permitting the dissection of roles for each neurone by researchers. The sensory  system 
exhibits a plastic behaviour that  changes with experience (gustatory plasticity  or salt 
chemotaxis learning); for example, NaCl is usually an attractive taste, but animals 
previously  soaked in a buffer containing NaCl in the absence of food show an 
avoidance behaviour towards NaCl rather than attraction. The ASE taste sensory 
(gustatory) neurones, ASEL and ASER (bilaterally  symmetrical pair, left and right, 
respectively), play a major role in salt-attraction behaviour.
ASEL and ASER are differentially  activated by salt, and each expresses different sets of 
receptor-type guanylyl cyclases, which mediate these responses. The switch between 
attraction and avoidance to salt is reversible and involves the diacylglycerol (DAG)/
protein kinase C (PKC) (Figure 1.2) and PI3K/PKB signalling pathways, which act 
antagonistically to one another (Adachi et al., 2010). When DAG concentration/PKC 
activity is high, animals display an attractive behaviour to salt, whereas when DAG/
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PKC is low, animals demonstrate avoidance. Constitutive attraction behaviour towards 
salt is observed when the DAG/PKC pathway is activated by genetic or 
pharmacological manipulation. Conversely, the PI3K/PKB pathway promotes salt 
avoidance. PTEN is a phosphatase which removes the 3’-phosphate from PI(3,4,5)P3, 
terminating PI3K signalling. The daf-18 mutant, which has a mutation in the gene 
encoding a homologue of PTEN, avoids salt  under naïve conditions (Adachi et al., 
2010). (The wild-type animal is attracted to salt under the same conditions.)
A C. elegans mutant, pe1209, was identified which displayed a reduced attraction to salt 
compared to wild-type animals under naïve conditions, and remained attracted to salt 
even after NaCl conditioning (i.e. exposure to NaCl in the absence of food). These 
animals were found to have a mutated pitp-1 allele, the sole C. elegans orthologue of 
RdgBα (Iwata et al., 2011). Wild-type PITP-1 expression was observed in many 
neurones throughout the nervous system, including the sensory neurones, ASE and 
AWC. (AWC neurones are olfactory  neurones, which sense odorants.) The re-
expression of PITP-1 in the pitp-1 mutant C. elegans fully  restored the behavioral 
defects of attraction and plasticity in the whole animal, with only partial restoration 
when PITP-1 re-expression was confined to ASE neurones (Iwata et al., 2011).
In contrast to the fly  rdgB and mouse vibrator mutants, C. elegans pitp-1 mutants 
suffered no cell morphological defects. Further to the defective salt attraction 
phenotype, pitp-1 mutants were found to be deficient in chemotaxis towards odorants 
sensed by the AWC neurone, benzaldehyde and isoamyl alcohol, and displayed minor 
defects in chemotaxis to the AWA-sensed odorants, diacetyl and pyrazine. The pitp-1 
mutants also suffered from inadequate osmotic avoidance, which is mediated by the 
ASH sensory neurones (Iwata et al., 2011).
In the wild-type ASER neurone, PITP-1 was found mainly in a punctate pattern along 
the axon and cell body. It co-localised with the synaptic vesicle marker, mCherry-
RAB-3 in the axon, indicating that PITP-1 is localised to pre-synaptic sites (Iwata et al., 
2011). UNC-104 (KIF1A) is essential for the trafficking of synaptic vesicles from the 
cell body to these sites in C. elegans; in unc-104 mutants, PITP-1 localisation was 
decreased in the axon and increased in the dendrite and cell body (Iwata et al., 2011), 
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confirming a requirement for functional trafficking of synaptic vesicles for the proper 
localisation of PITP-1.
At pre-synaptic sites, PI(4,5)P2 could be required intact for the assembly  of proteins 
involved in synaptic vesicle release at the membrane. Alternatively, its hydrolysis by 
PLC may be required to produce DAG, which binds Unc13 in C. elegans, a protein 
required for synaptic vesicle priming. Loss-of-function mutations in dgk-1, encoding 
DAG kinase (DGK), exhibit enhanced neurotransmission at the neuromuscular junction 
due to the accumulation of DAG (Miller et al., 1999; Nurrish et al., 1999). A loss-of-
function mutation in dgk-1 was observed to almost completely  suppress the pitp-1 
defects in attraction to both salt and benzaldehyde, indicating the importance of DAG 
signalling in the promotion of attraction behaviour (Iwata et  al., 2011). This suggests 
that PI delivered by PITP-1 to synaptic membranes is required for attraction to salt and 
benzaldehyde through PI(4,5)P2 hydrolysis to DAG, rather than for the intact  PI(4,5)P2 
itself.
The dgk-1 mutation suppressed the reduced attraction phenotype, but was unable to 
suppress the defect in plasticity of salt chemotaxis. This indicates a requirement for 
other PI derivatives, PI(4,5)P2 itself, PI(3,4,5)P3 or IP3 in the plasticity of chemotaxis. 
The involvement of the PI3K pathway in the function of PITP-1 was not examined. As 
in the Drosophila rdgB mutant, expression of the N-terminal PITP domain alone was 
able to rescue both behavioral phenotypes of the pitp-1 mutant, which implies that the 
principle function of PITP-1 in neurotransmission and behavioral plasticity is performed 
by the PITP domain, and could therefore be its ability to bind and transfer PI.
In C. elegans, ASER does not require PITP-1 for the primary sensory response, since 
sensory  transduction is mediated by guanylyl cyclases and cGMP-gated channels and 
does not require phosphoinositides. However, PITP-1 is required for the transmission of 
this sensory information at synapses and modulation of behaviour in response to pre-
conditioning. The common feature is the involvement of RdgBα in processes involving 
phosphoinositides.
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1.1.2: PITP and membrane trafficking
PITP in exocytosis
In secretory cells, a priming event (requiring ATP) and a triggering event (requiring 
Ca2+) are necessary for the fusion of secretory  granules with the plasma membrane. Rat 
brain cytosol was found to reconstitute this process in cytosol-depleted PC12 cells, and 
three priming-specific factors were isolated by gel filtration, PEP1-3. PEP3 was 
identified as PITP (Hay  and Martin, 1993), whilst PEP1 was identified as a type 1 PIP 
5-kinase (Hay et al., 1995). ATP is not required for PITP activity, but does provide the 
phosphate source for phosphorylation of PIP by PIP-5-K. Therefore, it  was proposed 
that PITP delivered PI for phosphorylation by the type 1 PIP 5-kinase. PLC activity was 
found to be dispensable; here instead PI(4,5)P2 is required for localisation of specific 
proteins to the plasma membrane to facilitate exocytosis.
In HL60 cells there is a requirement for GTP in Ca2+-mediated secretion. Upon 
permeabilisation of these cells with SLO, the ability of GTPγS to stimulate Ca2+-
dependent secretion of the marker protein, hexosaminidase, was diminished as cytosolic 
proteins leaked from the cells. Whereas the small GTPase Rho remained associated with 
the HL60 cell membranes, ADP-ribosylation factor (ARF) GTPase was washed out with 
the other cytosolic proteins, and indeed ARF1 and ARF3 were purified as reconstitution 
factors for GTPγS-stimulated Ca2+-mediated secretion in HL60 cells (Fensome et al., 
1996). At low protein concentrations, the effect  of recombinant PITP and ARF on 
secretion was additive, and absolutely  required the presence of GTPγS. PA has been 
shown to activate type 1 PI4P-5-K (Jenkins et al., 1994), for the production of PI(4,5)P2 
from PI(4)P, and PA is a product of PC hydrolysis by phospholipase D (PLD) (Figure 
1.2). In turn, ARF activates PLD, and ARF has been shown to stimulate PIP2 production 
in a manner comparable to PITP (Fensome et al., 1996). It therefore seems that PITP 
and ARF work synergistically to make PI(4,5)P2, required for the assembly of 
exocytosis effector proteins. PITP delivers PI to the plasma membrane for 
phosphorylation by  PI4K to PI(4)P; meanwhile ARF GTPase activates PLD to produce 
PA, which stimulates a type 1 PI4P-5-K to phosphorylate PI(4)P to PI(4,5)P2.
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PITP in secretory vesicle formation
A cell-free post-trans-Golgi network (TGN) secretory vesicle formation assay has been 
described (Ohashi and Huttner, 1994). PC12 neuroendocrine cells were pulse-labelled 
with [35S]-sulphate and the TGN membranes harvested by homogenisation and ultra-
centrifugation steps. Cytosol (‘post-nuclear supernatant’), from similar rounds of 
homogenisation and centrifugation of unlabelled PC12 cells was assessed for its ability 
to stimulate post-TGN vesicle formation. The transfer of marker proteins, heparan 
sulphate proteoglycan for constitutive secretory vesicles and secretogranin II for 
secretory granules, into the unlabelled cytosol was monitored (Ohashi and Huttner, 
1994). The efficiency  of post-TGN secretory vesicle formation decreased if the cytosol 
was diluted, indicating the requirement of a cytosolic factor for the formation of 
secretory vesicles from the TGN (Ohashi et al., 1995). The factor was isolated by 
fractionation, and was in fact found to be two proteins, PITPα and PITPβ. PITPα or 
PITPβ purified from bovine brain, or recombinant mouse PITPα, were each able to 
stimulate post-TGN secretory vesicle formation from the [35S]-sulphate-labelled PC12 
TGN membranes (Ohashi et al., 1995).
RdgBαI in the scission of vesicles from the TGN
The mammalian RdgBα protein was cloned as a mouse homologue of Dm-RdgBα, able 
to rescue the mutant fly rdgB phenotype (Chang et al., 1997). The mouse protein 
rescued both the retinal degeneration and the abnormal ERG. A second mammalian 
homologue, which shares 56% identical residues with the first protein, was 
subsequently  identified (Lu et al., 1999a). The first protein was therefore renamed 
RdgBαI and the second, RdgBαII. Transgenic expression of RdgBαII also suppressed 
the retinal degeneration phenotype of the rdgB flies, yet unlike RdgBαI, was unable to 
restore the electrophysiological light responses. In mice, knock-out of the gene 
encoding RdgBαII, PITPNM2, appear normal, yet deletion of the gene encoding 
RdgBαI, PITPNM1, is embryonic lethal (Lu et al., 2001). This indicates that RdgBαI 
and RdgBαII perform distinct roles in mammalian cells, and that RdgBαI likely 
performs an essential, housekeeping role.
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The RdgBα proteins were also independently  identified as binding partners for the 
protein tyrosine kinase PYK2, and were consequently  designated ‘Nir’ proteins (PYK2 
N-terminal domain-interacting receptors) (Lev et al., 1999). There are three Nir 
proteins: Nir1 (PITPNM3) lacks the N-terminal PITP domain, Nir2 refers to RdgBαI 
(PITPNM1) and Nir3 is RdgBαII (PITPNM2).
RdgBα proteins are large, membrane-associated multi-domain proteins (Figure 1.3 A, p. 
49). RdgBαI and Dm-RdgBα, when first cloned, were proposed to be integral 
membrane proteins consisting of six transmembrane domains (Vihtelic et al., 1993; 
Aikawa et al., 1999). However, subsequent biochemical analyses revealed that RdgBα is 
actually a peripheral membrane protein, which associates with the membrane through 
protein-protein interactions (Lu et al., 1999a; Litvak et al., 2002). For mammalian 
RdgBαII, 1 M NaCl, high pH and strong denaturants, known to disrupt protein-protein 
interactions, solubilised the protein completely. RdgBαII was not detected in either the 
TX-100-soluble or insoluble membrane fractions (Lu et al., 1999a).
RdgBαI localises mainly to the Golgi apparatus, and also to the ER (Aikawa et al., 
1999; Litvak et al., 2002). In contrast, the PITP domain (1-257 aa) expressed alone 
displays cytosolic staining (Litvak et al., 2002), indicating that the Golgi and ER 
localisation is dependent on a sequence distinct from the PITP domain (Litvak et al., 
2002). Depletion of RdgBαI from HeLa cells using RNAi resulted in a disorganised 
Golgi, with swollen cisternae and a re-distribution of Golgi markers (Litvak et al., 
2005).
An assessment of trafficking to and from the Golgi indicated a defect in traffic through 
the secretory pathway, from the Golgi to the plasma membrane, in RdgBαI-knockdown 
cells. Control and knockdown cells were infected with a temperature-sensitive strain of 
vesicular stomatitis virus (tsO45 VSV), which contained a glycoprotein (VSV-G) which 
misfolds at  40°c and fails to exit the ER. Dropping the temperature to 32°c enabled 
rapid folding and transport of VSV-G from the ER. Cells were kept at 40°c for 3 hr to 
accumulate VSV-G in the ER, and then the temperature was shifted to 32°c for different 
time periods. In control cells, all of the VSV-G had reached the plasma membrane by 45 
min at 32°c; in RdgBαI-knockdown cells, this took ~2 hrs (Litvak et al., 2005). In 
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RdgBαI-knockdown cells, expressed YFP-VSV-G was observed in highly  dynamic, 
long, tubular structures emanating from the TGN, and only a few intermediate carriers 
detached from the Golgi. By contrast, in control cells, YFP-VSV-G appeared in various 
intermediate carriers that moved rapidly  from the TGN towards the plasma membrane, 
indicating a defect in fission of vesicles from the Golgi apparatus in RdgBαI-
knockdown cells (Litvak et al., 2005).
The level of DAG at the Golgi apparatus is critical for membrane tubule constriction 
and can therefore affect membrane transport from the TGN. Methods used to monitor 
DAG levels detected lower levels at the Golgi in RdgBαI-knockdown cells than in 
control cells (Litvak et al., 2005). A GFP-PKD reporter construct, which binds to DAG 
at the Golgi in control cells, re-localised to the cytosol in RdgBαI-knockdown cells. 
One pathway to DAG production is via sphingomyelin (SM) synthase, which uses 
ceramide and PC to produce SM and DAG. Inhibition of ceramide synthesis with 
fumonisin B1 (FB1), similarly  re-localised the GFP-PKD reporter construct. Lastly, an 
in vitro DGK assay was used, and indicated that the DAG level in the Golgi of RdgBαI-
knockdown cells and FB1-treated cells was reduced by ~40% and ~70% respectively, 
compared to control cells (Litvak et al., 2005). By contrast, RdgBαI-knockdown Golgi 
membranes had a much higher level of PC.
RdgBαI interacts with Vesicle-associated membrane protein (VAMP)-associated protein 
(VAP) through its FFAT motif (two phenylalanines (FF) in an acidic tract (Loewen et 
al., 2003)), at 349-355 aa (Amarilio et al., 2005) (Figure 1.3 A). Although VAP is an ER 
integral membrane protein, siRNA knockdown of VAP resulted in an unusual Golgi 
morphology, with long tubules emanating from a dispersed Golgi complex (Peretti et 
al., 2008). The ceramide transfer protein (CERT) and oxysterol binding protein (OSBP), 
also have VAP-binding FFAT motifs. In wild-type cells, binding of 25-
hydroxycholesterol to OSBP promotes its translocation to the Golgi to enhance 
ceramide transport  by CERT (Perry  and Ridgway, 2006). However, CERT, OSBP and 
RdgBαI all re-localised to the cytosol upon VAP-knockdown. This re-localisation could 
be rescued, however, with over-expression of full-length RdgBαI, and only  partially 
rescued with expression of the PITP domain only of RdgBαI, which lacks the FFAT 
motif (Peretti et al., 2008).
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Both CERT and OSBP have PH domains that bind PI(4)P. VAP knockdown slightly 
reduced localisation of the GFP-OSBP-PH fusion protein to the Golgi, indicating a 
decline in PI(4)P levels (Peretti et al., 2008). Since RdgBαI has an N-terminal PITP 
domain, this points to a model in which RdgBαI binds VAP proteins at the ER via its 
FFAT motif, and its PITP domain swings between the ER and the Golgi at ER-Golgi 
membrane contact sites, delivering PI for phosphorylation to PI(4)P at the Golgi 
apparatus. Of note, a different study reported an interaction between RdgBαI and type 
III PI4K via 378 aa at the RdgBαI N-terminus, and PI4K activity was identified in 
RdgBαI immunoprecipitates (Aikawa et al., 1999). Since CERT transfers ceramide from 
the Golgi to the ER, it seems likely that it is the re-localisation of this protein upon 
VAP- or RdgBαI-knockdown that causes the decline in DAG levels, since SM synthase 
does not receive the ceramide it requires to synthesise DAG and SM. This also explains 
the increase in PC levels observed upon RdgBαI-knockdown, as PC is not used by SM 
synthase. Over-expression of RdgBαI alone was sufficient to restore all of the defects in 
VAP-knockdown cells, including PI(4)P levels, DAG levels, targeting of OSBP and 
CERT to the Golgi apparatus and protein transport from the TGN.
PITPβ in retrograde trafficking from the Golgi to the ER
Ablation of the PITPNB gene is embryonic lethal, yet ablation of PITPNA, the gene 
encoding PITPα, is not (Alb et  al., 2002). This suggests that PITPβ carries out an 
essential house-keeping function in mammalian cells. There are two isoforms of PITPβ 
due to alternative splicing of the PITPNB mRNA. These isoforms differ in their C-
termini. PITPβ is ubiquitously expressed in mammalian cells (Morgan et al., 2006), and 
localises to the Golgi in a variety of cell types (de Vries et al., 1995; 1996; Morgan et 
al., 2006; Shadan et al., 2008). More specifically, PITPβ has been reported to localise to 
the TGN, since it co-localises with the TGN38 marker (Phillips et al., 2006).
Major phosphorylation of PITPβ has been reported at Ser262, a residue unique to the C-
terminus of PITPβ-sp1 (van Tiel et al., 2002). This group observed that phosphorylation 
of Ser262 was required for targeting of PITPβ to the Golgi in NIH3T3 fibroblast  cells: 
the PITPβ S262A mutant was distributed throughout the cell, as was the wild-type 
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protein when cells were treated with a PKC inhibitor. In another study, the exchange of 
the C-terminal 28 residues between PITPα and PITPβ switched PITPα localisation to 
the Golgi apparatus and re-distributed PITPβ throughout the cytoplasm (Phillips et al., 
2006). It should be noted, however, that two studies failed to demonstrate a requirement 
for Ser262 phosphorylation in targeting PITPβ to the Golgi (Morgan et al., 2006; 
Phillips et al., 2006). Furthermore, PITPβ-sp2, which lacks the Ser262 residue, was 
observed to localise to the Golgi in COS-7 cells (Morgan et al., 2006) and in PITPα-/- 
murine embryonic fibroblasts (Phillips et al., 2006).
Depletion of PITPβ from HeLa cells by RNAi results in a compacted Golgi apparatus 
and distorted nucleus. In addition, there is a specific defect in retrograde traffic from the 
Golgi to the ER mediated by coat protein complex I (COPI)-coated vesicles (Carvou et 
al., 2010). The KDEL receptor, important for retrieval of ER resident proteins from the 
Golgi in COPI-coated vesicles, is arrested at the Golgi in PITPβ-knockdown cells. 
ERGIC-53, which also cycles between the ER-Golgi intermediate compartment 
(ERGIC) and the ER in COPI-coated vesicles, is arrested at the ERGIC in PITPβ-
knockdown cells.
The researchers report a reduction in PI(4)P by ~40% in PITPβ-knockdown cells, and 
mutants defective in PI binding and exchange were unable to rescue the PITPβ-
knockdown phenotype (Carvou et al., 2010). An early event in the formation of 
trafficking vesicles is the activation of ARF1 by Golgi-specific brefeldin A-resistant 
guanine nucleotide exchange factor 1 (GBF1). PI(4)P, produced by phosphorylation of 
PI by the type IIIα PI4K, is required for the localisation of GBF1 to the cis-Golgi 
membrane (Dumaresq-Doiron et  al., 2010). GBF1 then interacts with the γ-COP subunit 
of COPI, recruiting the COPI complex to the membrane prior to activation of ARF1 
(Deng et al., 2009). Here, PITPβ appears to be presenting PI to PI4KIIIα to produce PI
(4)P, required for the assembly of COPI-coated vesicles at the Golgi apparatus.
PITP and the endosomal trafficking pathway
The membranes of early endosomes and the internal vesicles of multi-vesicular 
endosomes are enriched in PI(3)P (Gillooly et al., 2000). Protein effectors bind to PI(3)
43
P using their FYVE domains; thus, PI(3)P regulates transport of cargo through the 
endosomal pathway. PI(3)P is formed by type II or III PI3Ks, which phosphorylate PI 
itself at the 3’-OH position of its inositol head group.
In yeast, the type III PI3K, Vps34p, exists in a complex with Vps15p, a 160 kDa serine/
threonine protein kinase. Vps15p recruits Vps34p to the Golgi and enhances its PI3K 
activity. A human homologue of Vps15p was identified in anti-PI3K 
immunoprecipitates from Jurkat cells (Panaretou et al., 1997). Being a protein of 150 
kDa, it was named ‘p150’. p150 displayed serine/threonine protein kinase activity  and 
increased the PI3K activity of the Vps34p human homologue, hVps34p, two-fold.
Furthermore, the GST-p150-PI3K complex expressed in Sf9 insect cells associated with 
PITPβ (Panaretou et al., 1997). PITP was immunoprecipitated from Jurkat cells using a 
mouse monoclonal anti-PITP antibody, and the immunoprecipitate monitored for its 
kinase activity  towards PI. PITP did co-immunoprecipitate with lipid kinase activity, 
specifically with PI3K, not PI4K, activity. The addition of either recombinant PITPα or 
recombinant PITPβ, pre-incubated with 1 mM PI, to the GST-p150-PI3K complex, 
resulted in a dose-dependent  increase in PI3K activity  (Panaretou et al., 1997). This 
study indicates that  PITP contributes to type III PI3K activity, and implicates a role for 
PITP in endosomal trafficking by providing PI for the local enrichment of endosomal 
membranes in PI(3)P.
Dm-PITP and cytokinesis
In contrast to mammalian cells, Drosophila has only a single class I PITP, Dm-PITP. 
Dm-PITP is 61-62% identical to mammalian PITPβ, and 59% identical to mammalian 
PITPα. Flies homozygous for a mutant allele of the giotto (gio) gene, which encodes the 
Dm-PITP protein, have been observed to frequently have multi-nucleate spermatids, 
indicative of failures in meiotic cytokinesis (the separation of the two daughter cells at 
the end of cell division) (Giansanti et al., 2006). Specifically, mutant gio spermatocytes 
were found to be defective in actomyosin ring constriction and furrow ingression. A 
similar phenotype was observed in mitotic cells (late telophase neuroblast cells in brain 
preparations from mutant flies).
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Since PITPs have been implicated in the budding of secretory vesicles from the TGN, 
and in the process of vesicle fusion with the plasma membrane, the behaviour of Golgi-
derived vesicles during meiotic division was analysed (Giansanti et al., 2006). In wild-
type spermatocytes, the Golgi stacks were observed to disassemble into numerous 
vesicle-like structures at metaphase of meiosis I, when the chromosomes line up along 
the cell equator. During anaphase the spindles shorten, separating the sister chromatids 
and moving them towards the spindle poles. In telophase, the nuclear envelope reforms 
around each set  of chromatids; at this time the Golgi-derived vesicles were concentrated 
near the spindle poles and excluded from the central region of the cell, where the 
cleavage furrow was beginning to form. By contrast, 61.7% of gio mutant 
spermatocytes displayed an abnormal localisation of vesicle-like structures at the cell 
equator (Giansanti et  al., 2006). Cleavage furrow formation requires the addition of new 
membranes, and in the mutant spermatocytes the Golgi-derived vesicles failed to fuse 
with the invaginating furrow membrane, resulting in the observed abnormal 
accumulation of these structures at the centre of the cell.
A rabbit polyclonal antibody raised against the entire protein indicated that Dm-PITP 
accumulated both at the cell poles and at an elliptical structure that encircled the 
chromosomes, during metaphase and anaphase of meiosis I of wild-type primary 
spermatocytes. As the spermatocytes progressed to telophase, the protein was still 
visible at the spindle poles, but was now also enriched at the cleavage furrow (Giansanti 
et al., 2006).
Notably, a similar phenotype to the gio mutant was observed for the four wheel drive 
(fwd) mutant, in which the gene encoding a PI4K was found to be mutated. Like the gio 
mutant, the fwd mutants displayed a specific defect in actomyosin ring constriction 
(Giansanti et al., 2006). This indicates that Dm-PITP and a Dm-PI4K are required for 
the fusion of Golgi-derived vesicles with the invaginating cleavage furrow, an event 
required for actomyosin ring constriction during both meiotic and mitotic cytokinesis.
45
Dm-RdgBα and light-induced arrestin trafficking
Activation of a GPCR promotes its phosphorylation by  a G protein-coupled receptor 
kinase (GRK) and the subsequent recruitment of the adaptor protein, arrestin. Arrestin 
binding uncouples the receptor from the G protein by steric hindrance, and promotes 
internalisation of the receptor by  recruitment of endocytic vesicle coat proteins. The 
predominant arrestin in Drosophila photoreceptor cells is Arr2. The exposure of dark-
adapted flies to a pulse of bright blue light maximally coverts the GPCR, rhodopsin, to 
its light-activated form, metarhodopsin. Under these conditions in wild-type flies, Arr2 
translocates to the rhabdomere. If the flies are then exposed to the dark for 3 hrs, 
rhodopsin-Arr2 complexes undergo clathrin-dependent endocytosis and movement into 
the cell bodies.
In the rdgB and cds mutants, Arr2 was not localised to the rhabdomere following the 
pulse of bright blue light, but was instead diffusely distributed between the cell bodies 
and the rhabdomeres (Lee et al., 2003). Further analysis indicated that rather than being 
unable to traffic, Arr2 was much slower in reaching the rhabdomere in rdgB and cds 
mutants than in wild-type flies. The fact that these flies have absent or defective RdgBα 
and CDP-DAG synthase proteins, respectively, indicates an involvement of 
phosphoinositides in arrestin trafficking. Lipid binding experiments indicated that Arr2 
did indeed bind phosphoinositides, most likely PI(3,4,5)P3 (Lee et al., 2003).
Comparative modelling identified three lysine residues in a basic patch as a putative 
phosphoinositide-binding site. The mutation of these residues to glutamine produced the 
Arr23K/Q mutant, which was unable to bind phosphoinositides. Like the wild-type Arr2 
in rdgB and cds mutant flies, Arr23K/Q was present diffusely throughout the cell bodies 
and rhabdomeres due to a delay in the light-dependent movement to the rhabdomeres 
(Lee et  al., 2003). This defect occurred in both directions: in wild-type flies, 3 hrs in the 
dark re-distributed the rhodopsin-Arr2 complexes into the cell bodies; for the Arr23K/Q 
mutant, this re-distribution was observed after 72 hrs. These experiments implicate 
RdgBα in PI delivery in Drosophila photoreceptor cells for production of PI(3,4,5)P3, 
required for effective arrestin trafficking.
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1.1.3: Summary
PITPs are implicated in a wide variety of cell signalling and membrane trafficking 
processes, and in all of these, a connection to phosphoinositides and the delivery  of PI 
can be envisaged. In some, a clear connection can be observed between PITP and the 
stimulation of lipid kinase activity  (Cunningham et al., 1995; Kauffmann-Zeh et al., 
1995; Panaretou et al., 1997), rather than the passive transfer of PI down a PI chemical 
gradient (Currie et al., 1997).
 
1.2: The PITP domain
1.2.1: Structure of the PITP domain
The original purification of PITP from bovine brain yielded two subforms that could be 
distinguished on the basis of their isoelectric points (Helmkamp et al., 1974). 
Subsequent analysis revealed that these two subforms were the PI- and PC-loaded forms 
of PITP (van Paridon et al., 1987b), due to the different charges on the phospholipid 
molecules. X-ray crystal structures of the class I proteins bound to PI or PC have been 
reported (Yoder et al., 2001; Tilley  et al., 2004; Vordtriede et al., 2005), and it appears 
that the charge imparted on the PITP by  the phospholipid is the only difference between 
the PI- and PC-bound structures.
The PITP domain is composed of eight β-strands that form a large, concave sheet, 
together with three long, and four shorter, α-helices (Figure 1.3 B). A single molecule of 
lipid cargo occupies a space between the β-sheet and two of the long α-helices, αA and 
αF, in the lipid-binding cavity. A polar region of the cavity accommodates the 
phospholipid head group, whilst two hydrophobic channels house the sn1 and sn2 fatty 
acyl chains. The C-terminal region, 233-271 aa, consists of the αG helix and an 11 aa 
extension, the latter of which limits access to the lipid-binding cavity (Yoder et al., 
2001) (also referred to as the cavity ‘lid’). With the lid closed PITP is transport-ready; 
the phospholipid is completely enclosed within the protein, shielded from the aqueous 
cytosol.
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(Facing page) Figure 1.3: The human PITP family and PITP domain structure
(A) Domain architecture of the human PITPs. Each family  member has the defining 
PITP domain at its N-terminus, yet differs in its C-terminal residues. Sequence length in 
amino acids is indicated at the top-right of each protein. Gene names are given on the 
right. (B) X-ray  crystal structure of PITPα with PI bound (PDB: 1uw5) (ʻclosedʼ 
structure). Regulatory  loop, blue (with Ser166 residue indicated); lipid exchange loop, 
green; αG helix and 11 aa C-terminal extension, red. WW203/204 are indicated, WW. 
(C) and (D) The apo-structure, devoid of lipid (PDB: 1kcm), shown as cartoon or 
surface, respectively. Numbering of secondary  structural elements is indicated in (C), 
α-helices αA-αG, β-strands β1-β8. In (D), the upper image has been captured looking 
ʻdownʼ the cavity, through the smaller opening, and the lower image has been captured 
looking ʻupʼ, through the larger opening. (Directions ʻupʼ and ʻdownʼ are relative to the 
structures shown in (B) and (C).) Inset images indicate the exposure of the Ser166 and 
Thr59 residues in the apo-structure. Exposure of Ser166 on the surface of the closed 
structure is shown for comparison. Thr59 is not exposed on the surface of the closed 
structure.
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Yoder and colleagues also defined the ‘regulatory loop’, an extensive loop region 
between strands β6 and β8 (119-190 aa) (Yoder et al., 2001) (Figure 1.3 B). They 
speculated that this region would be required for the association of PITP with a wide 
variety of lipid- and protein-modifying enzymes (Figure 1.5 C).
1.2.2: Membrane Interaction
An open or ‘apo’ structure of PITPα has also been reported, devoid of lipid (Schouten et 
al., 2002) (Figure 1.3 C & D). Earlier studies using proteases to assess the conformation 
of PITP showed that PITPα was highly  resistant to trypsin digestion alone, yet became 
susceptible to cleavage of its C-terminus when incubated with vesicles (Tremblay et al., 
1996). This indicates that  PITP adopts a tightly closed conformation when transporting 
lipid between membranes, and becomes more flexible, releasing its C-terminus, upon 
interaction with vesicles (Figure 1.5 A, p. 61). The apo-structure is therefore believed to 
only occur upon interaction with the membrane, when PITP is in the process of lipid 
exchange.
The apo-conformation of PITPα has been compared with its closed conformation to 
reveal that upon interaction with membranes, the lipid exchange loop swings outwards 
by ~90°. The C-terminal αG has moved outwards from the main structure by  20°, which 
is accompanied by  a partial unwinding of residues 254-257 and a disordering of the C-
terminal tail (258-271 aa) (Schouten et al., 2002). The lipid-binding core is largely 
unaffected: the peripheral β-strands, β2, β3 and β4, twist and flatten out. These 
conformational changes create a channel through the PITP protein (Figure 1.3 D), from 
a large opening between the β-sheet and the long helices, αA and αF. The channel 
terminates in a small hydrophobic opening between the N-terminus of helix αG and 
strands β2 and β3, near the phospholipid head group in the corresponding closed 
structure. It has been hypothesised that the small opening allows water molecules 
through, destabilising the hydrogen bond network holding the lipid head group in place, 
promoting deposition of the lipid cargo in the membrane (Wirtz et al., 2006). The large 
opening exposes a hydrophobic surface of ~1300 Å2 (Schouten et al., 2002). Residues 
70-78 aa of one lipid exchange loop insert  into and shield the exposed hydrophobic 
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surface of another PITP, and consequently  the apo-PITP structures form tight dimers in 
the crystal.
The finding that  the lipid-binding cavity is closed by a lid comprising the C-terminal 11 
aa (Yoder et  al., 2001), and that upon membrane interaction the C-terminal αG swings 
out from the main structure, exposing the cavity  so that PITP molecules dimerise to 
mask the hydrophobic surfaces (Schouten et al., 2002), supports earlier biochemical 
studies of the PITP C-terminus. Deletion of 5 or 10 amino acids (PITPα-Δ5 or -Δ10, 
respectively) reduced both the PI and PC transfer activity  of PITPα, although near-wild-
type PC transfer was retained at  high protein concentrations (Hara et al., 1997). Neither 
the PITPα-Δ20 mutant nor the PITPα protein digested with the protease subtilisin, 
which removed 24 aa from the C-terminus, exhibited PI transfer activity (Hara et  al., 
1997; Prosser et al., 1997). The PITPα protein treated with subtilisin was observed to 
dimerise when analysed by gel filtration (Prosser et al., 1997). Other studies showed 
that removal of 5, 12 or 18 amino acids from the C-terminus of PITPα resulted in an 
increased affinity for vesicles and membranes (Tremblay et al., 1996; 1998; Larijani et 
al., 2003). It is therefore clear that the C-terminal deletion mutants exhibit a reduced 
lipid transfer activity  because they have an increased affinity for the membrane. Some 
affinity of PITP for membranes is required, but if the affinity is too great, transfer 
activity will be greatly reduced or eliminated. This increased affinity comes from 
exposure of hydrophobic surfaces in the lipid-binding cavity.
Tryptophan 203 and 204
In the apo-structure of PITPα, Schouten and colleagues noted that the displacement of 
the C-terminal region and lipid exchange loop  would allow the aromatic residues, Y103, 
W203 and W204, and positively-charged residues, K105, K202 and K209, to contact 
the membrane (Schouten et al., 2002).
In the class I PITPs, the two tryptophan residues, W203 and W204, are located at the tip 
of the loop  between strand β8 and helix αF, facing the membrane interface (Figure 1.3 
B). Mutation of these two residues to alanine led to a loss of lipid transfer and of 
membrane association (Tilley et al., 2004; Shadan et al., 2008), indicating that these two 
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residues insert into the membrane. Insertion of the tryptophan residues into the 
membrane could indirectly  perturb the αG helix, via αF, causing a shifting of the C-
terminal lid residues. The use of tryptophan residues in membrane interactions is a 
common feature of membrane-active proteins (Yau et al., 1998).
Y103 lies next to the opening of the lipid-binding cavity, on the loop between strands β5 
and β6. Mutation of this site to an alanine residue produced a modest reduction in PI 
and PC transfer, yet no effect on lipid binding (Tilley et al., 2004). Therefore, the Y103 
residue may interact with the membrane but its presence is not required for the 
interaction to take place, unlike WW203/204.
Dynamics of membrane interaction
The class I proteins, PITPα and PITPβ, have a cysteine residue (C95) in their lipid head 
group-binding pocket (Figure 1.4), which can be modified by the addition of a thiol 
modifying agent, such as N-ethylmaleimide (NEM). Since PITP only  assumes its open 
conformation during interaction with a membrane, NEM is only able to modify C95 
when PITP is in the process of lipid exchange. Modification by NEM is irreversible, and 
PITPs modified in this way either remain membrane-associated, or eventually fall off 
and dimerise to shield their internal hydrophobic surfaces. Lipid transfer activity is 
inhibited. NEM  has therefore been used as a tool alongside gel filtration and 
immunofluorescence microscopy to investigate the dynamics of membrane interaction 
of PITPα and PITPβ (Shadan et al., 2008). Within 2 min of NEM treatment, the 
majority  of PITPβ shifted to a higher-molecular weight fraction, not associated with 
lipid transfer activity, indicating that almost the entire pool of PITPβ had sampled a 
membrane within 2 min. By contrast, a substantial portion of PITPα remained in the 
lower-molecular weight fractions at 10 min, suggesting that it had not undergone the 
same conformational change and was therefore not modified by  NEM (Shadan et al., 
2008). These experiments were carried out in PC12 cells under basal conditions, 
perhaps indicating the presence of a distinct pool of PITPα that may require some sort 
of ‘activation signal’ before it undergoes lipid exchange.
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An earlier study employed fluorescence lifetime imaging microscopy (FLIM) to 
examine fluorescence resonance energy transfer (FRET) between the EGFP-PITP donor 
fluorophore and BOPIDY-labelled phospholipid (PI or PC) acceptor fluorophore in 
COS-7 cells (Larijani et al., 2003). A reduction in EGFP lifetime indicated an 
interaction between PITP and phospholipid, as the energy was transferred to the 
acceptor fluorophore. In unstimulated cells, PITPα interacted with PI and PC similarly, 
at the plasma membrane and in the cytoplasm (includes ER). Upon EGF stimulation, the 
interaction between PITPα and either phospholipid was increased, most notably an 
increase of 30% was observed between PITPα and PI at  the plasma membrane. For 
PITPβ, EGFP lifetime decreased at the Golgi apparatus and plasma membrane in 
unstimulated cells, and was further reduced in the Golgi, plasma membrane and the 
cytoplasm upon EGF stimulation. At the Golgi, the reduction in lifetime corresponded 
to a 40% increase in FRET efficiency. Using the related technique, fluorescence 
recovery after photobleaching (FRAP), cells were selectively bleached at the cytoplasm, 
plasma membrane or Golgi apparatus, as appropriate, and fluorescence recovery 
monitored as a measurement of PITP mobility at that membrane. Following stimulation 
with EGF, the mobile fraction of PITPα at the plasma membrane decreased from 91% to 
68%, indicating a reduction in PITPα mobility at the plasma membrane in response to 
EGF stimulation. By  contrast, the mobility of PITPβ was unchanged upon EGF 
stimulation (Larijani et al., 2003).
1.2.3: PI- and PC-binding
PITPα and PITPβ can bind either PI or PC. PITPα has a 16-fold higher affinity for 
binding to PI than it does to PC (van Paridon et al., 1987a). PC accounts for ~40% 
cellular phospholipids whereas PI only accounts for 2-12% in most mammalian cells. 
Thus, the higher affinity of PI binding compensates for its lower concentration. In 
general, when PITPα is purified from tissue, it is loaded with PI and PC in 
approximately equal quantities (Helmkamp et al., 1974; Thomas et al., 1993), and the 
same is true for PITPβ (Morgan et  al., 2006). Comparison of the structures of the PI- 
and PC-bound PITPα reveals that both lipids occupy  the same space in the lipid-binding 
cavity, and in fact the only difference is that the inositol head group makes more 
53
hydrogen bonds with specific amino acid residues than does the choline moiety (Yoder 
et al., 2001; Tilley et al., 2004; Vordtriede et al., 2005) (Figure 1.4).
Phospholipid phosphate and acyl chain-binding
Residues that make contact with both PI and PC are those making contact with the 
phosphate group and the acyl chains. T97 and K195 form direct hydrogen bonds with 
oxygen atoms of the phosphate, and E218 and Y63 make direct hydrogen bond contact 
with the acyl chains (Figure 1.4).
PI inositol head group-binding
Five residues in the lipid-binding cavity make hydrogen bond contact with the inositol 
head group: Q22, T59, E86, K61 and N90 (Figure 1.4, left panel). Mutation of either 
K61 or N90 resulted in a complete loss of PI binding and transfer, but left  PC binding 
and transfer unaffected (Tilley et al., 2004; Carvou et  al., 2010). For E86, mutation to 
alanine reduced PI binding and transfer, with no effect on PC binding and transfer. 
However, the conservative mutation E86Q, was found to reduce both PI and PC binding 
(Tilley et al., 2004).
Threonine 59
Along with the side chain of K61, T59 forms a hydrogen bond with the 4’-OH on the 
inositol head group  of PI (Figure 1.4, left panel). In the PC-bound structure of PITPα, 
T59 makes van der Waals contact with one of the methyl groups of PC (Yoder et al., 
2001). Mutation of T59 to E, D, N or Q, abolishes PI transfer without a significant 
effect on PC transfer (Alb et al., 1995), whereas mutation of T59 to S, V or A retains 
some PI transfer activity (Tilley et al., 2004). Conceivably, the conservative substitution 
T59S might still be able to form a hydrogen bond with the inositol head group of PI. 
Valine and alanine are small, uncharged amino acids which might not interfere with 
inositol binding, but wouldn’t encourage it  either. The carboxylic acid functional groups 
of glutamic acid and aspartic acid could disrupt the local charge distribution and 
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disfavour inositol binding; likewise asparagine and glutamine, though uncharged, have 
a carboxyl group which could cause steric, as well as chemical, hindrance.
T59 belongs to a consensus site for phosphorylation by  PKC (Alb et al., 1995; Morgan 
et al., 2004), and prior to resolution of the first PITP crystal structure it  was widely 
thought that this residue was phosphorylated in vivo. My own inspection of the apo-
structure indicates that T59 is exposed in the channel through the protein (Figure 1.3 D), 
yet is completely buried in the closed structure. Mutation of T59, including to the 
phospho-mimetic, T59E, does not affect PC transfer, implying that the closed-open-
closed transition and PC-PC lipid exchange at membranes takes place. However, the 
RdgBαI T59E mutant associated with lipid droplets in HeLa cells (Litvak et  al., 2002). 
In RdgBαI, perhaps PC-PC lipid exchange activity  is not preserved. Instead RdgBαI 
becomes immobilised on lipid droplets, which are composed of neutral lipids. T59A, 
which retained some PI transfer activity for PITPα (Tilley  et al., 2004), was not 
observed on lipid droplets (Litvak et al., 2002).
PC choline head group-binding
Residues specific for PC binding and transfer are more difficult to predict from the 
crystal structures. C95 lies in the lipid-binding cavity and forms a hydrogen bond with 
PC indirectly via a water molecule (Figure 1.4, inset). Mutation of this residue to either 
threonine or alanine eliminates PC transfer, leaving PI transfer unaffected (Carvou et al., 
2010). F225 has also been shown to be important for PC transfer: when the large 
aromatic residue, phenylalanine, is present in this position, PC transfer activity is high. 
However, when it is replaced with a leucine residue, as in rodent PITPβ, PC transfer is 
lower (Vordtriede et al., 2005). (In rat PITPα and human PITPβ this residue is a 
phenylalanine.) The authors of this study found that by mutating this residue alone, they 
could switch the PC transfer specificity of rat PITPα and PITPβ, so that PITPα F225L ≈ 
PITPβ and PITPβ L225F ≈ PITPα.
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Figure 1.4: PI- and PC-binding residues in the PITPα lipid-binding cavity
Residues making hydrogen bond contact with the PI (left panel, PDB: 1uw5) and PC 
(right panel, PDB: 1t27) ligands in PITPα. Residues making hydrogen bond contacts 
with the lipid acyl chains, brown; the phospholipid phosphate group, red; inositol head 
group, blue. C95 and F225, lime green. Inset: PC head group and phosphate rotated to 
enable a clearer view of the C95 and F225 residues, and hydrogen bond network.
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The finding that the inositol head group  of PI is secured by direct hydrogen bonds with 
five residues in the PITP lipid-binding cavity, whereas choline makes none, gives a 
molecular grounding for the earlier report that PITP has a 16-fold-higher affinity for PI 
than for PC (van Paridon et al., 1987a).
Acyl chain selectivity
In the X-ray crystal structures of the PITP domain, clear channels for each of the sn1 
and sn2 fatty acid tails of the bound phospholipid molecule can be observed. The PI and 
PC molecular species bound by PITPα have been examined using tandem electrospray 
ionisation mass spectrometry (ESI-MS/MS), and compared with the profile of PI and 
PC molecular species in HL60 cells (Hunt et al., 2004). PITPα showed a selectivity 
towards two mono-unsaturated PC species in particular, 16:0/16:1 and 16:1/18:1 (the 
first number is the number of carbon atoms in the acyl chain, and the second is the 
number of double bonds). The preference for cellular PC species was observed in the 
order, 16:1>16:0>18:1>18:0>20:4. The PI species bound by PITPα were also 
principally short-chain saturated and mono-unsaturated species, in particular 16:0/16:1, 
16:1/18:1 and 16:0/18:1. The order of preference for PI molecular species exactly 
matched that seen for PC, 16:1>16:0>18:1>18:0>20:4>20:3, despite a much higher 
proportion of polyunsaturated PI species present in HL60 cells (Hunt et al., 2004).
The finding that PITP does not  favour binding of long-chain PI or PC molecular species 
confirmed earlier experiments with prenylacyl-containing phospholipids, which also 
reported a preference in chain length in the order 16:1>16:0>18:0 (van Paridon et al., 
1988).
1.2.4: Lipid presentation model and the PITP structure
The addition of PITP into permeabilised HL60 cells washed of cytosol increased the 
rate of lipid hydrolysis before the PI supply at the plasma membrane had been 
exhausted. This indicated to researchers that PLC and the lipid kinases preferred the 
substrate delivered by PITP to the PI already present in the signalling membrane 
(Cunningham et al., 1995). Indeed, the ability of PITP to stimulate lipid kinases was 
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also observed in other studies (Kauffmann-Zeh et al., 1995; Panaretou et  al., 1997), and 
gave support to the lipid presentation model of PITP function (Figure 1.5 B) 
(Cunningham et al., 1995).
From the first reported X-ray crystal structure of PITPα, in its closed conformation with 
PC bound (Yoder et al., 2001), it was unclear how PITP would present PI to lipid 
kinases, since the inositol head group  of PI appeared to be buried deep in the lipid-
binding cavity, away from the cavity opening. Yoder and colleagues postulated 
interaction of lipid-modifying enzymes with the regulatory loop of the PITP domain. 
The structure of the PITP apo-conformation revealed that upon interaction with the 
membrane, a channel opened up in the structure, with a small opening between the N-
terminus of αG helix and strands β2 and β3 (Schouten et al., 2002). This opening could 
expose the inositol head group  of a PI molecule bound in the lipid-binding cavity to a 
lipid kinase docked on the regulatory loop, in support of the lipid presentation model, 
although it has been noted that this opening is very small (Wirtz et al., 2006). PITP has 
no affinity  for transfer of PI(4)P (Schermoly and Helmkamp, 1983), promoting the 
deposition of this phosphoinositide to either a lipid kinase or into the membrane (Yoder 
et al., 2001). The evidence therefore supports the lipid presentation model up  to PI(4)P. 
Subsequent phosphorylation of PI(4)P to PI(4,5)P2 by PI4P-5-K could require a PITP 
co-factor, such as ARF (Fensome et al., 1996).
The notion that the PI, and subsequent PI(4)P, delivered by PITP is preferred by  PLC 
may involve its membrane localisation. PI(4,5)P2 is compartmentalised in mammalian 
cells into agonist-sensitive and -insensitive pools. Caveolae, which belong to the 
agonist-sensitive pool, are small invaginations in the plasma membrane rich in the 
protein, caveolin, and contain a variety  of proteins involved in cell signalling, including 
small and heterotrimeric G proteins, Src family kinases, MAP kinase, the EGF receptor 
and the platelet-derived growth factor receptor. They are also enriched in 
glycosphinglipids and cholesterol, making them resistant to (0.5%) Triton X-100 
(TX-100) extraction. It  has been reported that both 50 nM EGF and 10 µM bradykinin 
(GPCR agonist) treatment (5 min) of A431 cells stimulates a reduction in the caveolar 
PIP2, without any  change in PIP2 levels in the solubilised plasma membrane fraction 
(non-caveolar) (Pike and Casey, 1996). In this study, PIP2 was evenly distributed 
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between the caveolar and non-caveolar, solubilised plasma membrane fractions under 
basal conditions. PITP-delivered PI might be favoured by PLC because it has been 
deposited into the agonist-sensitive pool. The targeting of PITP to the agonist-sensitive 
pool could be mediated by protein-protein interactions.
A reduced mobility of PITPα at  the plasma membrane has been observed in response to 
EGF stimulation in COS-7 cells (15 min, 35 ng.mL-1) (Larijani et al., 2003). PITP has 
been detected in an endogenous signalling complex with the EGF receptor, PI4K and 
PLCγ in A431 cells, and this association increased following stimulation with 100 nM 
EGF for 5 mins (Kauffmann-Zeh et al., 1995). In the developing nervous system, PITPα 
interacts with DCC/neogenin via its C-terminus, as removal of the C-terminal 20 aa of 
PITPα abolished the interaction, and this association is increased 4-fold by addition of 
the agonist, netrin-1 (Xie et al., 2005). This localisation at the plasma membrane might 
focus PITPα into the local presentation of PI to PI 4-kinase from agonist-insensitive to 
agonist-sensitive pools.
1.2.5: Regulation of Lipid Transfer: Serine 166
The Ser166 residue is conserved in almost  all PITP sequences analysed and, like Thr59, 
is a consensus site for phosphorylation by PKC. PITPα can be phosphorylated in vitro 
by PKC (van Tiel et al., 2000; Morgan et  al., 2004), and Ser166 is phosphorylated upon 
stimulation of HL60 cells with either FMetLeuPhe or PMA, and in rat brain cytosol 
(Morgan et al., 2004). When PITPα is phosphorylated at  this residue, it is unable to 
exchange its bound PI for PC, yet retains the ability to exchange its bound PC for PI, 
thus providing a form of regulation of lipid transfer (Morgan et al., 2004). This implies 
that disassembly, but not re-assembly, of the hydrogen bond network securing the 
inositol head group of PI in place is permitted.
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(Facing page) Figure 1.5: Mechanisms of PITP activity
(A) In its closed, compact form, PITP shields a single PI or PC molecule from the 
aqueous environment and transports it between membranes. Once docked onto the 
membranes, PITP undergoes a conformational change to a relaxed, apo-structure, 
permitting the exchange of its phospholipid cargo. Diagram adapted from (Schouten et 
al., 2002). (B) The lipid presentation model: PITP transports PI from the ER to PI4K 
and PI4P-5-K at the plasma membrane. PI remains bound to PITP in the lipid-binding 
cavity  during sequential phosphorylation to PI(4)P, then PI(4,5)P2, before finally  being 
presented to PLC for hydrolysis. Diagram taken from (Cunningham et al., 1995). (C) (i) 
As shown in (A), the closed form of PITP mediates lipid transfer, and the relaxed, apo-
form is only  achieved at the membrane during lipid exchange. (ii) and (iii) demonstrate 
how PITP might present PI to a soluble PI3K and membrane-bound PI4K enzyme, 
respectively. Diagram taken from (Yoder et al., 2001).
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The phospho-mimetic mutant, S166E, was observed to be defective for both PI and PC 
binding and transfer, however (Morgan et al., 2004). The local concentration of negative 
charge and physical shape could act as a wedge to keep the lipid-binding cavity  shut. 
The elution profile after size exclusion chromatography  is distinct for phosphorylated vs 
non-phosphorylated PITPα, indicating that these two forms are structurally  distinct 
(Morgan et al., 2004). If interaction with other proteins through the regulatory loop is 
required for in vivo function (particularly  stimulated function), modification of Ser166 
would interfere with these interactions. In support of this, EGFP-PITPα S166E was 
observed to have a similar pattern of localisation as the wild-type protein in COS-7 
cells, but this was not observed to change upon EGF stimulation, unlike the wild-type 
protein (Larijani et al., 2003).
Ser166 lies in the regulatory  loop, between the β7 and β8 strands (Figure 1.3 B). Ser166 
is barely  exposed in the apo-structure, and this is not different to the closed form 
(Figure 1.3 D). Nevertheless, X-ray crystal structures present a single fixed snapshot of 
the protein structure. It is possible that the PITP domain is more flexible in this region, 
or undergoes a more dramatic conformational change than that observed in the crystal 
structures to date to enable phosphorylation of Ser166 by PKC.
The PITP domain belongs to the large Bet v 1 superfamily of proteins, which have a 
common fold. Also a member of this superfamily, steroidogenic acute regulatory protein 
(StAR) facilitates the movement of cholesterol from the outer to the inner mitochondrial 
membrane, providing the substrate for steroid hormone biosynthesis. At low pH, 
3.5-4.0, StAR partially  unfolds to form a highly-helical ‘molten globule’ structure, 
facilitating its entry  into mitochondria from the inter-membrane space, which has been 
made acidic by the action of the mitochondrial proton pump (Bose et al., 1999). 
Similarly, the Bet v 1 protein, the founding member of the Bet v 1 superfamily, 
undergoes a loss in tertiary structure upon interaction with membranes (Mogensen et al., 
2007). A comparable conformational change might be possible for PITP, enabling 
access to the PI head group for phosphorylation by lipid kinases.
The PI transfer activity  of lysates derived from rat cortical neurons stimulated with 
netrin-1 or BDNF has been assessed, and revealed that the activity was higher in lysates 
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derived from stimulated cells (Xie et al., 2005). The removal of PITPα from these 
lysates by  immunoprecipitation abolished the transfer activity, indicating that PITPα is 
the dominant PITP in these cells. The ability of netrin-1 and BDNF to stimulate transfer 
activity could reflect dephosphorylation of PITPα at Ser166 in response to stimulation.
Cells under-expressing the 43 kDa inositol polyphosphate 5-phosphatase, which 
specifically removes the phosphate from the 5’-OH of IP3, experience a 2.6-fold 
elevation in the basal level of IP3 and a 4.1-fold increase in the concentration of 
intracellular Ca2+ (Speed et  al., 1999). In these cells, a 32% decrease in PI(4,5)P2 mass 
was observed, and PI transfer activity  was found to be reduced by  up to 70% compared 
to control cells, despite no difference in the amount of PITPα expressed (Speed and 
Mitchell, 2000). (The expression of other PITP family  members was not assessed.) This 
may represent negative feedback, where high IP3 and Ca2+ activates PKC to promote 
phosphorylation of PITP Ser166, to inhibit PI delivery and to switch off PLC activity. 
The significant depletion in PI(4,5)P2 (and also PI and PI(4)P) was only  observed in the 
caveolin-rich triton-insoluble fraction, not in the triton-soluble membrane fraction 
(Speed and Mitchell, 2000), again indicating that PITP delivers PI specifically  to the 
agonist-specific pool.
1.3: The Class IIB soluble PITP, RdgBβ
In contrast to the other members of the PITP family, very little is known about the third 
soluble PITP, RdgBβ, and for this reason, RdgBβ will be the focus of this study going 
forward. RdgBβ was originally cloned in 1999 from a human infant brain cDNA library 
in a screen looking for novel human homologues of Dm-RdgBα (Fullwood et al., 1999). 
This protein is 332 amino acids long, with a calculated molecular mass of 38 kDa. 
Subsequently  a second, shorter splice variant was identified in mouse (Takano et al., 
2003), 269 amino acids in length, with a molecular mass of 31.7 kDa. For clarity I will 
refer to the long splice variant as RdgBβ-sp1, and the shorter variant as RdgBβ-sp2.
The gene encoding the RdgBβ protein, PITPNC1, lies on chromosome 11 in the human 
genome. The coding region for RdgBβ is made up of 10 exons and PITPNC1 mRNA is 
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alternatively spliced to produce the two splice variants. RdgBβ-sp1 is encoded by  exons 
1-8 and 10, whereas RdgBβ-sp2 is encoded by exons 1-9. Therefore, RdgBβ-sp1 and -
sp2 share an identical N-terminal region, but differ from one another in their C-terminal 
residues; the C-terminus of RdgBβ-sp1 is encoded by  exon 10 and the C-terminal 
region of RdgBβ-sp2 is encoded by exon 9.
Northern analysis indicated that  RdgBβ-sp1 is ubiquitously  expressed in humans, with 
particularly strong expression in the heart, muscle, kidney, liver, and peripheral blood 
leukocytes (Fullwood et al., 1999). In the mouse, the use of RT-PCR indicated that 
RdgBβ-sp1 was expressed in the brain at E15, P0 and P49, and in the P49 heart, liver, 
kidney  and testes (Takano et al., 2003). In situ hybridisation histochemistry was used to 
examine the localisation of mRNAs in the mouse brain: RdgBβ-sp1 was almost absent 
from the embryonic brain (E15), and increased after birth. At P7, RdgBβ-sp1 staining 
was detected weakly  in all areas of the brain except the olfactory  bulb, Purkinje cell 
layer and white matter. This is consistent  into P49, with moderate RdgBβ-sp1 
expression also detected in the Purkinje cell layer of the cerebellum by this time. By 
P49, RdgBβ-sp1 expression was intense in the dentate gyrus, with moderate expression 
in the thalamus (Takano et al., 2003).
By contrast, RdgBβ-sp2 expression in the brain was relatively higher in the embryonic 
stages, declining after birth. At E15, weak RdgBβ-sp2 transcript expression was 
observed in the ventricular and mantle zones of the cerebral cortex. By P7, RdgBβ-sp2 
expression had gone from the cerebral cortex, and very weak staining was observed in 
the internal granule cell layer. At P49, weak RdgBβ-sp2 staining was observed in the 
granule cell layer of the cerebellum and in the ependyma (Takano et al., 2003). The use 
of RT-PCR confirmed RdgBβ-sp2 expression in the mouse brain at E15, P0 and P49, 
and in addition, expression in the P49 heart and small intestine (Takano et al., 2003).
Confocal laser scanning immunofluorescence microscopy of HEK-293 cells expressing 
FLAG-RdgBβ-sp1 showed diffuse staining throughout the cytoplasm (Fullwood et al., 
1999). PC12 cells expressing GFP-RdgBβ-sp1 or GFP-RdgBβ-sp2 confirmed the 
RdgBβ-sp1 localisation to the cytoplasm, and revealed that RdgBβ-sp2 is weakly 
present in the nucleus, as well as in the cytoplasm (Takano et al., 2003).
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RdgBβ-sp1 has been observed to exhibit  robust PI transfer activity, comparable to that 
of PITPα, which is unaffected by removal of its C-terminal tail (Fullwood et al., 1999). 
In a protein-lipid overlay assay, the GST-tagged RdgBβ-sp2 bound to PI only, not to any 
of the other phospholipids, including PC, or phosphorylated PI derivatives (Takano et 
al., 2003).
1.4: An interaction between RdgBβ and ATRAP
A physical interaction between RdgBβ and the Angiotensin II receptor-associated 
protein, ATRAP, has been reported from a yeast two-hybrid screen (Rual et al., 2005). 
A later screen used RdgBβ as the bait, identified ATRAP as the target protein in the 
interaction, and reported the mRNA nucleotide accession numbers as BC007905 and 
BC017328, respectively  (Venkatesan et al., 2009). This RdgBβ sequence is the short 
splice variant, RdgBβ-sp2.
1.4.1: ATRAP
ATRAP itself was identified in a yeast two-hybrid screen against a mouse kidney 
cDNA library looking for novel interacting partners of the murine Angiotensin II type 1 
receptor (AT1R) C-terminus (Daviet et al., 1999). Subsequently, the human homologue 
was cloned from a foetal brain cDNA library (Wang et al., 2002). ATRAP, encoded by 
the AGTRAP gene, is an integral membrane protein with three transmembrane domains 
at its N-terminus, and a hydrophilic C-terminal tail (Lopez-Ilasaca et al., 2003). The 
first transmembrane domain contains a signal peptide sequence which acts as a signal 
anchor domain to position the protein in the ER membrane. The N-terminus of ATRAP 
is oriented outside of the cell (or inside intracellular organelles) and its C-terminus 
projects into the cytosol (Lopez-Ilasaca et al., 2003). The mouse protein is small, 
comprising 161 aa with a molecular weight of 17.8 kDa.
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ATRAP tissue expression
ATRAP is widely expressed in human, mouse and rat tissues. Assessment of ATRAP 
mRNA expression in the mouse by northern blot indicated relatively high levels in the 
kidney, testes and heart, but lower levels in the lung, liver, spleen and brain (Daviet et 
al., 1999). Using RT-PCR, ATRAP mRNA expression has been observed in all mouse 
tissues examined, with expression highest in the kidney and declining in the order: 
kidney  > testes ≈ adrenal gland > heart > lung > liver ≈ brain ≈ spleen (Oppermann et 
al., 2010). RT-PCR also detected ATRAP transcripts in the mouse aortic tissue and 
vascular smooth muscle cells (VSMCs) (Daviet et  al., 1999), and similarly in rat 
VSMCs in culture and in situ in the aortic wall (Azuma et al., 2007). RT-PCR confirmed 
the presence of ATRAP mRNA in mouse heart and in primary  cultured mouse 
cardiomyocytes (Tanaka et  al., 2005). In human tissues, northern blot analysis noted 
ATRAP expression in almost all of the tissues examined, with particularly abundant 
expression in the kidney, heart, pancreas and thyroid (Wang et al., 2002).
In the mouse, western blotting has detected high ATRAP protein expression in kidney, 
lung and testes. More moderate levels were observed in the spleen, and lower 
expression observed in the heart, brain, liver, skeletal muscle and aorta (Tsurumi et al., 
2006). Another study observed ATRAP protein in mouse liver, spleen, heart, intestine 
and pancreas, and by immunohistochemistry  noted ATRAP expression in the zona 
fasciculata of the adrenal cortex (Oppermann et al., 2010). Western blotting, 
immunofluorescence microscopy and immunohistochemical analyses all demonstrated 
that ATRAP protein is expressed in rat VSMCs in culture and in situ in the aortic wall 
(Azuma et al., 2007).
ATRAP protein expression has been reported to be regulated at the level of 
transcription. In mouse distal convoluted tubule cells of the renal cortex, serum 
starvation was shown to upregulate AGTRAP gene expression, in response to the runt-
related transcription factor, Runx3 (Matsuda et al., 2011). Conversely, chronic 
Angiotensin II infusion (200, 1000 or 2500 ng.kg-1.min-1 for 14 days) significantly 
suppressed ATRAP expression in the outer medulla of the kidney, which could be 
blocked using the AT1R antagonist, olmesartan (Wakui et  al., 2010a). Similarly, 
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expression of ATRAP was reduced in mouse hearts from animals infused with 200 
ng.kg-1.min-1 for 14 days (Wakui et al., 2010b). Lastly, basal expression of ATRAP was 
suppressed in a mouse brown adipocyte cell line in response to treatment with a β3-
adrenergic receptor agonist, mediated by  the PKA and JAK/STAT signalling pathways 
(Westphal et al., 2008).
ATRAP subcellular localisation
Immunofluorescence microscopy has demonstrated that  HA-tagged ATRAP expressed 
in COS-7 cells localises to intracellular cytoplasmic compartments as well as to the 
plasma membrane (Daviet et al., 1999), a distribution confirmed for the endogenous 
protein in HEK-293 cells (Lopez-Ilasaca et al., 2003). Specifically, ATRAP co-localises 
with a vesicle marker of the endocytic pathway, GFP-RhoB, and the trans-medial Golgi 
marker, ECFP-β-1,4-galactosyltransferase. It co-localises with structures stained by  the 
fluorescent dye, 3,3’-dihexyloxacarbocyanine iodide (DiOC6), which stains ER, vesicle 
membranes and mitochondria, and partially co-localises with the protein calreticulin, an 
ER marker (Lopez-Ilasaca et al., 2003). Markers of lysosomes and peroxisomes did not 
co-localise with ATRAP. ATRAP was also observed to co-localise with GFP-RhoB and 
ECFP-β-1,4-galactosyltransferase when over-expressed in the human cardiomyocyte 
cell line, H9c2, in neonatal mouse cardiomyocytes (Tanaka et al., 2005), and in cultured 
rat VSMCs (Azuma et al., 2007). A quantitative analysis suggested that  67% of total 
ATRAP was co-localised with endosomes (the GFP-RhoB marker) in unstimulated cells 
(Azuma et al., 2007), indicating that ATRAP constitutively localises to the endocytic 
pathway. Analysis of the distribution of ATRAP indicated that there is no significant 
change in the overall distribution of ATRAP upon stimulation of cells with Angiotensin 
II (Lopez-Ilasaca et al., 2003; Azuma et al., 2007). ATRAP was not observed to co-
localise with caveolin-rich domains at the plasma membrane (Lopez-Ilasaca et al., 
2003).
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1.4.2: ATRAP and Angiotensin II signalling
The ATRAP-AT1R interaction
ATRAP specifically interacts with the last 20 aa of the AT1R (residues 339-359), but not 
with the C-termini of the AT2R, the m3 muscarinic, bradykinin B2, or endothelin B 
receptors, nor did it  associate with the Gs-coupled β2-adrenergic receptor (Daviet et al., 
1999). The ATRAP-AT1R interaction has been confirmed for the human proteins (Wang 
et al., 2002), and the mouse proteins over-expressed in H9c2 cardiomyocytes (Tanaka et 
al., 2005), and in rat VSMCs by co-immunoprecipitation and bioluminescence 
resonance energy transfer (BRET) analysis (Azuma et al., 2007). Approximately 10% of 
ATRAP protein associated with the AT1R in unstimulated cells (Daviet et al., 1999), and 
although this early study showed that stimulation of cells with Angiotensin II had no 
effect on the ATRAP-AT1R interaction in immunoprecipitation experiments, later 
studies showed that the interaction was enhanced upon stimulation of the cells with 
Angiotensin II more than 2-fold (Tanaka et al., 2005; Azuma et al., 2007). 
Immunofluorescent microscopy has indicated that upon stimulation with Angiotensin II, 
the AT1R and ATRAP are co-localised in intracellular compartments, rather than at the 
cell periphery  (Daviet et al., 1999; Lopez-Ilasaca et al., 2003; Tanaka et al., 2005). 
Experiments using deletion mutants identified the AT1R-binding site in the C-terminus 
of ATRAP, between 110 and 122 aa (Lopez-Ilasaca et al., 2003).
Angiotensin II signalling
Angiotensin II is an octapeptide hormone produced by the renin-angiotensin system in 
vertebrates. This hormone plays a central role in the regulation of blood pressure and 
maintenance of the water-electrolyte balance through a direct action on tubular re-
absorption in the kidney, constriction of blood vessels and stimulation of the release of 
aldosterone from the adrenal cortex. Angiotensin II also plays a role in cardiovascular 
disease, including hypertension, cardiac hypertrophy, myocardial infarction and 
atherosclerosis.
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At the cellular level, Angiotensin II has growth factor and cytokine-like properties: it 
modulates contraction and regulates cell growth, apoptosis and differentiation. It is pro-
inflammatory, stimulates the production of other growth factors (e.g. platelet-derived 
growth factor) and vasoconstrictors (e.g. endothelin-1), and it trans-activates growth 
factor receptors (e.g. EGF receptor and insulin-like growth factor receptor) (Touyz and 
Berry, 2002).
There are two receptors for Angiotensin II in humans: AT1R, of which there are two 
sub-types, AT1aR and AT1bR, and the type 2 receptor (AT2R). Both are GPCRs with 
seven transmembrane domains. The majority of the known actions of Angiotensin II are 
mediated by the AT1R. The AT1R, but not AT2R, undergoes internalisation in response to 
agonist stimulation (Turu et al., 2006). Upon agonist  binding, the AT1R associates with 
heterotrimeric G proteins of the Gq/11 or G12/13 class, stimulating PLCβ, promoting Ca2+ 
mobilisation and subsequent PKC activation. In addition, Angiotensin II promotes the 
activation of PLD, PLA2, ERK1/2, NAD(P)H oxidase, and subsequently stimulates 
gene transcription (Touyz and Berry, 2002).
ATRAP has been reported to have a negative effect on Angiotensin II signalling and 
promote internalisation of the AT1R. Over-expression of ATRAP suppresses inositol 
phosphate production by PLC in response to Angiotensin II stimulation (Daviet et al., 
1999; Lopez-Ilasaca et al., 2003), without any  change in PLCβ or PLCγ protein 
expression (Daviet et al., 1999). The use of ATRAP C-terminal deletion mutants 
indicated that the ATRAP-AT1R interaction is necessary  for the suppression of PLC 
activity (Lopez-Ilasaca et al., 2003). Membrane preparations from HEK-293 cells 
expressing AT1R, with or without ATRAP co-expression, were assessed for GTP binding 
as a measure of G protein coupling: cells expressing ATRAP experienced a reduction in 
GTP binding following Angiotensin II stimulation (Lopez-Ilasaca et al., 2003).
Radioligand binding assays using membrane preparations indicated that ATRAP over-
expression did not significantly affect the number of AT1aR receptors or their affinity for 
Angiotensin II (Daviet et  al., 1999), but similar assays in intact adult VSMCs indicated 
that the Angiotensin II-induced down-regulation of surface receptors was exaggerated 
by ATRAP over-expression (Cui et al., 2000). This notion, that ATRAP increases AT1R 
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internalisation in response to Angiotensin II stimulation, was confirmed using flow 
cytometry  (Lopez-Ilasaca et al., 2003), and in VSMCs using quantitative fluorescence 
analysis and a surface AT1R binding assay (Azuma et al., 2007). This latter study 
reported that ATRAP increased receptor internalisation, even under basal conditions. 
The removal of Angiotensin II indicated that ATRAP significantly  inhibited the 
recovery of cell surface AT1R, since the receptor was maintained in intracellular 
compartments (Tanaka et al., 2005; Azuma et al., 2007). These experiments indicate that 
ATRAP associates with the AT1R under basal conditions, and that the interaction 
increases in response to Angiotensin II stimulation, promoting uncoupling of the 
receptor from G proteins and receptor internalisation. It seems plausible that  it is the 
uncoupling from Gq that attenuates inositol phosphate production by  PLC in response to 
Angiotensin II.
In addition to its effect on PLC signalling, the effect of ATRAP on other signalling 
pathways downstream of Angiotensin II has been assessed. In VSMCs, ATRAP 
suppressed the Angiotensin II-induced phosphorylation of PKB and STAT, as well as 
ERK phosphorylation after 60 min (but not  30 min) (Cui et  al., 2000). In a different 
study, Angiotensin II-induced phosphorylation of ERK1/2 and JNK was not affected by 
ATRAP over-expression, however. Instead, activation of p38MAPK in response to 
Angiotensin II was significantly  suppressed by over-expression of ATRAP (Tanaka et 
al., 2005).
Angiotensin II induces expression of the immediate early gene, c-fos (Sadoshima and 
Izumo, 1993). However, over-expression of ATRAP abolished the Angiotensin II-
induced DNA synthesis, monitored by the incorporation of [3H]-thymidine for 48 hrs 
(Cui et al., 2000). Another measure of DNA synthesis is by  monitoring 5-
bromodeoxyuridine (BrdUrd) incorporation. In control VSMCs, Angiotensin II 
treatment promoted an increase in BrdUrd incorporation of 1.4-fold at  48 hrs, yet 
ATRAP over-expression completely suppressed this activity  (Azuma et al., 2007). Over-
expression of ATRAP in CHO-K1 cells stably expressing the AT1R led to a decrease in 
both the basal and Angiotensin II-stimulated transcriptional activity of the c-fos 
promoter luciferase reporter gene (Lopez-Ilasaca et al., 2003). Likewise, knock-down of 
ATRAP expression by transfecting ATRAP siRNA increased the basal level of c-fos 
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promoter activity 1.6-fold, and sensitised the effect of Angiotensin II on promoter 
activity, increasing it 2.1-fold (Azuma et al., 2007).
ATRAP-knockout mice (ATRAP-/-) have been reported to be viable and grossly  normal, 
yet have a significantly  higher mean systolic and mean arterial blood pressure than 
wild-type mice (Oppermann et al., 2010). The plasma volume of the knockout mice was 
increased by over 20%, relative to the wild-type mice. A ligand binding assay using 
[125I]-Angiotensin II indicated that ATRAP-/- mice had enhanced surface expression of 
AT1R in the renal cortex (Oppermann et al., 2010).
Transgenic mice with cardiac-specific ATRAP over-expression (ATRAP-Tg52) are 
protected from Angiotensin II-mediated cardiac hypertrophy (Wakui et al., 2010b). In 
littermate control mice, Angiotensin II infusion significantly  increased the diastolic 
intraventricular septum and diastolic left ventricle posterior wall thickness and heart/
body weight ratio, measures of cardiac hypertrophic responses, yet in the ATRAP-Tg52 
mouse these responses to Angiotensin II infusion were completely suppressed. 
Likewise, upregulation of the cardiac hypertrophy-related genes, atrial natriuretic 
peptide and brain natriuretic peptide, by Angiotensin II infusion, was completely 
suppressed in ATRAP-Tg52 mice (Wakui et al., 2010b). Left ventricular p38MAPK was 
activated at 30 min and 14 days of Angiotensin II infusion in the littermate controls, yet 
in the ATRAP-Tg52 mice, p38MAPK was not at  all activated. In this study, left  ventricular 
JNK and ERK were not significantly  activated by Angiotensin II infusion in either the 
littermate controls or the ATRAP-Tg52 mice (Wakui et al., 2010b).
Another transgenic mouse has been reported in which ATRAP mRNA was increased 
3-4-fold in the heart, aorta and femoral artery (ATRAP-Tg) (Oshita et al., 2006). These 
mice showed no significant change in body  weight, systolic blood pressure, heart rate or 
heart/body weight ratio. The placement of a polyethylene cuff around the femoral artery 
was used to induce inflammatory vascular injury and remodelling responses, and this 
has been shown to be accompanied by an increase in AT1R and AT2R expression. 
Proliferation of VSMCs and neointimal formation in the femoral artery was assessed 14 
days after cuff placement and was found to be attenuated in the ATRAP-Tg mice. 
Superoxide production, NADPH oxidase activity and expression of p22phox, a 
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membrane-associated NAD+/NADPH oxidase subunit, were all attenuated in the injured 
artery of ATRAP-Tg compared with the wild-type mice (Oshita et al., 2006).
1.4.3: Other ATRAP-protein interactions
RACK1
Human ATRAP has been shown to interact with the receptor for activated C kinase, 
RACK1 (GNB2L1) (Wang et al., 2002). As its name suggests, RACK1 was originally 
identified as a scaffold protein for active PKC, directing its intracellular localisation 
(Mochly-Rosen et al., 1991), although many tens of binding partners of RACK1 have 
now been identified (McCahill et al., 2002). RACK1 binding partners can be divided 
into two groups, depending on whether stimulation is required for the interaction or not. 
The interaction between ATRAP and RACK1 is constitutive, occurring irrespective of 
phorbol ester stimulation (Wang et al., 2002).
The ATRAP-RACK1 association is interesting in light of the fact that the ATRAP 
domain is present in multi-domain proteins in lower organisms (ciliates and 
choanoflagellates1) alongside a C2 domain for Ca2+-dependent  phospholipid binding 
(similar to the C2 domain in mammalian PKC), a protein kinase catalytic domain and a 
Ser/Thr kinase catalytic domain. This may  indicate a critical role for PKC in mediating 
the function of ATRAP.
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1 In the ciliate, Paramecium tetraurelia strain d4-2, the ATRAP domain is present in the following 
proteins alongside a C2 domain (gene name, accession no.): GSPATT00019026001, 
XP_001452241; GSPATT00011180001 , XP_001442945; GSPATT00004336001 , 
XP_001423640. In the choanoflagellate, Monosiga brevicollis MX1, the ATRAP domain is 
present alongside an ankyrin repeat domain, a protein kinase catalytic domain, an ADP 
ribosylation domain (which catalyses the transfer of ADP-ribose from NAD+ to substrates), and a 
Ser/Thr kinase catalytic domain in the protein with gene name, MONBRDRAFT_38704, 
accession no., XP_001749410.
CAML
Due to the ability of ATRAP to suppress Angiotensin II signalling, a yeast two-hybrid 
screen was carried out  to identify interacting partners of ATRAP. This study reported an 
interaction between ATRAP and the calcium-modulating cyclophilin ligand (CAML) 
(Guo et al., 2005). CAML activates the capacitative pathway of Ca2+ entry from the 
extracellular medium, which activates the phosphatase, calcineurin, which in turn 
dephosphorylates the nuclear factor of activated T cells (NFAT), permitting its entry into 
the nucleus to stimulate gene transcription. CAML is membrane-associated and 
interacts with ATRAP via its N-terminal, cytosolic domain (Guo et al., 2005). CAML 
and ATRAP were observed to co-localise at peri-nuclear ER structures, in a pattern 
similar to the distribution of endogenous ATRAP.
Treatment of HEK-293 cells expressing the AT1R with 100 nM  Angiotensin II for 18 hr, 
or CAML over-expression, increased transcription of the NFAT reporter gene 4-fold. 
Conversely, ATRAP over-expression reduced the basal NFAT reporter activity and 
reduced the Angiotensin II-induced activity (Guo et al., 2005).
Angiotensin II has also been shown to induce vascular senescence through stimulation 
of the AT1R, and plays a critical role in vascular ageing and age-related vascular 
diseases. Senescence can be assessed by staining with senescence-associated β-
galactosidase (SA-β-gal). Angiotensin II stimulation of mouse VSMCs was observed to 
significantly enhance SA-β-gal staining of control cells, starting 5 days after treatment, 
whereas cells prepared from transgenic mice with 3-4-fold more ATRAP protein 
expression in the heart, aorta and femoral artery (ATRAP-Tg mice) (Oshita et al., 2006), 
had markedly  lower numbers of SA-β-gal-positive cells (Min et al., 2009). This effect of 
ATRAP over-expression was blocked by treatment with the AT1R antagonist, valsartan. 
In contrast to control cells, which proliferated for 5 days before reaching a plateau, 
ATRAP-Tg VSMCs continued to proliferate until day 10 (Min et al., 2009). 
Senescence in response to Angiotensin II is mediated by the NFAT pathway, and 
treatment of VSMCs with NFAT siRNA markedly  attenuated the Angiotensin II-induced 
increase in SA-β-gal-positive cells, as well as the expression of p53 and p21, which are 
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important components in the induction of cellular senescence (Min et  al., 2009). 
ATRAP-Tg mice showed marked attenuation of Angiotensin II-induced NFAT 
transcriptional activity by the tenth day of treatment.
Lastly, UV irradiation markedly enhanced NFAT transcriptional activity in wild-type 
VSMCs, whereas this UV-irradiation-induced NFAT transcription was reduced in 
ATRAP-Tg VSMCs. In contrast to stimulation of NFAT with Angiotensin II, treatment 
with the AT1R antagonist, valsartan, did not alter NFAT transcriptional activity in either 
wild-type or ATRAP-Tg VSMCs (Min et al., 2009). This indicates an AT1R-independent 
role for ATRAP in the NFAT pathway. Since ATRAP interacts with CAML (Guo et al., 
2005), an upstream activator of NFAT, this likely indicates distinct roles for the ATRAP-
protein interactions in the more general suppression of Angiotensin II signalling by 
ATRAP.
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1.5: Thesis Aims
RdgBβ is a member of the PITP family, yet unlike the other PITPs, its biochemical 
properties have been scarcely characterised. This study aims to shed light on the role of 
this protein in mammalian cells through characterisation of its protein-protein 
interactions and lipid-binding properties.
• The PITPs differ mainly  in their C-terminal residues. Most notably, RdgBβ-sp1 has a 
much longer C-terminal domain than either of the other two soluble PITPs, PITPα and 
PITPβ. The first  aim is therefore the characterisation of the C-terminus of RdgBβ-sp1, 
using bioinformatic tools to assess whether this region contains any secondary 
structural elements, potential phosphorylation sites or other recognition motifs.
• An interaction between RdgBβ and ATRAP has been reported (Rual et al., 2005; 
Venkatesan et al., 2009). Both proteins are highly  expressed in the heart and kidney 
(Daviet et al., 1999; Fullwood et al., 1999; Wang et al., 2002; Takano et al., 2003; 
Tanaka et al., 2005; Tsurumi et al., 2006; Oppermann et al., 2010). The second aim of 
this thesis will be to establish whether RdgBβ interacts with ATRAP in mammalian 
cells, using co-immunoprecipitation experiments. Whether RdgBβ is involved in 
Angiotensin II-stimulated PLC activity will also be examined.
• PITPα and PITPβ bind and transfer PI and PC between membranes. RdgBβ-sp1 
transfers PI in a manner comparable to that of PITPα (Fullwood et al., 1999). The 
lipid binding properties of RdgBβ have been poorly characterised: RdgBβ-sp2 has 
been reported to bind PI in a lipid overlay assay, not to PC (Takano et al., 2003). The 
PITP domain of RdgBβ shares 41% sequence identity with the class I PITPs. The third 
aim will be to establish whether RdgBβ binds PI and PC, like PITPα and PITPβ, using 
a permeabilised HL60 cell assay.
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CHAPTER 2: Materials and Methods
2.1: Bioinformatical sequence analysis and comparative modelling
Visualisation of protein structures was achieved using the PyMOL Molecular Graphics 
System, Version 0.99, Schrödinger, LLC.
2.1.1: Disorder prediction
The RdgBβ sequence Q9UKF7.2 (PITC1_HUMAN) was used as the target sequence 
for modelling of the RdgBβ PITP domain. The sequence was first uploaded to the 
DISOPRED2 Disorder Prediction Server (Ward et al., 2004) to predict the end of the 
compact PITP domain.
2.1.2: Template identification, structural alignment and comparative 
modelling
A PSI-BLAST search was performed using the RdgBβ PITP domain sequence as the 
query against the Protein Databank from the NCBI server (Altschul et al., 1997; 
Schäffer et al., 2001) to identify closely-related structures. The structure showing the 
highest sequence identity to the target was chosen to be the template: PDB: 1t27 (rat 
PITPα complexed with PC, (Yoder et al., 2001)). MODELLER was used for the 
template-target structure alignment (Figure 2.1 A) and comparative modelling (Eswar et 
al., 2006), largely using scripts based on the tutorials. The alignment was examined for 
insertions and deletions (‘indels’) and mapped onto the template structure visualised 
using PyMOL. If an indel occurred in a possible region of secondary structure, different 
positions of the indel were considered and several models made to compare the possible 
alignment options. Through comparison of the energy  profiles for the variants I 
established that the original indels identified by the initial MODELLER structure 
alignment were best tolerated in the modelled structure. Five models were made from 
each alignment and the model performing best in terms of objective function (low), 
discrete optimised protein energy  (DOPE) score (low) and GA341 score (high), were 
chosen for further analysis.
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(Facing page) Figure 2.1: Comparative modelling of the RdgBβ PITP domain
(A) Template-target structure alignment of the 1t27 structure and human RdgBβ 
sequence (residues 1-251). The alignment was generated using MODELLER and used 
as the template for modelling the RdgBβ PITP domain. Void-contacting residues are 
surrounded by  a small black box. Larger yellow boxes denote regions of secondary 
structure, α=helix, β=sheet. (B) PDB: 1t27 structure interpretation by  LIGPLOT, 
obtained from PDBsum (Laskowski, 2009). Hydrogen bonds are indicated by  a green 
dashed line labelled with the length of the bond in angstrom (Å); residues making non-
bonded contacts with the ligand (i.e. contacts involving either a carbon or a sulphur 
atom, where the interaction distance is ≤3.9Å) are shown with red ʻeyelashesʼ, where 
the eyelashes point towards the contacted atom of the ligand. The appropriate atom 
has eyelashes pointing back. (C) RdgBβ PITP domain comparative model, with void in 
blue.
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Objective function or molecular probability distribution function (molpdf) is a relative 
score defined as the sum of all of the restrained terms that modeller is optimising when 
generating the final model; GA341 is a score indicating the reliability  of the model, 
derived from statistical potentials. In cases where two different models satisfied these 
criteria, a DOPE score was generated for each residue and plotted on a graph. The 
model with the overall lowest profile at  particular regions of interest  in the protein was 
taken forward for further analysis.
2.1.3: Mapping of the lipid-binding cavity
Void determination was carried out using AVP (Another Void Program, (Cuff and 
Martin, 2004)). Unlike other void or cavity identification programs, AVP allows the user 
to define the radius of both the probe and solvent molecules. Initially an analysis of the 
1t27 crystal structure was performed. It appeared necessary to delete both the ligand and 
the solvent co-ordinates from the PDB file to gain an accurate representation of the 
main cavity volume. Initially the program was run using a probe radius of 0.5Å and a 
solvent radius of 1.4Å, the standard radius of a water molecule. AVP operates by 
creating a box around the protein structure and then filling the space between the 
protein and the edges of the box with solvent molecules. Probe molecules are then 
placed where they  will fit in the box that has not already been defined as either protein 
or solvent. Use of the solvent radius 1.4Å did not return any large cavities of the 
expected size in the PITPα structure 1t27, indicating that the inside of the cavity is 
exposed to the solvent, even when the protein adopts its ‘closed’ conformation. To 
identify the large lipid-binding cavity it was therefore necessary to increase the solvent 
radius to 5.0Å. The program outputs a list of residue atoms adjacent to the identified 
voids. This list was compared to the output of the LIGPLOT program (Wallace et al., 
1995) for the 1t27 structure (Figure 2.1 B), which returned a list of all of the residues in 
the protein adjacent  to the selected ligand. Many  more residues were defined as 
touching a void by AVP than were identified by LIGPLOT as lining the PC-binding 
cavity. This is because a small probe size such as 0.5Å may also identify  improper 
packing in a protein molecule, not just regions of the protein large enough to 
accommodate atoms or other molecules. A probe size of 1.2-1.4 Å was more appropriate 
(Cuff and Martin, 2004).
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Probe sizes of 1.2 Å and 1.4 Å were tested sequentially. The 1.2 Å probe identified all 
of the residues identified by LIGPLOT as well as some additional residues, but not 
nearly as many  as the 0.5 Å probe, which defined 48.0% of the total residues of PITPα 
as contacting a void (compared to 21.8% for the 1.2 Å probe, 18.5% for the 1.4 Å probe 
and 9.0% for the LIGPLOT output). At the 1.4 Å probe size, some of the LIGPLOT 
residues had been lost. 1.2 Å was therefore chosen as the probe size for the analysis of 
the RdgBβ model. The RdgBβ model in grey with determined void (blue) is shown in 
Figure 2.1 C. Residues contacting the void are indicated on the structural alignment 
(Figure 2.1 A).
2.1.4: Multiple sequence alignment
Multiple sequence alignments were carried out using Vector NTI (Invitrogen) or 
MATLAB student version R2011a, unless otherwise indicated. In MATLAB, the 
multialign command was used to align multiple sequences using a progressive method. 
The default scoring matrix was used: the ‘BLOSUM80’ to ‘BLOSUM30’ series.
2.1.5: Identification of trypsin cleavage sites
The PeptideCutter tool on the ExPASy  proteomics server (Gasteiger, 2003) was used to 
predict trypsin cleavage sites in the RdgBβ-sp1 and -sp2 sequences, with a cleavage 
probability of <80% excluded (3 sites).
2.1.6: Identification of PEST sequences
The PEST sequences were identified using the pestfind algorithm on the Emboss server 
(http://emboss.bioinformatics.nl/) (Rogers et al., 1986). PEST motifs are defined as 
hydrophilic stretches of ≥12 aa with at least one proline, one glutamic acid or aspartic 
acid, and one serine or threonine residue. They  are flanked by lysine, arginine or 
histidine residues; these positively  charged residues are not allowed within the PEST 
sequence.
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2.2: Molecular biology: engineering of expression vectors
2.2.1: Starting plasmids
RdgBβ
Double-stranded DNA plasmid pEFPLink2-FLAG-RdgBβ-sp1 (human RdgBβ-sp1 
cDNA sequence with an N-terminal FLAG tag, under the control of the elongation 
factor 1a promoter) was a gift  from Prof. Justin Hsuan (Dept. of Medicine, University 
College London) (Fullwood et al., 1999). This construct was used as the starting 
sequence by Dr. Roman Holic from which to clone RdgBβ-sp1 into pRSET-C-His 
vector (Invitrogen) for bacterial expression of the recombinant protein, using the XhoI/
EcoRI restriction sites (pRSET-C-His-RdgBβ-sp1) (Figure 2.2 A). The same sites were 
used by Roman Holic to clone RdgBβ-sp1 into the pIRES2-EGFP bis-cistronic vector 
(BD Bioscience) for mammalian expression of the untagged protein with EGFP co-
expression.
The RdgBβ-sp1 truncated mutant (recombinant protein), pRSETc-RdgBβ-sp1 1-263, 
primer design was carried out by  Roman Holic, with the substitution of a stop codon 
after residue 263; PCR, mini-preps and other later stages were carried out by myself.
The human RdgBβ-sp2 IMAGE clone cDNA (IMAGE: 4299595) was obtained from 
MRC Geneservice and cloned into the pRSET-C-His vector for bacterial expression 
using the XhoI/EcoRI restriction sites (pRSET-C-His-RdgBβ-sp2) (Figure 2.2 A) by  Dr. 
Clive Morgan.
ATRAP
The double-stranded DNA plasmid pcDNA3-HA-ATRAP (mouse ATRAP sequence 
with an N-terminal HA tag, under the control of the CMV promoter) was a gift from Dr. 
Marco Lopez-Ilasaca (Brigham and Women’s Hospital, Harvard Medical School, 
Boston, MA, U.S.A.) (Daviet et al., 1999) (Figure 2.2 B).
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(Facing page) Figure 2.2: Plasmid maps
(A) Map of the pRSET-C plasmid showing the site of the ampicillin resistance gene (for 
selection in bacterial cells) and site of RdgBβ-sp1 or -sp2 inserted coding sequences. 
Expression in prokaryotes is driven by  the strong bacteriophage T7 promoter (ʻPʼ). 
ʻATGʼ indicates the START codon (coding for a methionine), followed by  the N-terminal 
polyhistidine sequence (ʻ6x Hisʼ). XhoI, EcoRI and HindIII indicate the position of the 
restriction endonuclease recognition sequences discussed in the text. (B) Map of the 
pcDNA3-HA-ATRAP plasmid. Site of the ampicillin resistance gene is indicated, as well 
as the neomycin resistance gene (for selection in mammalian cells to create stable cell 
lines). Expression in mammalian cells is driven by  the strong CMV promoter (ʻPʼ) 
indicated. (C) Map of the pcDNA3.1(+/-) plasmid with the sites of the restriction 
endonuclease recognition sequences in the multiple cloning site (ʻMCSʼ) indicated. (+) 
and (-) plasmids contain the MCS in different orientations.
82
83
AT1R
The rat AT1aR sequence with an N-terminal HA tag in the pcDNA3.1(+) expression 
vector, pcDNA3.1-HA-AT1aR, was a gift from Dr. Kevin Catt, NICHD, NIH, Bethesda, 
MD, USA.
2.2.2: Gene cloning with the addition of a protein tag
Antibodies which recognise common protein tags have been well-characterised, are 
commercially available and cheap. Common protein tags used are FLAG 
(DYKDDDDK), HA (YPYDVPDYA) and Myc (EQKLISEEDL). The RdgBβ-sp1 and -
sp2 sequences were amplified from the pRSET-C-His vectors by PCR, with the addition 
of the nucleotide sequence for one of the protein tags in the forward primer. The 
amplified sequences were then cloned into the pcDNA3.1(-) vector, rather than the (+) 
vector, due to the orientation of the multiple cloning site (Figure 2.2). In the pcDNA3.1 
vector, strong protein expression is driven by the CMV promoter. By contrast, the 
elongation factor 1a promoter in the pEFPLink2 plasmid is a relatively weak promoter.
2.2.3: Primer design
Since both splice variants of RdgBβ share the same N-terminal sequence, the same 
forward primers could be used for each splice variant, one for each protein tag: FLAG, 
HA, Myc. Only a single reverse primer was required for each splice variant (Figure 2.3 
A). The sequence for a restriction enzyme cleavage site was inserted into each primer: 
XhoI site into all of the forward primers, EcoRI into the RdgBβ-sp1 reverse primer, and 
HindIII into the RdgBβ-sp2 reverse primer.
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The primers were designed following guidelines set out by Sambrook and Russell 
(Sambrook, 2001), together with protocol guides in the Fermentas and NEB product 
catalogues. To summarise, PCR primers were designed according to the following rules:
1. Primers should have 40-60% GC content (guanine and cytosine nucleotides), with 
an even distribution of all four bases along the length of the primer.
2. The region of the primer complementary to the template should be 18-25 
nucleotides long, and members of a primer pair should not differ by >3 nucleotides.
3. No inverted repeat sequences or self-complementary sequences >3 nucleotides in 
length should be  present, as these may form hairpin structures.
4. The calculated Tm (melting temperature) values of members of a primer pair should 
not differ by >5°c.
5. The 3’ base of each primer should be a single G or C, not GC or CG, etc.
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(Facing page) Figure 2.3: Cloning RdgBβ with the addition of an N-terminal tag
(A) Strategy  for N-terminal protein sequence tagging, by the addition of the tag 
nucleotide sequence in the forward primer. (B) Agarose NA gel showing the first 
successful PCR of FLAG-RdgBβ-sp1 and -sp2 (5 μL PCR product per lane; 1 μL 
pRSET-C-RdgBβ-sp2 plasmid). (C) Agarose Prep gel of the FLAG-RdgBβ inserts after 
digestion. The exact insert size is 1037 nucleotides for sp1 and 845 nucleotides for 
sp2. The darker region indicates where the gel has broken, just above the insert bands. 
The inserts were isolated from this gel for ligation into the digested vector. (D) Ligated 
plasmids were used to transfect COS-7 cells. Cells were  harvested 48 hrs after 
transfection, and 45 μg lysates were subjected to western blotting using anti-RdgBβ 
antibody  #101 (left panels) or anti-FLAG antibody  (right panels). FLAG-RdgBβ-sp2 is 
not detected by either antibody, despite a correct sequencing result.
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2.2.4: Primer sequences
^ Restriction endonuclease cleavage site.
Red Valine, start of protein coding sequence (mutated from methionine, ATG).
Blue Tag nucleotide sequence.
Green Alanine, inserted as a spacer.
FLAG-RdgBβ forward primer (65 nucleotides, 23 complementary).
(Tm = 89.9°c, GC = 50.7 %).
5’ - GACC^TCGAGCAATGGATTACAAGGATGACGACGATAAGGCAGTG
CTGCTGAAAGAGTACCGGATC – 3’
HA-RdgBβ forward primer (68 nucleotides, 23 complementary).
(Tm = 92.1°c, GC = 55.8 %).
5’ -GACC^TCGAGCAATGTACCCATACGACGTCCCAGACTACGCTGCAGTG
CTGCTGAAAGAGTACCGGATC – 3’
Myc-RdgBβ forward primer (71 nucleotides, 23 complementary).
(Tm = 90.6°c, GC = 49.2 %).
5’ - GACC^TCGAGCAATGGAACAAAAACTCATCTCAGAAGAGGATCTGGCA
GTGCTGCTGAAAGAGTACCGGATC – 3’
RdgBβ-sp1 reverse primer (68 nucleotides, 68 complementary).
(Tm = 88.9°c, GC = 45.5 %).
5’ -AAGCTTCG^AATTCTTACTCAGATTTGGGCCGACATGGCTTATCTG
AAGAGTGCATGCCGGGTAAATTC – 3’
RdgBβ-sp2 reverse primer (68 nucleotides, 68 complementary).
(Tm = 91.3°c, GC = 50.0 %).
5’ –GCAGCCGGATCA^AGCTTTCATGTACTTGTTTGGGCATGACTCTCT
ATGTCATCCACAGGGGAGGAATG – 3’
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2.2.5: PCR
Primers were manufactured by Sigma-Aldrich custom oligos service. The primers were 
centrifuged prior to opening, then diluted to 100 µM with molecular grade water. The 
tubes were vortexed and then frozen at -20oc for 15 mins to help  to dissolve the DNA. 
The RdgBβ-sp1 and -sp2 pRSET plasmids were diluted to 25 ng.µL-1; the primers were 
further diluted to 125 ng.µL-1 (≈ 6.25 µM).
Six reaction mixtures (50 µL) were set up in coloured, thin-walled PCR tubes on ice:
 5 µL 10X Pfu reaction buffer (Stratagene)
 1 µL dNTP mix (Stratagene)
 2 µL dsDNA template (50 ng; 125 nM) (pRSET-C-His-RdgBβ-sp1/sp2)
 1 µL forward primer (FLAG/HA/Myc) (125ng)
1 µL reverse primer (sp1/sp2) (125ng)
 39 µL molecular grade water
 1 µL Pfu turbo DNA polymerase (Stratagene)
Pfu DNA polymerase has intrinsic 3’→5’ exonuclease activity and therefore was added 
last to prevent the degradation of the primers. The elongation time of this enzyme is 2 
min.kb-1.
The PCR tubes were briefly  vortexed and centrifuged, before being placed into the PCR 
machine (Techne GeneE Thermal Cycler). The PCR programme used is detailed in 
Table 2.1; the parameters were chosen according to Fermentas recommendations. The 
most sensitive parameter was the primer annealing temperature. This should be 5°c 
lower than the lowest primer Tm. Initially the Tm of the full primer length was 
considered: the lowest Tm was 88.9°c, and so 80°c was chosen for primer annealing.
After two failed attempts at the PCR I realised the Tm should refer only  to the region of 
the primer complementary to the template sequence. At this point  I also realised my 
primers were too long; although rule 2 from the primer design guidelines states that 
primer pair lengths should not differ by more than 3 nucleotides, it wasn’t until after I 
had designed and ordered the primers that I realised this applied to the region of the 
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primer complementary to the plasmid sequence, i.e. 23 nucleotides. The Tm of the 
forward primers therefore decreases from 89.9-92.1°c to just 54°c, with a GC content of 
52%. The reverse primer Tm is 88.9-91.3°c. The primer annealing temperature was 
dropped to 49°c and this time, the PCR was successful (Figure 2.3 B).
Programme Segment Temperature Time Activity
1 - 95°c 3 min Initial denaturation
2 (25 cycles) 1 95°c 2 min Denaturation
2 49°c 2 min Primer annealing
3 72°c 4 min Extension
3 - 72°c 10 min Final extension
Table 2.1: Overview of PCR program for tagging RdgBβ
2.2.6: DNA gel electrophoresis
An agarose gel was run after the PCR to verify the presence of an amplified product. A 
1% Agarose gel was made by dissolving 0.5 g Agarose NA (or Agarose Prep, if excision 
of the DNA from the gel was required), in 50 mL Tris-acetate-EDTA buffer (TAE; 0.8 
mM Tris-HCl pH 8.0, 0.4 mM acetic acid, 0.02 mM EDTA; 1X TAE buffer was 
diluted from a laboratory stock solution of 50X, 40 mM Tris-HCl pH 8.0, 20 mM acetic 
acid, 1 mM  EDTA), using a microwave at full power for 1 min. The agarose solution 
was then allowed to cool so that it was still warm but no longer burns to the touch. 
(Ethidium bromide is broken down at higher temperatures.)
2.5 µl ethidium bromide (of 10 mg.mL-1 stock, for 50 mL agarose) was pipetted directly 
onto the gel tray, which was locked into the Bio-Rad gel caster. The agarose solution 
was then poured into the tray and mixed with the ethidium bromide using the comb. The 
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comb was placed into the designated comb slots at one end of the gel, and the gel left at 
room temperature for ~30mins to set.
Once the gel had set, the gel in its tray with the comb still in place was transferred to the 
Bio-Rad Mini-Sub Cell GT Cell (for submerged horizontal electrophoresis), with the 
comb end (sample wells) at the black (negative electrode) end. TAE buffer was poured 
into the apparatus, up  to the line indicated on the side. The comb was then removed, 
allowing buffer to fill the wells.
Samples were loaded: 5 µL PCR product + 1 µL 6X DNA loading dye (Blue #R0611 or 
Orange #R0639, Fermentas), alongside 1 µg (10 µL) Fermentas GeneRuler 1 kb DNA 
ladder (0.1 µg.µL-1, #SM0313, Fermentas) in narrow lanes (Figure 2.3 B). When 
purification of DNA was required, the whole DNA sample was loaded onto the Agarose 
Prep gel (in wide lanes), mixed with an appropriate quantity  of loading dye. A single 
sample typically took up 2 wide lanes (Figure 2.3 C).
The safety  lid was then placed onto the apparatus in the correct  orientation, and 
electrical leads plugged into the Bio-Rad Power-Pac 3000. Agarose NA gels were run at 
100 V for ~30 mins; Agarose Prep gels have a lower melting temperature, and were 
therefore run at 60 V until the dye front had travelled ⅔-¾ along the gel.
2.2.7: Digestion
The remainder of the PCR product (~45 µL) was purified using the GENECLEAN kit 
(MP Biochemicals).  The purified DNA was eluted in 30 µL molecular grade water and 
digested in 50 µL:
 30 µL PCR product
 5 µL 10X BSA
 5 µL 10X NEBuffer2* (New England Biolabs)
 1 µL restriction enzyme 1 (XhoI for both sp1 and sp2)
 1 µL restriction enzyme 2 (EcoRI for sp1; HindIII for sp2)
 Molecular grade water to 50 µL.
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*NEBuffers: XhoI and EcoRI have high activity  in buffers 2, 3 or 4; HindIII only  has a 
high rate of activity in buffer 2.
The mixture was briefly centrifuged, then placed at 37°c for 2 hrs. The entire digestion 
was then run on a 1% Agarose Prep gel for isolation of the digested inserts (e.g. FLAG-
sp1 and FLAG-sp2, Figure 2.3 C). Digestion of the pcDNA3.1(-) plasmid with XhoI 
and EcoRI for sp1, or XhoI and HindIII for sp2, was carried out in 50 µL, as above, only 
with 7 µg plasmid (7 µL of 1 µg.µL-1) instead of the PCR product. The digested plasmid 
was also run on an Agarose Prep gel.
For excision of the insert or digested plasmid, the gel was illuminated on a UV light 
box, briefly so as not to introduce mutations. The insert and cut plasmid were excised 
from the gel using a razor blade, and transferred into a pre-weighed 1.5 mL eppendorf 
tube. The tube with gel fragment was weighed again, and the DNA purified from the gel 
using the GENECLEAN Turbo kit. The purified DNA was eluted in molecular grade 
water.
2.2.8: Ligation
The ligation of the digested insert into the digested plasmid was carried out in 20 µL:
 4 µL 5X ligase buffer (thawed slowly on ice)
 0.5 µL T4 DNA ligase
 1 µL digested pcDNA3.1(-) plasmid
 4 µL digested insert
 Molecular grade water to 20 µL
The ligation mixture was subjected to a brief vortex and incubated at room temperature 
for 1-2 hrs. For the HA- and Myc-tagged proteins, the first ligation was unsuccessful 
using the ratio of insert to digested plasmid above. Samples of the digested plasmid and 
insert were run side-by-side on an Agarose NA gel to estimate their relative 
concentrations. The insert band on the gel was very faint, so its quantity was maximised 
in the ligation mixture to 14.5 µL.
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2.2.9: Transformation of XL1-blue competent cells
Pouring agar plates
Luria agar (25 g.L-1) was autoclaved in Duran bottles and stored at room temperature 
until required. To make agar plates, the lid of the Duran bottle was loosened, and the 
bottle placed into the microwave on full power for ~1 min 10 sec to melt  the agar. The 
bottle was then allowed to cool so that it was still warm but no longer burned to the 
touch (hand hot). (The ampicillin will be degraded if the agar is too hot.) 100 µL 
ampicillin solution (100 mg.mL-1 stock) was added to the 100 mL Luria agar, giving a 
final ampicillin concentration of 100 µg.mL-1. The addition of ampicillin permitted the 
selection of bacteria containing a plasmid carrying the ampicillin resistance gene.
With a bunsen flame close by to create aseptic conditions, 10 mL agar solution was 
poured into each of ten, 10 cm-diameter Petri dishes, which had been labelled on their 
bases. The plates were allowed to cool at room temperature until required.
Transformation of bacteria
The required number of agar plates were placed in the dry  incubator at 37°c, upside 
down, propped at an angle on their lids to remove any moisture that had accumulated, 
for 1-2 hrs prior to use. Two plates were prepared per ligation.
For each ligation, 10 µL of ligation mixture was placed into a labelled eppendorf tube 
on ice, followed by  100-200 µL XL1-blue super-competent cells. The tubes were flicked 
briefly to ensure the contents were properly mixed, and incubated on ice for 20-30 mins. 
(For purified DNA, 1-2 µL DNA was used per transformation, where the concentration 
was 0.1-1.0 µg.µL-1, as after a mini- or maxi-prep.)
The bacteria were then administered a ‘heat shock’ by  placing the tubes into a water 
bath at 42°c for 45 sec (30 sec-1 min), before returning to ice for 2 mins.
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500-800 µL Miller’s Luria broth (LB) was added to each tube, the tubes inverted several 
times to ensure adequate mixing, and then placed at 37°c for 1 hr, either in a water bath 
or dry incubator. (200 mL LB (25 g.L-1) was previously made up  in a 250 mL Duran 
bottle and autoclaved. The bottle was stored at RT.)
With a bunsen flame close by, 300-500 µL transformed cells (i.e. half the combined 
volume of cells and added LB) were transferred onto each of two labelled agar plates 
and spread using a glass cell spreader, which had been sterilised with ethanol in the 
bunsen flame.
The agar plates were then returned to the dry incubator at 37°c, with the agar on the 
bottom for ~30 mins. Once the liquid had been absorbed by the agar, the plates were 
inverted and left in the incubator overnight. (Alternatively, plates were placed in the 
dark at RT over a weekend.)
2.2.10: Growth of bacterial culture, mini-prep and DNA sequencing
The next step was to get  the plasmid sequenced. Four ‘mini-prep’ cultures per ligation 
were set up  and grown for ~16 hrs in an incubator shaker at 37°c: 5 µL ampicillin (of 
100 mg.mL-1 stock, giving a final ampicillin concentration of 100 µg.mL-1 in 5 mL 
culture) was added to 5 mL LB in a 15 mL falcon tube under aseptic conditions. A 
sterile pipette tip was then used to pick a single colony from the agar plate, which was 
then ejected directly into the tube. The falcon tubes were vortexed prior to overnight 
incubation.
The plasmid DNA was purified from the bacterial culture the following day using the 
QIAGEN QIAprep  miniprep kit, following the manufacturer’s instructions. The final 
elution was carried out in 50 µL molecular grade water.
The DNA concentration of the purified DNA was measured using a spectrophotometer 
at 260 nm absorbance. Of the four mini-preps carried out per ligation, the two with the 
highest DNA concentration were sent to Eurofins MG Operon for sequencing. 1.5 µg of 
each nucleic acid preparation was sent (at a concentration of 100 ng.µL-1).
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In addition, the purified plasmid was transfected into COS-7 cells, and the lysate 
subsequently  subjected to SDS-PAGE and western blotting using a primary antibody 
directed against the added protein tag (Figure 2.3 D). (See method for transient 
transfection using FuGENE HD below.)
2.2.11: Site-directed mutagenesis
In order to assess the contribution of a single amino acid to protein function, site-
directed mutagenesis can be used to substitute one or two nucleotides. The method used 
broadly  followed that given in the Stratagene QuikChange kit. Short DNA primers were 
designed that complemented the parent plasmid exactly, barring for the one or two 
nucleotide alteration. PCR was then used to amplify the parent plasmid, incorporating 
the base change.
Primer design
Primers were designed using the online tool, PrimerX (http://www.bioinformatics.org/
primerx/). For these primers, criteria given in the Stratagene QuikChange protocol was 
followed, which was more specific than that detailed in Section 2.2.3:
1. Primers should be 25-45 bases in length, with a Tm ≥78°c.
2. The desired mutation should be in the middle of the primer with ~10-15 bases of 
correct sequence on both sides.
3. A GC content of >40% is recommended, and each primer should terminate in one or 
more C or G bases.
Site-directed mutagenesis was used to introduce the following mutations into 
pcDNA3.1-FLAG-RdgBβ-sp1: S274A, T278A, S299A, SS274/299AA, and the 
truncated mutant 1-250, where I251 was mutated into a stop codon (I251_STOP). The 
double mutant SS274/299AA was made by mutating S299A in the pcDNA3.1-FLAG-
RdgBβ-sp1-S274A plasmid. The primer sequences and technical information are given 
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below. The star (*) above and below the primer sequence indicates the position of the 
substituted residue(s).
Primers were manufactured by Sigma-Aldrich custom oligos service or Eurofins MWG 
Operon. The websites automatically calculated the degree to which secondary structure 
formation within the primers was possible, or whether the uploaded sequences were 
susceptible to dimerisation. If strong secondary  structure formation or dimerisation was 
predicted, I returned to the PrimerX list of designed primer options and chose a more 
appropriate sequence.
S274A
                             **
    Forward: 5' CAGTGCGCCTTCTGCTGCTCCATCCAC 3'
    Reverse: 5' GTGGATGGAGCAGCAGAAGGCGCACTG 3'
                            **
     GC content: 62.96%           Location: 807-833
     Melting temp: 75.3°C         Mismatched bases: 2
     Length: 27 bp                Mutation: Substitution
     5' flanking region: 13 bp    Forward primer MW: 8123.38 Da
     3' flanking region: 12 bp    Reverse primer MW: 8439.56 Da
T278A
                                 *
    Forward: 5' CTTCTAGTGCTCCATCCGCCCCTCTCTCCACAGAC 3'
    Reverse: 5' GTCTGTGGAGAGAGGGGCGGATGGAGCACTAGAAG 3'
                                 *
     GC content: 60.00%           Location: 815-849
     Melting temp: 83.8°C         Mismatched bases: 1
     Length: 35 bp                Mutation: Substitution
     5' flanking region: 17 bp    Forward primer MW: 10474.94 Da
     3' flanking region: 17 bp    Reverse primer MW: 11031.24 Da
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S299A
                            *
    Forward: 5' CCCCGGAAAAAGGCTGCCCCAGAAAC 3'
    Reverse: 5' GTTTCTGGGGCAGCCTTTTTCCGGGG 3'
                             *
     GC content: 61.54%           Location: 883-908
     Melting temp: 77.0°C         Mismatched bases: 1
     Length: 26 bp                Mutation: Substitution
     5' flanking region: 12 bp    Forward primer MW: 7928.27 Da
     3' flanking region: 13 bp    Reverse primer MW: 8016.27 Da
I251_STOP
                                    *** 
    Forward: 5' CCACCAACAAGAAAATCGGCTAATTCCCACCTGCAATTTCTATC 3'
    Reverse: 5' GATAGAAATTGCAGGTGGGAATTAGCCGATTTTCTTGTTGGTGG 3'
                             ""  ***
     GC content: 43.2%           Location: 731-774
     Melting temp: 76.8°C         Mismatched bases: 3
     Length: 44 bp                Mutation: Substitution
     5' flanking region: 20 bp    Forward primer MW: 13332.86 Da
     3' flanking region: 21 bp    Reverse primer MW: 13728.03 Da
PCR
Reaction mixtures were set up on ice, exactly as detailed in section 2.2.5. The PCR 
program used was a combination of that recommended by the Stratagene QuikChange 
protocol, and the program used for tagging of the RdgBβ sequences (Table 2.2). The 
pcDNA3.1(-) plasmid is 5.4 kb in length, and FLAG-RdgBβ-sp1 insert is approximately 
1 kb in length, giving a total plasmid size of ~6.4 kb. An extension time of 13 min was 
therefore chosen to allow for the extension rate of 2 kb.min-1 by Pfu DNA polymerase.
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Programme Segment Temperature Time Activity
1 - 95°c 2 min Initial denaturation
2 (16 cycles) 1 95°c 2 min Denaturation
2 (5°c lower than lowest 
primer Tm)
1 min Annealing
3 68°c 13 min Extension
3 - 68°c 10 min Final extension
Table 2.2: Overview of PCR program for site-directed mutagenesis
Digestion of parental DNA
Once the PCR program had finished, the tubes were removed from the thermal cycler 
and placed on ice for 2 mins. 1 µL DpnI restriction enzyme (10 U.µL-1 stock) was added 
to each tube to digest the parental, non-mutated DNA. The tubes were then centrifuged 
briefly before being placed in either the water bath or dry  incubator at 37°c for 1 hr. 2 
µL DNA was then used to transform XL1-blue competent cells, mini-preps made and 
mutated DNA sent for sequencing as described above.
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2.3: Production of Recombinant Proteins
2.3.1: Principle
Recombinant proteins can be produced by transforming bacteria, specifically the BL21 
(DE3) pLysS competent E. coli strain (Stratagene), with a plasmid containing the gene 
of interest. This E. coli strain carries a chloramphenicol resistance gene, allowing for 
their selection in culture. IPTG (Isopropyl β-D-1-thiogalactopyranoside) is used to 
induce expression of the cloned gene. The bacteria are lysed and the recombinant 
protein purified using a His tag (short  sequence at  the protein N-terminus containing six 
histidine residues), which has been added to the nucleotide sequence. Recombinant 
proteins enable the analysis of protein function in in vitro assays.
2.3.2: Growth of bacterial cultures
Transformation of the BL21 (DE3) pLysS cells with the pRSET plasmid was carried out 
as detailed above for the XL1-blue cells (Section 2.2.9). The transformed cells were 
spread onto Luria agar plates containing both ampicillin and chloramphenicol, rather 
than ampicillin alone, however.
Four litres of bacterial culture were routinely  grown for one recombinant protein 
preparation. Initially four 5 mL starter cultures were set up: 5 mL LB in a 15 mL falcon 
tube, with 100 µg.mL-1 ampicillin (5 µL of 100 mg.mL-1 stock made up in water, filter 
sterilised) and 40 µg.mL-1 chloramphenicol (5 µL of 40 mg.mL-1 stock made up in 
100% ethanol). A single colony from the Luria agar plate was picked using a sterile 
pipette tip and used to inoculate one starter culture. The starter cultures were placed at 
37°c in an incubator shaker for ~6 hrs.
One starter culture was then transferred into each of four 1L glass flasks containing 200 
mL LB, 100 µg.mL-1 ampicillin and 40 µg.mL-1 chloramphenicol. The cultures were 
placed back into the incubator shaker for 16 hrs at 37°c.
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Following this incubation, glycerol stocks were made if required: 1 mL of bacterial 
culture was added to 1 mL 30% glycerol in LB (autoclaved previously) in a sterile 2 
mL screw-cap tube, and vortexed before long-term storage at -80°c.
The remainder of each of the bacterial cultures was then transferred to each of four 
flasks containing 900 mL LB with 100 µg.mL-1 ampicillin and 40 µg.mL-1 
chloramphenicol, giving 1100 mL total in each 2 L flask. These large flasks were then 
placed into the incubator shaker at 37°c for 1½ hrs.
The bacteria were then induced to begin synthesis of the recombinant protein by  the 
addition of 0.5 mM IPTG (1 mL of 500 mM stock) to each large flask. The flasks were 
returned to the incubator shaker, this time at the lower temperature of 27°c for 4-6 hrs.
The bacterial culture was next spun down in large beakers at 6000 rpm for 10 min, in a 
Sorvall RC 5B Plus ultracentrifuge using a GS-3 rotor. A total of three spins were 
required to clear the entire 4 L culture. The supernatant was discarded, and the cell 
pellets transferred into a single labelled 50 mL falcon tube. The pellet was re-suspended 
in 20 mL Sonication buffer (50 mM phosphate buffer pH 8.0 [11.65 mL 1 M 
Na2HPO4, 0.85 mL 1M NaH2PO4], 300 mM NaCl, 1% Triton X-100) with 20 µL 
DNase (Sigma-Aldrich). The tube was placed at -20°c for 16 hrs so that ice crystals 
formed rapidly to pierce the membranes and burst open the cells.
2.3.3: Purification of recombinant protein
The bacterial pellet was thawed at room temperature (2-3 hrs), divided equally  between 
two 50 mL ultracentrifuge tubes and centrifuged at  37,000 rpm for 30 mins at 4oc in a 
Kontron ultracentrifuge.
The recombinant protein was captured using its His tag on a nickel column. The column 
was prepared at room temperature: 2 mL HIS-Select Nickel Affinity  Gel (P6611, 
Sigma) was placed into a PD-10 column (Disposable Chromatography Column, Bio-
Rad Laboratories). (2 mL is the bed volume, i.e. 0.5 mL per litre of culture.) The ethanol 
was first allowed to run off of the beads, then the beads washed in 25mL Low Salt 
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buffer (50 mM phosphate buffer pH 6.0 [23.3 mL 1 M Na2HPO4, 1.70 mL 1M 
NaH2PO4], 300 mM NaCl, 10% glycerol) to remove any residual ethanol. The 
bacterial cell supernatant was placed into the column. The nozzle cap was secured with 
parafilm, the lid replaced, and the column placed onto the rotating wheel for >30 min at 
4°c for capturing of the recombinant protein.
After capturing, the nozzle cap and lid were removed from the column and excess liquid 
allowed to run off. The column was washed first in 25 mL low salt buffer, followed by 
25 mL High Salt buffer (50 mM phosphate buffer pH 6.0 [23.3 mL 1 M Na2HPO4, 
1.70 mL 1 M NaH2PO4], 525 mM NaCl, 10% glycerol). 3 mL (1.5 X bed volume) 
500 mM  Imidazole in High Salt Buffer was applied to the column and the flow-through 
collected in a clean 15 mL falcon tube. The eluted 3 mL liquid was then pipetted onto a 
Buffer Exchange column, pre-equilibrated in PIPES/salts pH 6.8 (20 mM PIPES, 137 
mM NaCl, 2.7 mM KCl). (PIPES, 1,4-Piperazinediethanesulfonic acid, P6757, Sigma-
Aldrich.) The excess liquid was allowed to run straight through as waste.
A clean 15 mL falcon tube was next  placed underneath the Buffer Exchange column. 4 
mL PIPES/salts was pipetted directly onto the column to elute the recombinant protein 
into the collection tube in PIPES/salts. Both the nickel column and buffer exchange 
column were washed and stored in PBS-azide for re-use.
The concentration of the purified recombinant protein was first assessed using the BCA 
assay (Section 2.3.4). 1.0, 2.0 and 5.0 µg of the freshly made protein were then run 
alongside 1.0, 2.0 and 5.0 µg recombinant PITPα on a SDS-PAGE gel stained with 
Coomassie dye, and the protein concentration of the new recombinant protein 
preparation adjusted accordingly, to account for impurities. The protein preparation was 
aliquoted into appropriate volumes (usually 100 µL) and stored at -80°c.
2.3.4: BCA assay for protein concentration
The Bicinchoninic Acid (BCA) kit (BCA1, Sigma-Aldrich), was used to assess protein 
concentration. Protein standard solutions were made up as indicated in Table 2.3, in 
distilled water, PBS or PIPES/salts, as appropriate, and stored at  -20°c. The assay was 
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performed in a 96-well plate. 10 µL of each standard was pipetted into plate wells in 
duplicate. Purified protein or lysate of unknown concentration was diluted (usually 
three dilutions, 1:5, 1:10 and 1:20), and 10 µL of the diluted protein pipetted onto the 
plate alongside the standards, in duplicate.
A BCA/Copper (II) sulphate solution was made by  mixing BCA solution and Copper 
(II) sulphate solution in a 50:1 ratio. 200 µL of this was pipetted into each well of the 
96-well plate containing diluted protein or protein standard. The plate was then placed 
into the dry incubator for 30 min at 37°c whilst the colour developed. The relative 
intensity of the coloured liquids was read using a plate reader at λ=540nm.
Concentration 
(mg.mL-1)
Dilution factor Sigma 
standard (μL)
Diluent (μL) Total (μL)
0.1 10 30 270 300
0.2 5 60 240 300
0.3 3.33 100 233 333
0.4 2.5 120 180 300
0.5 2 150 150 300
0.8 1.25 240 60 300
1.0 1 < 300 0 < 300
Table 2.3: BCA assay protein standards
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2.4: Co-immunoprecipitation for analysis of protein-protein interactions
2.4.1: COS-7 cell culture
COS-7 cells (cell line originally derived from African green monkey kidney cells) were 
routinely grown in Dulbecco’s Modified Eagle Medium (DMEM) cell culture medium 
supplemented with 10% heat-inactivated FCS 2 , 4 mM L-glutamine, 0.5 iu.mL-1 
penicillin and 50 µg.mL-1 streptomycin, in a T75 cell culture flask. In general, cells 
were split 1:5 for 48 hrs growth or 1:10 for 72 hrs, in a class II laminar flow cabinet.
2.4.2: Transient transfection of DNA plasmids using FuGENE HD
For immunoprecipitation experiments, COS-7 cells were seeded onto 10 cm cell culture 
plates (one per condition, 10 mL media per plate), at  a concentration of 1.0-2.0 x 105 
cells.mL-1, 6-16 hrs prior to transfection to allow the cells to adhere to the plastic.
Transfection was carried out using FuGENE HD (Roche Diagnostics). The ratio of 
plasmid DNA:transfection reagent required was determined empirically by western 
blotting of lysate derived from cells transfected with differing ratios of cDNA:FuGENE 
HD. For COS-7 cells this ratio was established to be 2:6 (Figure 2.4). For transfection 
of one well of a six-well plate, 2 µg DNA was used, along with 100 µL Opti-MEM and 
6 µL FuGENE HD. These amounts were scaled up  to 10 µg DNA, 500 µL Opti-MEM 
and 30 µL FuGENE HD for transfection of one 10 cm plate (containing 10 mL media). 
These quantities were used for each plate in an experiment, and the amount of a single 
plasmid was kept consistent throughout. An example is given in Table 2.4, for an 
experiment containing four conditions.
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2 Heat-inactivation was carried out by placing the unopened 500 mL bottle of FCS in a 
water bath at 56°c for 1 hr.
Condition Empty control 
vector 
(pcDNA3.1) (μg)
pcDNA3.1-FLAG-
RdgBβ-sp1 (μg)
pcDNA3-HA-
ATRAP (μg)
Control 10 0 0
FLAG-RdgBβ-sp1 5 5 0
HA-ATRAP 5 0 5
FLAG-RdgBβ-sp1 
+ HA-ATRAP
0 5 5
Table 2.4: Example quantities of cDNA for transfection of two or more plasmids
In preparation for transfection, plasmid DNA and FuGENE HD were warmed to room 
temperature. FuGENE HD was subjected to 1 s vortex prior to use. Opti-MEM  was 
warmed to 37°c in a water bath. Appropriate volumes of plasmid DNA were placed into 
labelled 1.5 mL eppendorf tubes. To this, the required volume of Opti-MEM  was added. 
FuGENE HD was then added to each tube by pipetting directly into the Opti-MEM (the 
undiluted transfection reagent should not be allowed to touch the sides of the tube). The 
tubes were vortexed for 2 s before incubating at room temperature for 15 min to allow 
DNA-transfection complex formation to take place. Complexes were added dropwise to 
the cell culture dishes, and the dishes returned to the incubator.
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Figure 2.4: Identification of the optimum DNA: FuGENE HD ratio
COS-7 cells were seeded into wells of a six-well plate (2 mL per well) at a 
concentration of 1.0 x 105 cells.mL-1. Transfection was carried out 6 hrs post-seeding, 
once the cells had adhered to the plastic. 2 μg pIRES2-RdgBβ-sp1 plasmid was 
transfected per well; complex formation was carried out for each with the volume of 
FuGENE HD transfection reagent indicated above the membrane (μL). One well of the 
six-well plate was transfected per condition. Control (Ctrl) are untransfected COS-7 
cells. Cells were harvested 46 hrs post-transfection, in 100 μL RIPA buffer + protease 
inhibitors per well. 40 μg cell lysate was loaded per lane of a 12% resolving gel 
alongside 40 ng recombinant His-RdgBβ-sp1. Separated proteins were transferred to 
PVDF membrane and subjected to western blotting using the anti-RdgBβ antibody 
#101.
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2.4.3: Treatment of cells with chemical compounds
Cells for immunoprecipitation experiments were harvested two days after transfection, 
i.e. 42-48 hrs, depending on the time of transfection. For treatment with chemical 
compounds, the cell culture media was aspirated and replaced with fresh media 
containing the compound at the appropriate time prior to cell harvest (Table 2.5).
Treatment name Function Concentration Time Manufacturer & Cat. No.
Angiotensin II Hormone 100 nM - 1 μM
10 
min-16 
hrs
Sigma-Aldrich 
A9525
Bisindolylmaleimide I
(BIM-I, GF 109203X)
Protein kinase C 
inhibitor
5 μM 4-16 hrs
Calbiochem 
#203290
EGF Growth factor 50 ng.mL-1 30 min
Calbiochem 
#324831
H-89 Protein kinase A inhibitor 10 μM 16 hrs
Calbiochem 
#371963
Insulin Hormone 100 nM 30 min Calbiochem #407709
Ionomycin Calcium ionophore 5 μM
1-4 
hrs
Calbiochem 
#407950
LY294002 PI 3-kinase inhibitor 10 μM 16 hrs
Calbiochem 
#440206
MG-132 (Z-leu-leu-
leu-al)
Proteasome 
inhibitor 20 μM 4 hr
Sigma-Aldrich 
C2211
PMA Phorbol ester 100 nM 1-16 hrs
Sigma-Aldrich 
P8139
Table 2.5: Chemical compounds.
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2.4.4: Cell harvest
The cell culture plates were removed from the incubator and placed on ice. The media 
was aspirated from all plates, and the cells washed twice with cold PBS. The final wash 
was removed and the cell culture plates propped at  45° to enable residual liquid to 
collect and be removed from the plate. The plates were placed horizontal again, and 1 
mL cold Buffer B (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1% 
TX-100 plus protease inhibitors (Sigma-Aldrich, P8340)), was added to each plate. 
Phosphatase inhibitors were also added to the cell harvest buffer for experiments 
examining the RdgBβ-sp1-14-3-3 interaction, since phosphorylation is required for this 
interaction. (Phosphatase inhibitor cocktail 2 for tyrosine protein phosphatases, acid and 
alkaline phosphatases, Sigma-Aldrich, P5726; phosphatase inhibitor cocktail 3 for 
serine/threonine protein phosphatases and L-isozymes of alkaline phosphatase, Sigma-
Aldrich, P0044.) The cells were scraped using a cell scraper. Again the plates were 
propped at 45° to allow the cells to collect in one place. The cells were next transferred 
to a labelled 1.5 mL eppendorf tube. The contents of the tubes were sonicated 1 x 15 s, 
then centrifuged at 10,000 rev.min-1 for 10 min at 4°c. The cleared supernatant was 
transferred to a fresh eppendorf tube, and the protein concentration of the lysate 
assessed using the BCA assay (Section 2.3.4). Typical lysate concentrations were in the 
range 1.5-2.5 mg.mL-1.
2.4.5: Treatment of cells with DSS cross-linkers prior to cell harvest
Disuccinimidyl suberate (DSS) is a chemical cross-linker. N-hydroxysuccinimide 
(NHS) ester groups at either end of a 8-carbon (11.4 Å) spacer arm react with amine 
groups (for example, on lysine residues) to form a non-cleavable bond between 
interacting proteins. DSS is membrane-permeable: cells do not have to be permeabilised 
for the compound to gain access to intracellular proteins.
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Method
A 50 mM DSS solution was freshly made up in DMSO. While the compound was 
dissolving, the cell culture dishes were placed on ice and cells washed twice with ice-
cold PBS. The final wash was replaced with 200 mM  sodium phosphate, 150 mM  NaCl 
pH 7.4 (10 mL per plate).
100 µL of the DSS solution was added to each plate to give a 0.5 mM final DSS 
concentration and 1% DMSO concentration. The cells were incubated in the DSS 
solution for 2 hrs on ice.
Excess DSS was quenched by the addition of 1.12 mL 1 M Tris-HCl pH 7.4, giving a 
final concentration of 100 mM  Tris. The cells were incubated in this solution on ice for 
15 mins.
The solution was then completely aspirated from the cell culture dishes and replaced 
with 1 mL cold Buffer B plus protease inhibitors per plate. The cells were harvested 
exactly as described in section 2.4.4.
2.4.6: Immunoprecipitation
For immunoprecipitation of HA-ATRAP via its HA tag, 300 µg lysate was added to 1.5 
µg anti-HA monoclonal antibody (7.5 µL HA-probe (F-7) 200µg.mL-1 stock, Santa cruz 
(sc-7392) (mouse IgG2a)) in a 1.5 mL eppendorf tube, and the tubes placed on the 
rotating wheel at 4°c for 1 hr for protein capture by the antibody. Meanwhile, 20 µL 
Protein A/G PLUS-Agarose (Santa cruz, sc-2003) in a fresh tube was washed twice in 
500 µL Buffer B (10,000 rev.min-1 for 2 min at 4°c). The supernatant was removed by 
aspiration following each centrifugation. The lysate/antibody tubes were removed from 
the rotating wheel and centrifuged, 10,000 rev.min-1 for 2 min at 4°c. The lysate/
antibody was then transferred to the prepared Protein A/G PLUS-Agarose tube. These 
tubes were then placed onto the rotating wheel for 1 hr at 4°c for capture of the antibody 
Fc region by the Protein A/G.
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Alternatively, for immunoprecipitation of RdgBβ via its FLAG tag, anti-FLAG antibody 
was used, already conjugated to beads (ANTI-FLAG M2 Affinity Gel (Sigma A2220)). 
40 µL ANTI-FLAG M2 Affinity  Gel per immunoprecipitation was washed twice in 500 
µL Buffer B (10,000 rev.min-1 for 2 min at 4°c), prior to the addition of 300 µg lysate to 
each tube. The tubes were then placed onto the rotating wheel for 2 hr at  4°c for capture 
of the FLAG-tagged protein by the ANTI-FLAG M2 affinity gel.
In both cases, if the volume of 300 µg lysate was less than 100 µL, 50-100 µL Buffer B 
was added to the tube to ensure the beads were able to move around adequately during 
the capturing step. Following the capturing step(s), the tubes were centrifuged at 10,000 
rev.min-1 for 2 min at 4°c. The supernatant  (unbound protein) was aspirated carefully. 
The beads were washed three times in 500 µL Buffer B, with the final wash transferred 
to a fresh eppendorf tube to eliminate any protein which may have adhered to the side 
of the tube. The final wash was aspirated, and the beads boiled at 95°c for 10 min in 20 
µL 2X SDS-PAGE sample buffer. The immunoprecipitates were then loaded onto an 
SDS-PAGE gel for analysis of potential protein-protein interactions by western blotting.
2.5: SDS-PAGE Gel Electrophoresis and Western Blotting
2.5.1: Principle
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique used to separate proteins according to their mass. Protein samples are boiled 
in sample buffer containing SDS and β-mercaptoethanol to denature the proteins. SDS 
binds tightly and evenly to the uncoiled polypeptide chain so that the charge-density 
along its length is approximately equal. The reducing agent β-mercaptoethanol breaks 
disulphide bonds, disrupting protein tertiary  structure. SDS is also present throughout 
the gel and running buffer, ensuring the proteins remain as denatured monomers.
The gel may  be stained with a Coomassie stain for visualisation of all the proteins 
present on the gel (typically for µg purified protein), or the proteins may be transferred 
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to PVDF membrane to enable the detection of a single protein of interest using a 
primary antibody raised against that protein, in a process known as western blotting.
2.5.2: Pouring SDS-PAGE gels
For my experiments, the SDS-PAGE gels were cast in Bio-Rad mini-gel casting 
apparatuses. Glass plates (one small and one large piece of glass per gel) with minimal 
chips were placed on absorbent tissue paper and the side to be in contact with the gel 
wiped clean first with distilled water, and then with 70% ethanol. The comb and 1.5 mm 
spacers (for a gel 1.5 mm thick) were similarly cleaned before assembly of the gel 
cassette.
The resolving gel mixture was made up  first. The percentage of acrylamide in the 
resolving gel dictates how fast the gel will run, and different acrylamide percentages 
may be chosen depending on the size of protein that needs to be resolved. The larger the 
protein of interest, the lower the percentage of acrylamide in the resolving gel. In this 
thesis I typically  used an 8% gel to resolve ubiquitin, and 12% resolving gels mostly  for 
all other proteins (RdgBβ, ATRAP, PITPα, PITPβ, ARF, 14-3-3) - occasionally 10% for 
resolution of RdgBβ. Table 2.6 details the volumes of stock solutions required to make 
8, 10 or 12% resolving gels. The gel mixture was made up in a small glass flask. The 
APS and TEMED were added immediately prior to gel pouring since these are the 
ingredients that make the gel set. The gel mixture was applied between the two glass 
plates using a disposable plastic pasteur pipette, up to 1 cm below where the edge of the 
comb would reside. To this, 1 mL isobutanol saturated with water was added to exclude 
oxygen from the gel. The resolving gel was left  on the bench at room temperature for 
~30 mins to set.
Once the resolving gel had set, the isobutanol was tipped from the apparatus, and the 
top of the gel washed using a wash bottle containing distilled water. Residual water was 
removed using blotting paper. Next, the stacking gel mixture was made up (Table 2.7), 
and applied between the glass plates on top of the resolving gel, without delivery of any 
air bubbles. The 10- or 15-well comb was then positioned in the stacking gel, and the 
gel allowed to set for > 45 min at room temperature.
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Once the gel had set, the gel cassette was removed from the casting apparatus and 
clipped into the electrode assembly, one gel on each side (or one gel and one empty 
cassette). The electrode assembly with gel cassettes was subsequently  placed into the 
Bio-Rad mini-protean tank and the combs removed from the gels.
SDS-PAGE running buffer (25 mM Tris-HCl pH 8.3, 193 mM glycine, 0.1% SDS; 
typically 10X stock solution stored at RT) (800 mL per min-protean tank) was poured 
into the tank, filling the inner tank between the electrodes first, encouraging air bubbles 
to escape from the sample wells in the process. Running buffer was then poured into the 
lower tank, and the gels were now ready for loading of the protein samples.
Acrylamide (%)
8 10 12
ddH2O 8.0 mL 7.25 mL 6.50 mL
Acrylamide 3.0 mL 3.75 mL 4.50 mL
1.5 M Tris-HCl pH 8.8 3.75 mL 3.75 mL 3.75 mL
10% (w/v) SDS 150 μL 150 μL 150 μL
10% (w/v) APS 120 μL 120 μL 120 μL
TEMED 12 μL 12 μL 12 μL
Table 2.6: SDS-PAGE resolving gel recipe
Volume of solutions required for two mini-gels (15.0 mL) using 40% acrylamide solution 
(BP14021, Fisher Scientific). APS, ammonium persulphate; TEMED, N,N,N',N'-
tetramethylethylenediamine.
111
ddH2O 3.80 mL
Acrylamide 0.60 mL
1.5 M Tris-HCl pH 8.8 1.50 mL
10% (w/v) SDS 60 μL
10% (w/v) APS 24 μL
TEMED 6 μL
Table 2.7: SDS-PAGE stacking gel recipe
Volume of solutions required for two mini-gels.
2.5.3: SDS-PAGE sample buffer
Prior to loading onto an SDS-PAGE gel, an appropriate volume of sample buffer was 
added to the protein sample to produce a final concentration (i.e. 1 X) of 10% (v/v) 
glycerol, 62.5 mM Tris-HCl pH 6.8, 2% SDS, 80 µg.mL-1 bromophenol blue, 5% β-
mercaptoethanol. SDS-PAGE sample buffer was typically made as 10 mL of 2X and 
4X solution, which gives 20 x 500 µL aliquots. Aliquots were stored at -20°c. Tris-HCl 
pH 6.8 was kept at 4°c as a 1 M stock solution. Bromophenol blue stock was kept at 
room temperature as a 5 mg.mL-1 slurry in ddH2O, and vortexed well before use.
The protein sample was boiled in sample buffer at 95°c for 10 min prior to loading onto 
the gel. Samples were loaded alongside 10 µL molecular weight markers to allow the 
determination of protein molecular weight, e.g. SeeBlue Plus2 Pre-Stained Standard 
(Invitrogen), SpectraTM Multicolor Broad Range Protein Ladder (SM1841 or SM1842, 
Fermentas), or PageRulerTM Plus Prestained Protein Ladder (SM1811 or SM1812, 
Fermentas). Samples, particularly for western blotting, were loaded in the reverse order, 
i.e. from right to left.
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2.5.4: SDS-PAGE running conditions
Once the protein samples had been loaded, the gel was run at 130 V for 90-95 mins or 
until the dye front reached the desired point on the gel or fell off of the end of the gel. 
The apparatus was dismantled. The stacking gel was carefully cut from the rest of the 
gel using the edge of a spacer, then placed into either distilled water for Coomassie 
staining or blotting buffer for western blotting.
2.5.5: Gradient gels
For resolution of proteins of a range of molecular weights, NuPAGE Novex 4-12% Bis-
Tris Gel 1.5mm, 10 well (Invitrogen, NP0335), were used in an XCell SureLock 
MiniCell. The apparatus was assembled following the manufacturer’s instructions. The 
gel was run at 200 V for 35 mins, in NuPAGE MES SDS Running Buffer (Invitrogen, 
NP0002).
2.5.6: Coomassie staining of gels
Coomassie blue stain (0.1% (w/v) Coomassie blue R250, 40% methanol, 10% acetic 
acid, 50% distilled water) and destain (40% methanol, 10% acetic acid, 50% 
distilled water) were made up  in 2 L amber bottles and stored at room temperature. The 
SDS-PAGE gel was washed briefly in distilled water in a small plastic box prior to the 
addition of the Coomassie stain. Clingfilm was used to cover the box. The gel was then 
either: (a) incubated in stain overnight at room temperature on a rocker, followed by  a 
brief wash in distilled water, then incubated in destain during the next day (with a small 
piece of sponge to aid in the removal of the stain); or (b) microwaved in stain for ~40 s 
to encourage the gel to take up the solution more easily, incubated in the stain at room 
temperature for 20 min, given a brief wash in distilled water, followed by incubation in 
destain at room temperature overnight without rocking.
Once the destaining was complete, by either method, the gel was re-hydrated in distilled 
water, the protein bands imaged using a Fujifilm LAS-3000 imaging device, and 
quantified using AIDA software. Where appropriate, an unpaired t test was carried out 
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as an assessment of statistical significance, using the GraphPad QuickCalcs tool (http://
www.graphpad.com/quickcalcs/).
2.5.7: Protein transfer to PVDF membrane
Proteins separated by  SDS-PAGE were transferred to PVDF membrane by the 
application of an electric field across the blotting sandwich. A piece of PVDF 
membrane was cut to an appropriate size (7 x 10 cm) and activated in methanol for 5 
min before equilibration in Blotting buffer (25 mM Tris-HCl pH 8.3, 192 mM, 10% 
methanol). Blotting buffer was typically  stored as a 10X solution: 250 mM Tris-HCl 
pH 8.3, 1.92 M  glycine, with 10% methanol added upon dilution to a 1X solution. 800 
mL chilled Blotting buffer was required per mini-protean tank. The SDS-PAGE gel 
(home-made or pre-cast), blotting cassette, sponges and blotting paper were all 
equilibrated in Blotting buffer prior to assembly of the blotting sandwich.
The blotting sandwich was assembled in a large plastic box containing 1-2 cm blotting 
buffer. The plastic cassette was placed in the box first, with the outer side of the black 
leaflet face down. One sponge followed by one piece of blotting paper was placed onto 
the black leaflet. The gel was placed onto the blotting paper next with the ‘front’ of the 
gel (that which faced the inner chamber during SDS-PAGE) facing up so that the 
molecular weight markers were on the right. The PVDF membrane was placed on top of 
the gel and rolled over with a section of a 10 mL tube pipette to eliminate air bubbles. 
The second piece of blotting paper was placed on top of the membrane, rolled again, 
and then the second sponge completed the blotting sandwich. The sandwich was placed 
inside the blot transfer unit, with the black leaflet of the sandwich facing the black side 
of the blot transfer unit, alongside a second sandwich or blank plastic cassette, inside a 
Bio-Rad Mini Protean tank. A small magnetic stirrer was placed into the tank, and an ice 
block placed alongside the blot transfer unit in the tank. The tank was then placed onto a 
magnetic stirring device, which was turned on. Blotting buffer was poured into the tank, 
to the top. It was important that the membrane was not allowed to dry out at any point.
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The lid was placed onto the tank, with the electrodes appropriately aligned and 
connected to the power pack. Blot transfer was carried out at 20 V for 16 hrs or 100 V 
for 60 min.
2.5.8: Western blotting
Blocking
Once blot transfer was complete, the blotting apparatus was dismantled. The membrane 
was cut at this point  to the size of the gel while it  was still in place, before being 
submerged in phosphate-buffered saline-0.02% tween (PBS-T) or Tris-buffered 
saline-0.02% tween (TBS-T) in a small plastic box. In general, cold PBS-T was used for 
the western blots in this thesis, whilst cold TBS-T was used for Far Western blotting 
(Section 2.5.11). (PBS: 20 mM phosphate buffer pH 7.0 [10 mM Na2HPO4, 2 mM 
KH2PO4], 300 mM NaCl or 1 tablet dissolved in 200 mL distilled water (P4417, Sigma-
Aldrich) = 10 mM phosphate buffer pH 7.4, 2.7 mM KCl, 137 mM NaCl.)
The membrane was then stained in indian ink (1:1000 dilution in PBS-T) for 10 min or 
until the protein bands appeared. Excess ink was washed from the membrane by a brief 
wash in PBS-T. The membrane was then blocked in 5% milk-PBS-T for 1 hr RT on the 
platform rocker.
Primary antibody incubation
After blocking, the membrane was placed inside a 50 mL falcon tube (one membrane 
per tube) for subsequent antibody  incubations. The appropriate primary antibody was 
diluted in PBS-T as indicated in Table 2.8 (5 mL per membrane), and the membrane 
incubated in antibody on a tube roller for 2 hrs at room temperature or 16 hrs at 4°c.
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Antigen Name Manufacturer/
Cat. No. or ref.
Species Dilution for 
WB
Typical quantity 
of lysate loaded 
onto gel (μg)
14-3-3 pan 
14-3-3 
(K-19)
Santa Cruz 
Biotech., sc-629
Rabbit 1:1000 3-5
ARF1 ARF, 
#678
Skippen et al., 
2002
Rabbit 1:2000 
(affinity 
purified)
10-12
FLAG DDK OriGene 
Technologies, 
TA50011
Mouse 1:2000 or 
1:5000 for 
IP: FLAG re-
probe
10-15
(FLAG-RdgBβ-
sp1)
FLAG OctA 
(D-8)
Santa Cruz 
Biotech., sc-807
Rabbit 1:500 10
(FLAG-RdgBβ-
sp1)
HA HA-
probe 
(F-7)
Santa Cruz 
Biotech., 
sc-7392
Mouse 1:1000 or 
1:5000 for 
IP: HA re-
probe
3-5
(HA-ATRAP)
PITPα 674 Morgan et al., 
2004
Rabbit 1:1000 
(affinity 
purified)
15
PITPβ 1C1 Morgan et al., 
2006
Mouse 1:1000 
(affinity 
purified)
15
RdgBβ 101 Garner et al., 
2011
Rabbit 1:1000 
(serum)
(30-50 ng 
recombinant 
protein)
Ubiquitin Ub Sigma-Aldrich, 
U5379
Rabbit 1:100 (IP only)
Table 2.8: Primary antibodies used for western blotting
Antibodies raised in mouse are monoclonal; those raised in rabbit are polyclonal.
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Primary antibody detection
After incubation with primary antibody, the membrane was washed with PBS-T three 
times for 5 mins each on the tube roller. Protein A conjugated to horseradish peroxidase 
(Protein A-HRP) (14-50-00, Kirkegaard & Perry Laboratories (KPL)) was used as the 
‘secondary antibody’, at 1:2500 dilution in 5% milk-PBS-T. Protein A is a 
Staphylococcus aureus protein that recognises antibody in its native (tertiary) structure 
but not denatured antibody eluted from an IP (Lal et al., 2005). An immunoprecipitate 
run on a western blot displays characteristic heavy chain (~50 kDa) and light chain (~25 
kDa) antibody  bands, which can be a menace if the protein of interest is either of those 
sizes. 
Blot exposure and imaging
Following secondary antibody incubation, the membrane was washed three times with 
PBS-T for 5 min each on the tube roller. For exposure, the membrane was placed into a 
plastic pocket cut to size with a single edge binding the two leaflets. 0.5 mL of each 
ECL or ECL Advance solution (ECL Western Blotting Detection Reagents, GE 
Healthcare) was mixed together and pipetted onto each membrane so that it  was 
completely covered. The top leaflet of the plastic pocket was placed over the membrane 
(being careful not to trap any air bubbles against the membrane), and the membrane 
incubated in the solution for one minute. Excess liquid was then squeezed out from the 
pocket and from the membrane using absorbent paper. The chemoluminescence was 
measured using a LAS-3000 imaging system. Protein bands were quantified using 
AIDA software.
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2.5.9: Stripping of western blots for re-probing
For re-probing, the western blot membrane was rinsed with PBS-T, then heat-sealed 
into a polythene bag along with 10 mL Stripping buffer (0.2 M glycine-HCl pH 2.5, 
0.05 % tween-20, 100 mM β-mercaptoethanol). The bag was immersed horizontally 
in a water bath pre-heated to 80°c for 20 mins. After incubation, the membrane was 
removed from the polythene bag into a small sandwich box containing PBS-T. The 
membrane was washed several times with PBS-T to remove the stripping buffer. The 
membrane was now ready for blocking in 5% milk-PBS-T and probing with primary, 
then secondary antibody, as described above.
2.5.10: Far western blotting
Far western blotting is an adaptation of western blotting, used for analysis of direct 
protein-protein interactions. The method used is as described by Moorhead and 
colleagues (Moorhead et al., 1999), and the reagents were a generous gift  from Prof. 
Carol MacKintosh (MRC Protein Phosphorylation Unit, University of Dundee).
Immunoprecipitates (Section 2.4) were separated by SDS-PAGE as described above, 
and transferred to PVDF membrane. Longer blot transfer was preferred here (20 V, 16 
hrs), to allow the proteins to renature and re-acquire their tertiary structure. The blot 
transfer apparatus was then dismantled, and the membrane transferred to a small plastic 
box containing TBS-T (20 mM  Tris-HCl pH 7.4, 150 mM NaCl, 0.02% tween-20). The 
membrane was stained with indian ink (1:1000 dilution in TBS-T), and then blocked in 
5% BSA-TBS-T for 1 hr RT.
The membrane was washed briefly  in TBS-T before being transferred to a 50 mL falcon 
tube for all subsequent washes and incubations at room temperature on a tube roller. 
Here, the membrane was incubated with 1 µg.mL-1 recombinant 14-3-3 with a 
digoxigenin (DIG) tag - BMH1 and BMH2 Saccharomyces cerevisiae 14-3-3 isoforms - 
in 5% BSA-TBS-T for 2 hrs.
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The membrane was next washed in TBS-T three times for 5 min each time, before 
incubation with anti-DIG antibody  Fab fragments conjugated to HRP (DIG-HRP) in 
TBS-T (1:2500 dilution), for 45 mins. Three 5 min washes followed this, and the 
protein bands exposed using ECL reagents as for western blotting.
2.5.11: Trypsin digestion of recombinant RdgBβ protein
100 µg recombinant RdgBβ-sp1 or -sp2 (in 500 µL) was incubated with 5 µL trypsin-
EDTA solution (Sigma-Aldrich, T3924) at 37°c. 50 µL (10 µg) aliquots were removed 
directly  into SDS-PAGE sample buffer at 0, 2, 5, 10 min. Trypsin digestion was carried 
out by Michelle Li.
2.5.12: Cycloheximide treatment of transiently-transfected cells
COS-7 cells grown on 16 x 3.5 cm cell culture dishes (2 mL media per dish) were 
transiently  transfected. Two days later, the cell culture media was aspirated and replaced 
with fresh media containing 100 µg/ml cycloheximide (CHX). After 0, 2, 4 or 6 hrs the 
media was removed and the cells washed twice in PBS. The cells were harvested in 300 
µL RIPA buffer per well (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100 
(v/v), 0.5% sodium deoxycholate (w/v), 0.1% SDS (w/v), protease inhibitors) and 
incubated on ice for 30 min. The tubes were centrifuged 12,000 rev.min-1 for 15 mins at 
4°c, and the supernatant transferred to a fresh tube. The BCA assay  was used to assess 
the protein concentration of the lysates. 50 µg protein was boiled with SDS-PAGE 
sample buffer and loaded per lane of the gel. The cycloheximide experiments presented 
in this thesis were carried out by Michelle Li.
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2.5.13: In vitro PKC phosphorylation assay
The method used was based on that described in Morgan et al., 2006. Reaction mixtures 
were prepared in 50 µL (in 1.5 mL eppendorf tubes) on ice:
 20 µL RdgBβ-sp1 or -sp2 (10 µg, diluted in PIPES/salts, pH 6.8).
 10 µL PKC* (350 ng) or 4 µL 2.5X buffer + 2 µL dH20 for control.
 20 µL 2.5X buffer, 100 µg.mL-1 PS, 10 µg.mL-1 DAG + 100 µM Mg-ATP.
* PKC purified from rat brain (Calbiochem #539494), predominantly the conventional 
isoforms, α, β1, β2 and γ. Concentration: 35 µg.mL-1 in 20 mM  Tris-HCl pH 7.5, 100 
mM NaCl, 500 µM  EDTA, 500 µM EGTA, 1 mM DTT, 10% glycerol. Stock activity: 
1600 U.mg-1 protein.
2.5X buffer: 50 mM Tris-HCl pH 7.5, 12.5 mM MgCl2, 500 µM CaCl2.
The following lipids were dried down under nitrogen gas and sonicated until dissolved 
in 1 mL 2.5X buffer:
 250 µg PS (25 µL of 10 mg.mL-1 stock).
 25 µg DAG (2.5 µL of 10 mg.mL-1 stock).
250 µM Mg-ATP was next added to the 1 mL sonicated lipids (2.5 µL of 0.1 M stock).
Final reaction conditions:
 10 µg RdgBβ
 350 ng rat brain PKC
 20 mM Tris-HCl pH 7.5
 5 mM MgCl2
 200 µM CaCl2
 100 µM Mg-ATP
 100 µg.mL-1 PS
 10 µg.mL-1 DAG
RdgBβ-sp1 or -sp2 was incubated -/+ rat  brain PKC for 1 hr at 30°c in a water bath. The 
reaction was quenched by the addition of 16.67 µL of 4X SDS-PAGE sample buffer. 
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The tubes were vortexed, then boiled at 95°c for 10 mins. Following SDS-PAGE buffer 
addition, the concentration of RdgBβ was 150 µg.mL-1.
2.5.14: Reconstitution of the RdgBβ-14-3-3 interaction in vitro
Assay conditions:
 120 µg recombinant PITP protein (RdgBβ-sp1/PITPα) (200 µg.mL-1)
 1 mM Mg-ATP
 0.4 iu.mL-1 SLO
 100 nM Ca2+ (pCa7) or 10 µM Ca2+ (pCa5)
 +/- 100 nM PMA
The assay was prepared in 1.5 mL eppendorf tubes on ice, in a total volume of 600 µL. 
The components were added in the following order:
 100 µL RdgBβ-sp1/PITPα
 400 µL HL60 cells * + Mg-ATP
 50 µL PMA or buffer for control
 50 µL SLO + pCa7 or pCa5
* 60 mL HL60 cells (60 x 106 cells) were washed twice in 50 mL PIPES buffer and re-
suspended in 2.4 mL PIPES. 
The tubes were vortexed briefly, and then incubated in the waterbath at 37°c for 20 min. 
Immediately  following the incubation, the assay  tubes were centrifuged at 3000 
rev.min-1 for 5 min at 4°c. 550 µL supernatant was then transferred to a fresh eppendorf 
tube and centrifuged again, at 12,000 rev.min-1 for 15 min at 4°c.
Of this >500 µL supernatant:
• 100 µL was transferred into a 1.5 mL eppendorf tube containing 40 µL nickel beads 
(HIS-select nickel affinity gel, Sigma-Aldrich, P6611) which had been washed twice 
in 500 µL PIPES/salts pH 6.8 buffer, at 10,000 rev.min-1 2 min 4°c (i.e. as for Co-IPs).
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• 400 µL was transferred to a mini-spin column containing 120 µL nickel beads that had 
been washed twice in 500 µL PIPES/salts pH 6.8 buffer, at 3,000 rev.min-1 5 min 4°c 
(as for the Lipid Binding assay, Section 2.8.2).
In addition, 100 µL PIPES/salts pH 6.8 buffer was added to each tube or mini-spin 
column. The lids were then replaced and the eppendorf tubes and mini-spin columns 
placed onto the rotating wheel at 4°c for 1 hr re-capturing of the His-tagged 
recombinant proteins. After the 1 hr re-capturing, the nickel beads in the eppendorf 
tubes were washed three times in 500 µL PIPES/salts buffer, with the final wash 
transferred to a fresh eppendorf, exactly as for immunoprecipitation. The captured 
proteins were eluted in 20 µL 2X SDS-PAGE sample buffer. After boiling at 95°c for 10 
min and a brief centrifuge (2 min 12,000 rev.min-1), the full volume of supernatant was 
applied to an SDS-PAGE gel. Meanwhile, the nickel beads in the mini-spin columns 
were washed twice in 500 µL low salt buffer, followed by twice in 500 µL high salt 
buffer. The captured proteins were then eluted in 500 µL imadazole and buffer 
exchanged to 1 mL PIPES/salts pH 6.8 buffer. 45 µL of this purified protein was boiled 
with 15 µL 4X SDS-PAGE sample buffer, 50 µL of which was run on an SDS-PAGE 
gel.
2.6: PLC assay in intact cells
This assay was carried out in three different cell types/systems: HEK-293 cells  (Human 
embryonic kidney cell line, ATCC No. CRL-1573) transiently transfected with 
pcDNA3.1-HA-AT1R, COS-7 cells transiently transfected with pcDNA3.1-HA-AT1R, 
and HEK-293 stably  expressing the Angiotensin II type 1 receptor (AT1R, FLAG-
tagged) (HEK-293-AT1 cells). The former two cell types were co-transfected with 
pcDNA3.1-FLAG-RdgBβ-sp1 and/or pcDNA3-HA-ATRAP alongside pcDNA3.1-HA-
AT1R. HEK-293 and HEK-293-AT1 cells were seeded onto cell culture dishes pre-
coated with poly-L-lysine solution and transfected using TurboFect  reagent. COS-7 
cells were seeded directly  into the cell culture dishes and transfected with FuGENE HD 
as detailed in Section 2.4.2. COS-7, HEK-293 and HEK-293-AT1 cells were all 
routinely grown in DMEM media supplemented with 10% HI FCS, 4 mM  L-glutamine, 
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0.5 iu.mL-1 penicillin and 50 µg.mL-1 streptomycin, in a T75 cell culture flask. The 
HEK-293 cells had a doubling time of ~10 hrs, and therefore were split 1:3 for 24 hrs 
growth, 1:10 for 48 hrs or 1:15-1:20 for 72 hrs growth. By contrast, HEK-293-AT1 cells 
grew much slower, with a doubling time of ~24 hrs, and so were split  1:2 for 24 hrs, 1:5 
for 48 hrs or 1:10 for 72 hrs growth.
HEK-293-AT1 cells were a generous gift  from Dr. Tamas Balla, NIH, Bethesda, USA. In 
order to maintain the stable AT1R expression, HEK-293-AT1 cells were grown in 
DMEM  supplemented with 10% heat-inactivated FCS, L-glutamine, penicillin, 
streptomycin and 500 µg.mL-1 G-418 (Geneticin) during routine culture but not when 
cells were set up for experiments.
2.6.1: Coating of cell culture plates with poly-L-lysine solution
200 µL 0.01% poly-L-lysine solution (P4832, Sigma-Aldrich) was placed into each well 
of a six-well plate. The plate was placed into the incubator at 37°c for a minimum of 1 
hr for coating. When required, the plate was removed from the incubator and solution 
aspirated.
Cells of the appropriate type were trypsinised and counted, and seeded into the 
appropriate number of wells of a six-well plate, in triplicate, at 2.0 x 105 cells.mL-1. 
Seeding of cells was carried out 6-16 hrs prior to transfection, to ensure the cells had 
adhered to the substratum prior to transfection.
2.6.2: Transfection of HEK-293 cells with TurboFect
As for FuGENE HD transfection, Opti-MEM  was warmed to 37°c in a water bath, 
whilst the cDNA and TurboFect (Fermentas #R0531) were used at room temperature. 
The TurboFect reagent was vortexed for 2 s before use. The ratio of TurboFect to 
cDNA for use in HEK-293 cells was determined as for FuGENE HD, and like FuGENE 
HD, was determined as 2:6.
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For each well of a six-well plate (35 mm diameter), 2 µg plasmid DNA was placed into 
a labelled 1.5 mL eppendorf. To this, 200 µL Opti-MEM was added, followed by  6 µL 
TurboFect, which was pipetted directly  into the Opti-MEM to prevent it from touching 
the plastic of the eppendorf tube. The tube was vortexed immediately, and then 
incubated at room temperature for 15-20 mins to enable complex formation to take 
place. The cDNA-transfection reagent was then added drop-wise to the appropriate well 
of the cell culture plate. The plate was returned to the incubator, 42-48 hrs prior to the 
experiment.
2.6.3: Labelling the cells with [3H]-inositol
The next day, the media were aspirated from the wells and replaced with M199 medium 
supplemented with 1% HI dialysed FCS, 4 mM L-glutamine, 0.5 iu.mL-1 penicillin, 50 
µg.mL-1 streptomycin and 2-5 µCi.mL-1 [3H]-inositol (ART 0116A, American 
Radiolabeled Chemicals, Inc.). The amount of radioactivity added was dependent on the 
age of the radioactive stock, since the inositol itself had been observed to degrade over 
time. M199 medium contains low inositol, and dialysis removes small molecules, 
including inositol, from the FCS. The cell culture plates were returned to the incubator 
for 24 hrs labelling.
For cells pre-treated with PMA, the time for labelling with [3H]-inositol was reduced to 
16 hrs and was carried out  in conjunction with 100 nM  treatment, in M199 medium 
supplemented with 1% HI dialysed FCS, 4 mM L-glutamine, 0.5 iu.mL-1 penicillin, 50 
µg.mL-1 streptomycin. For the PMA-pre-treated cells, PMA was maintained in the 
HEPES buffer throughout the experiment: in the washes and in the buffer containing 
Angiotensin II for stimulation.
2.6.4: PLC assay
HEPES  buffer (also known as Tyrodes buffer; 20 mM HEPES pH 7.2 (H9136, 
Sigma-Aldrich), 137 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 5.6 mM 
glucose, 1 mg.mL-1 BSA),  was made fresh on the day of the experiment and warmed to 
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37°c in a dry  incubator; methanol was chilled in a Duran bottle on ice. For the PLC 
assay, HEPES buffer was supplemented with 10 mM LiCl throughout the experiment.
The cell plates were removed from the incubator, briefly  viewed under the microscope 
to gauge health, and then washed twice in HEPES/LiCl buffer. The final wash was 
replaced with 1.5 mL buffer per well, and the plate placed at 37°c for 20 min to 
equilibrate. Meanwhile, the stimulant was prepared at room temperature at 4X 
concentrated, in a volume of 500 µL per well.
Once equilibrated, the 500 µL stimulant was added to the 1.5 mL buffer already present 
in each well of the six-well plate, as appropriate, and the plates returned to the incubator 
for the required amount of time.
A number of 15 mL solvent tubes were labelled, one for each well. Immediately  after 
the stimulation step, the cell culture plates were removed from the incubator and placed 
on ice. The solution was completely  aspirated from each of the wells and replaced with 
500 µL cold methanol to quench the cells.
The cells were then scraped from each well using a cell scraper. An additional 500 µL 
methanol was added following scraping, rinsing the cell scraper in the process. The 1 
mL methanol/cells was transferred to the appropriate solvent tube. The cell scraper was 
wiped on absorbent tissue between wells.
900 µL distilled water, followed by 1 mL chloroform, was added to the methanol/cells 
in each of the solvent tubes, and the tubes vortexed for 5 s. The tubes were next 
centrifuged at room temperature, 2,000 rev.min-1 for 10 mins to separate the aqueous 
and lipid phases. The top, aqueous phase was clear by completion of the centrifugation.
Isolation of the inositol phosphates using Dowex columns
Dowex columns constituted Dowex 1 x 8 anion exchange resin in a glass Pasteur 
pipette. These short columns were regenerated at the beginning of each experiment by 
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washing three times with 2 mL 2 M ammonium formate/0.1M formic acid, followed by 
3-5 washes with 2 mL distilled water.
1 mL of the aqueous layer from each solvent tube was loaded onto a prepared Dowex 
column, and the liquid allowed to run through. This 1 mL was of a possible 2 mL, and 
was taken into account in the data analysis.
The columns were then washed with 6 mL distilled water (3 x 2 mL) to elute unbound 
[3H]-inositol, followed by 6 mL 5 mM sodium tetraborate/60 mM  sodium formate to 
elute glycerophosphoinositol.
The columns were now transferred to large scintillation vials, and the total inositol 
phosphates eluted by the application of 3 mL 1 M  ammonium formate/0.1 M  formic 
acid to each column, 1 mL at a time. When the elution was complete, 5 mL UltimaFLO 
scintillation fluid was added to each vial, and the radioactivity  contained within the 
vials counted using the liquid scintillation counter. 
The entire lower chloroform layer from each solvent tube (~900 µL) was removed to a 
small scintillation vial, and the lipids dried using the Savant SpeedVac (~30 min). 100 
µL methanol was placed into each of these vials to re-solubilise the lipids, followed by 3 
mL Ultima GOLD scintillation fluid. The vials were vortexed and the radioactivity 
contained within them counted using the liquid scintillation counter.
Data analysis
A mean of the triplicate inositol phosphate values was calculated (dpm) and expressed 
as a proportion of the inositol phosphates produced in control-transfected cells treated 
with the same stimulation. This enabled multiple experiments to be combined. Where a 
single experiment was carried out (n=1), error bars are not shown; for n=2, error bars 
are standard deviation; and for n≥3, standard errors are given.
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2.7: Lipid binding assay
2.7.1: Principle
In order to monitor the binding of lipids by  PITPs, HL60 cells were metabolically 
labelled with [14C]-acetic acid to label all lipids. The cells were permeabilised with 
SLO, which binds to cholesterol. SLO monomers diffuse laterally in the membrane and 
oligomerise with one another to form large transmembrane pores that can reach up to 35 
nm in diameter. These pores allow the passage of proteins up  to 100 kDa in size (Walev 
et al., 2001), including PITPs, without affecting the structural integrity of the cell. This 
assay required that the recombinant PITPs carried out a single round of membrane 
docking and lipid exchange to pick up  a radioactive lipid. The proteins were then re-
captured using their His-tag, lipids extracted using Chloroform-Methanol, and the lipids 
resolved using thin layer chromatography (TLC).
2.7.2: HL60 cell culture
HL-60 cells (ATCC No. CCL-240) were routinely grown in suspension in 40 mL 
RPMI-1640 medium (Sigma-Aldrich, R0883), supplemented with 11.5% HI FCS, 4 
mM L-glutamine, 0.5 iu.mL-1 penicillin and 50 µg.mL-1 streptomycin in a T75 cell 
culture flask. Cells were re-suspended before splitting by gently pipetting up and down. 
Confluent cells are 1 x 106 cells.mL-1, and were not diluted beyond 1 x 105 cells.mL-1. 
The doubling time of HL60 cells is ~24 hrs, and so they were split  1:4 for 48 hrs 
growth, to 0.25 x 106 cells.mL-1 (i.e. 10 mL confluent cells added to 30 mL fresh 
media), or 1:8 for 72 hrs growth, to 0.125 x 106 cells.mL-1. All cell culture was carried 
out under aseptic conditions in a class II laminar flow cabinet.
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2.7.3: Radionucleotide labelling of HL60 cells
[14C]-acetic acid, [3H]-choline and [3H]-ethanolamine
Unless otherwise indicated, 10 mL confluent  HL60 cells (107 cells) were required per 
assay volume on the day of the experiment. For [14C]-acetic acid or [3H]-choline 
([methyl-3H]-choline chloride) labelling, the required volume of cells in normal growth 
media (RPMI-1640, 11.5% HI FCS, 4 mM  L-glutamine, 0.5 iu.mL-1 penicillin and 50 
µg.mL-1 streptomycin) was supplemented with 1 µCi.mL-1 (37 kBq.mL-1) radioactivity 
for 48-72 hrs growth prior to the experiment. For [3H]-ethanolamine-labelling, the 
concentration of radioactivity was increased to 10 µCi.mL-1, for 72 hrs growth.
[3H]-sphingosine
40 x 106 HL60 cells were centrifuged at 1,300 rev.min-1 5 min RT. The cell pellet was 
washed once in 40 mL PBS before resuspension in 40 mL unsupplemented RPMI-1640 
media, 2% BSA (from a 30% sterile fatty  acid-free stock solution) and 0.1 µCi.mL-1 
(3.7 kBq.mL-1) sphingosine, D-erythro [3-3H] (ARC (UK)). The cells were returned to 
the incubator for 24 hrs labelling prior to the lipid binding experiment.
For the experiment in which HL60 cells were labelled with different radionucleotides, 
and the extracted lipids run alongside one another on a TLC plate, 20 mL HL60 cells 
were labelled with [3H]-sphingosine in supplemented RPMI-1640 growth media.
[3H]-palmitic acid
[3H]-palmitic acid is stored in toluene (methyl benzene), which must be removed prior 
to addition to the cells. The required volume of radioactivity was placed into a 50 mL 
falcon tube and dried under nitrogen gas to remove the toluene. 3 mL fresh HEPES 
buffer was added to the dried lipids and sonicated for 3 x 15 s to re-suspend the palmitic 
acid. Meanwhile, 20 mL unlabelled, confluent HL60 cells were centrifuged at 1,300 
rev.min-1 for 5 min RT to remove the growth medium, washed once with 20 mL PBS, 
and then re-suspended in 17 mL HEPES buffer. The re-suspended cells were added to 
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the [3H]-palmitic acid tube, the contents mixed by inverting, and the tube placed in the 
dry incubator at 37°c for 3 hrs.
[3H]-inositol
For labelling with [3H]-inositol, the required number of cells were first  transferred into a 
50 mL falcon tube and centrifuged at 1,300 rev.min-1 to pellet the cells. The supernatant 
was discarded and cell pellet  re-suspended in the appropriate volume of M199 
supplemented with 10% HI dialysed FCS, 4 mM L-glutamine, 0.5 iu.mL-1 penicillin and 
50 µg.mL-1 streptomycin, together with 1-4 µCi.mL-1 (37-148 kBq.mL-1) myo-[2-3H]-
inositol for 48-72 hrs labelling. The HL60 cells did not tend to grow as fast in M199 as 
they did in RPMI, and so the cells were seeded at twice the usual concentration.
2.7.4: Lipid binding assay
Permeabilisation of HL60 cells with SLO
Labelled HL60 cells were washed twice in PIPES  buffer (20 mM PIPES  pH 6.8, 137 
mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 5.6 mM glucose, 1 mg.mL-1 BSA), with 
centrifugation at  1200 rev.min-1 for 5 mins, and then resuspended in 5 mL 
Permeabilisation Cocktail (0.6 iu.mL-1 SLO, 2 mM  Mg-ATP). Cells were permeabilised 
in a water bath at 37°c for a maximum of 10 min.
Chilled PIPES buffer was added to ~45 mL, and the tube centrifuged at 3000 rev.min-1 
for 5 mins at 4°c. The permeabilised cells were washed twice in 30 mL PIPES, and then 
re-suspended in an appropriate volume of PIPES buffer for the experiment, 
supplemented with 1 mM Mg-ATP. A small volume of permeabilised cells was also 
taken into account for extraction of the total HL60 cellular lipids (‘total lipids’).
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Lipid binding by recombinant PITP
The assay volume was 600 µL, of which the following was added in the order given, to 
labelled 1.5 mL eppendorf tubes on ice:
  100 µL PITP protein (200 µg.mL-1; 120 µg protein per assay tube).
  500 µL permeabilised cells.
In some experiments these volumes were adjusted, for example for more dilute 
recombinant protein preparations, but the total assay  volume was maintained at 600 µL. 
The recombinant protein was diluted in PIPES/salts buffer (20 mM PIPES pH 6.8, 
137 mM NaCl, 2.7 mM KCl). This enabled the removal of 2.4 µg of the diluted protein 
(2% protein present  in one assay volume) to run on an SDS-PAGE gel for Coomassie 
staining, without BSA contamination. This was further diluted with PIPES/salts buffer 
and 2X SDS-PAGE sample buffer to a final volume of 20 µL, and boiled for 10 min at 
95°c.
PITP protein was incubated with permeabilised HL60 cells in a water bath pre-heated to 
37°c for 20 mins. Immediately following this incubation, the assay tubes were 
centrifuged at 3,000 rev.min-1 for 5 min at 4°c. 550 µL of the supernatant was 
transferred to a fresh eppendorf tube and centrifuged again, this time at  11,500 x g for 
10 min at 4°c to remove any remaining debris.
Recapturing of the His-tagged PITP
120 µL HIS-select nickel affinity gel (Sigma-Aldrich, P6611) (‘nickel beads’) was 
placed into the required number of mini-spin columns (one per assay tube). The nickel 
beads were washed twice in 500 µL PIPES/salts by centrifugation at 3,000 rev.min-1 for 
5 min at  4°c. 500 µL cleared supernatant was then placed onto the mini-spin column. 
This supernatant contained cytosolic proteins, and, more importantly, the recombinant 
PITP with bound radiolabelled lipid. With the lids replaced, the columns were placed 
onto the rotating wheel for 30 mins at 4°c for capturing.
130
Washing of the nickel beads, elution of protein and buffer exchange
Following the re-capturing step, the mini-spin columns were centrifuged at 3,000 
rev.min-1 for 5 min at 4°c, to elute unbound material. The nickel beads were washed 
twice with 500 µL Low Salt buffer (50 mM phosphate buffer pH 6.0 [23.3 mL 1 M 
Na2HPO4, 1.70 mL 1 M NaH2PO4], 300 mM NaCl, 10% glycerol), followed by twice 
with High Salt buffer (50 mM phosphate buffer pH 6.0 [23.3 mL 1 M Na2HPO4, 
1.70 mL 1 M NaH2PO4], 525 mM NaCl, 10% glycerol). Finally, the recombinant 
proteins were eluted into fresh 2 mL eppendorf tubes by  the addition of 500 µL of 500 
mM imidazole (in high salt buffer) to each column with centrifugation 3,000 rev.min-1 
for 5 min at 4°c.
Buffer exchange columns were prepared by washing twice with PIPES/salts buffer. 
These columns were re-used between experiments and were stored in PBS-0.05% 
sodium azide (w/v). 500 µL eluted protein was loaded onto a prepared buffer exchange 
column. The displaced liquid was allowed to run through; the recombinant protein was 
captured by  the resin. The column was then placed into a 15 mL solvent tube, and 1 mL 
PIPES/salts applied to the column to elute the protein into the solvent tube.
20 µL of the eluted protein was transferred to a 1.5 mL eppendorf tube containing 6.67 
µL 4X SDS-PAGE sample buffer, which was then vortexed briefly and boiled at 95°c 
for 10 min before running on an SDS-PAGE gel alongside the input sample. The gel 
was stained with Coomassie and protein bands quantified to assess protein recovery.
2.7.5: Lipid extraction and analysis of phospholipids by TLC
The ‘total lipids’ sample retained from the beginning of the experiment was diluted to 1 
mL with buffer and transferred to a labelled 15 mL solvent tube alongside the eluted 
proteins. To each solvent tube, the following was added:
  3.75 mL Chloroform: Methanol (1:2 (v/v)).
  1.25 mL chloroform.
  1.25 mL water.
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The mixture was vortexed for 5 s, and a separation of lower organic and upper aqueous 
phases was observed. The tubes were then centrifuged at 2,000 rev.min-1 for 10 min RT 
to ensure clean separation of the phases.
Two 1.5 mL eppendorfs were labelled per 15 mL solvent tube. The lower organic layer 
was removed from the solvent tubes and divided between the two eppendorf tubes. The 
eppendorfs were then placed into the Savant SpeedVac (pre-cooled for >30 min prior to 
use), without lids attached for ~1.5 hrs, until the lipids (and the tubes) were completely 
dry.
50 µL fresh chloroform was placed into each of the dried lipid tubes, the lids rapidly 
closed, and the tubes vortexed to re-suspend the lipids.
10 µL of the re-suspended ‘total lipids’ was placed into a small liquid scintillation vial. 
The chloroform rapidly evaporated. 100 µL methanol was added to re-suspend the 
lipids. 3 mL UltimaGOLD scintillation fluid was then placed into the vial, the vial 
vortexed, and the sample counted using a liquid scintillation counter.
The lipid samples were then spotted onto a Whatman silica gel 60 TLC plate which had 
been desiccated in an oven at 100°c for >1 hr previously to remove any moisture on the 
plate. The lipids were each spotted in a distinct narrow line, 2 cm from the bottom of the 
plate. Alongside, 50,000-100,00 dpm of the total HL60 lipids were spotted and/or 12-24 
µg unlabelled lipid standard for identification of phospholipids bound, as required.
Once the lipid spots were dry, the TLC plate was placed into a solvent tank containing 
Chloroform: Methanol: Acetic acid: Water (75: 45: 3: 1 v/v) . This solvent system was 
prepared and placed into the tank several hours before the tank was required to allow 
the solvent to equilibrate throughout the tank and chromatography paper. The solvent 
front was allowed to migrate to approximately 5 mm from the top of the plate (~1.5 hr) 
before the plate was removed from the tank and allowed to dry in a fume hood. The 
plate was then incubated with a clean white Fuji phosphor imager screen for 
approximately 5 days before imaging using a Fuji BAS1000 phosphor imager. SDS-
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PAGE gels and TLC plate images were quantified by  2D densitometry using AIDA 
software. Data analysis was carried out as described in the text and/or figure legends.
2.7.6: Identification of bound lipids
For the experiment in which HL60 cells were labelled with different radionucleotides 
and the extracted lipids run alongside one another on a TLC plate, six cultures of 20 
mL HL60 cells were set up  with the radionucleotides indicated in Table 2.9. Labelling 
was carried out  as described in Section 2.7.3: [3H]-inositol in M199 medium, [3H]-
palmitic acid in HEPES, and all others in supplemented RPMI-1640 medium. 
After labelling, the cells were transferred to 50 mL falcon tubes and washed once in 20 
mL PBS. The cell pellet was re-suspended in 1 mL and transferred to a 15 mL solvent 
tube for lipid extraction. 3.75 mL Chloroform: Methanol (1:2 v/v) was added, followed 
by 1.25 mL chloroform and 1.25 mL water. The tubes were vortexed for 5 s, then 
centrifuged to separate the lower organic and upper aqueous phases. The lower, 
chloroform-soluble phase was carefully removed to 2 x 1.5 mL eppendorf tubes per 
label, and the lipids dried using the Savant  SpeedVac. The dried lipids were re-
suspended in 50 µL fresh chloroform, and 10 µL of each was transferred into a small 
liquid scintillation vial for counting using the liquid scintillation counter. Radioactivity 
incorporation is recorded in Table 2.9.
Approximately  100,000 dpm of each sample was spotted onto a TLC plate, which was 
then placed into a solvent tank containing the solvent system Chloroform: Methanol: 
Acetic acid: Water (75: 45: 3: 1 v/v). As before, the TLC plate was removed from the 
tank once the solvent tank had migrated to ~5 mm from the top of the plate. The plate 
was allowed to dry before being incubated with a blue phosphor imager screen for 
approximately one week before being imaged using a BAS-1000 phosphor imager.
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No. Radionucleotide Labelling 
concen-
tration 
(μCi/ml)
Labelling 
time 
(hrs)
Radioactivity 
in 10 μL 
extracted 
lipid (dpm)
Amount 
of lipid 
spotted 
onto TLC 
plate 
(dpm)
1 Sphingosine, D-erythro-
[3-3H]
0.5 48 800,182 150,000
2 Choline chloride
methyl-[3H]
1 48 327,926 100,000
3 [3H]-inositol 2 48 135,300 100,000
4 [3H]-ethanolamine 
hydrochloride
10 24 3,239,743 200,000
5 [3H]-palmitic acid (C16:0) 2 3 303,687 175,000
6 [14C]-acetic acid 1 48 197,824 75,000
Table 2.9: Radionucleotide labelling of HL60 cells
2.7.7: Purification of RdgBβ-bound lipids by two-dimensional TLC
The binding assay was scaled up, such that 50 x 106 (50 mL) [14C]-acetate-labelled 
HL60 cells and 300 µg recombinant RdgBβ-sp1 protein was used for a single 
incubation. The assay was otherwise carried out as described above. In addition, lipids 
were extracted from 10 mL unlabelled HL60 cells, and 40 mL permeabilised [14C]-
HL60 cells.
The extracted lipids were dried and re-suspended in 2 x 50 µL chloroform per sample. 
10 µL of the total labelled lipids, counted using the liquid scintillation counter, 
contained 2,384,908 (~2,400,000) dpm. Two 2D TLC plates were run, one with total 
[14C]-HL60 lipids and the other with RdgBβ-bound [14C]-lipids. 10 µL of the total [14C]-
HL60 lipids (240,000 dpm), was spotted into one corner (2 cm from each edge) of one 
20 x 20 cm TLC plate. This was 1/10th of the total volume, therefore equivalent to 4 
mL cells. The dried unlabelled lipids were also re-suspended in 2 x 50 µL chloroform. 
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So that both TLC plates ran the same, approximately the same mass of material needed 
to be run on both plates. Therefore, 40 µL of the unlabelled lipids, corresponding to 4 
mL cells, was added to the lipids extracted from RdgBβ, and spotted onto the corner of 
the second TLC plate.
Both TLC plates were placed facing one another into the first tank, with the spotted 
lipids at the bottom-left of each plate. This first tank had been prepared with the solvent 
system, Chloroform: Methanol: 28% Ammonia (65: 35: 5 v/v). The solvent  was allowed 
to migrate to within ~5 mm of the top of the plates, and then the plates were removed 
and allowed to dry in the fume hood.
Both plates were then placed into the second tank, again facing one another, but rotated 
90° counter-clockwise so that the origin was now on the bottom right  of each of the 
plates. This second tank had been prepared with the solvent system, Chloroform: 
Methanol: Acetic acid: Water (75: 45: 3: 1 v/v). As before, the solvent was allowed to 
migrate to within ~5 mm of the top of the plates, the plates were removed, allowed to 
dry, and then placed with a white phosphor imager screen for 5 days prior to imaging.
2.7.8: Phospholipid deacylation: treatment with a primary amine
The PI and mystery lipid radioactive spots derived from the lipids bound by RdgBβ-sp1 
were excised from the 2D TLC plate: the silica was moistened using a fine water spray, 
scraped, and the scrapings transferred to a 15 mL solvent tube. 1 mL distilled water was 
added and the tube vortexed to break up the silica. 3.75 mL Chloroform: Methanol (1:2 
v/v) was added to the tube, followed by 1.25 mL chloroform and 1.25 mL distilled 
water. The tube was vortexed (>5 s), then centrifuged at  2,000 rev.min-1 10 min RT to 
separate the organic and aqueous phases. The lower organic phase was removed and 
separated equally between two 1.5 mL eppendorf tubes. The lipid were then dried using 
the Savant SpeedVac.
The air was evacuated from one each of the lipid tubes using nitrogen gas, and these 
‘untreated’ tubes were placed at -20°c during monomethylamine treatment of the other 
lipid tubes.
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Monomethylamine reagent was made previously  by Dr. Alison Skippen, using the 
method introduced by Clarke and Dawson (Clarke and Dawson, 1981), and stored at 
-20°c. Monomethylamine gas was passed into a 40 mL mixture of Methanol: Water: n-
Butanol (4: 3: 1 v/v) contained in a graduated container in an ice bath, until the volume 
in the flask had increased to 65 mL.
200 µL monomethylamine reagent was placed into each of the two remaining tubes 
containing dried lipid, and the tubes incubated at 53°c for 30 mins. The tubes were then 
returned to the SpeedVac to remove the monomethylamine reagent, which is volatile, 
and to dry the treated lipids. The ‘untreated’ lipid tubes were now removed from the 
freezer. 100 µL dH2O was added to each of the four lipid tubes, followed by 375 µL 
Chloroform: Methanol (1:2 v/v). The tubes were vortexed, and then 125 µL chloroform, 
followed by  125 µL water, was added. The tubes were vortexed, centrifuged, and each 
of the lower organic layers removed to fresh eppendorf tubes and dried once more in the 
SpeedVac. The dried lipids were next re-suspended in 50 µL fresh chloroform and 
spotted onto a TLC plate. The solvent-soluble lipids were resolved in the solvent 
system, Chloroform: Methanol: Acetic acid: Water (75: 45: 3: 1 v/v).
2.7.9: PLA2 treatment of [3H]-ethanolamine liposomes
Total HL60 cell lipids labelled with [3H]-ethanolamine, which had been left over from 
previous experiments and stored at -20°c, were combined into a single 1.5 mL 
eppendorf tube and dried using the Savant SpeedVac. The dried lipids were then re-
suspended in 1 mL PIPES/salts pH 6.8 buffer with the aid of 3 x 15 s sonication bursts. 
10 µL liposomes contained 369,840 dpm (~370,000 dpm) radioactivity.
100 µL [3H]-ethanolamine liposomes was placed into each of four labelled eppendorf 
tubes on ice, and incubated with 1 U phospholipase A2 (from bee venom, P-9279, 
Sigma-Aldrich), for 0, 1, 2 or 4 min in a water bath at 25°c. The hydrolysis reaction was 
terminated by  the addition of 375 µL Chloroform: Methanol (1:2 v/v), the tube vortexed 
and returned to ice. Once all of the incubations had finished, 125 µL chloroform and 
125 µL water were added to each tube, the tubes vortexed and then centrifuged in a 
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table-top  centrifuge at 10,000 rev.min-1 2 min RT. The lower, organic phase was then 
removed to a fresh eppendorf tube, and the lipids dried using the Savant SpeedVac. The 
dried lipids were re-suspended in 50 µL fresh chloroform, 10 µL counted using the 
liquid scintillation counter, and 100,000 dpm spotted onto a TLC plate alongside 
unlabelled phospholipid standards, PE, PMME and PI.
2.7.10: Preparation of samples for mass spectrometry
For analysis of bound lipids by  mass spectrometry, the experiment was carried out as 
described above (Sections 2.7.4), with minor modifications. The amount of recombinant 
protein was increased to 600 µg in each assay  volume, and the amount of cells for each 
assay was increased to 50 mL confluent cells. HL60 cells were unlabelled for mass 
spectrometry. All chloroform extractions were performed in borosilicate glass screw-
capped tubes to prevent polymer contamination of the samples. The organic phase was 
carefully  transferred into glass amber vials using a glass pasteur pipette and the lipids 
dried using the Savant SpeedVac. The air was evacuated from the glass vial and 
replaced by nitrogen gas to prevent oxidation of the lipids. Samples were transported to 
Southampton at 4°c within 24 hrs of completion of the experiment. All mass 
spectrometry  and subsequent data analysis was carried out by  our collaborators, Dr. 
Alan Hunt and Grielof Koster (University of Southampton).
The phospholipids were analysed by electrospray ionisation mass spectrometry (ESI-
MS) using a Quatro Ultima triple quadrupole mass spectrometer (Micromass, 
Wythenshaw, UK) equipped with direct infusion or nanoflow interfaces, depending on 
the sample size (Hunt et al., 2004). A full screening of glycerophospholipid species was 
carried out under both positive and negative ionisation with selective precursor of all 
phospholipids of potential interest, including PA, PC, PE, PI, PS and related 
lysophospholipids. Bacterial lipids including PG were absent from all samples. The PA 
species were identified from scanning for the precursors of the glycerophospholipid 
fragment (m/z -153) and their identities and dominant acyl compositions confirmed by 
specific peak fragmentations, while the PI species were detected by scanning for the 
precursor of inositol phosphate (m/z -241).
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2.7.11: Treatment of [14C]-PI and [14C]-PC with PLD
Total HL60 [14C]-lipids from previous experiments were removed from the freezer, 
where they had been stored at -20°c, and the chloroform replenished where required. 
The lipids were spotted in 4 cm-wide bands, 2 cm from the bottom of two TLC plates. 
The lipids were migrated in the usual solvent system, Chloroform: Methanol: Acetic 
acid: Water (75: 45: 3: 1 v/v), and the plates placed with a white phosphor imager screen 
for 24 hrs prior to imaging. The [14C]-PI and [14C]-PC lipids were identified and the 
silica scraped into 50 mL falcon tubes, one for each lipid. The lipids were extracted in 
2.5 mL: first, 2.5 mL water was placed into the falcon tubes with the scraped silica, and 
the tubes vortexed for >5 s. Next, 7.5 mL chloroform: methanol (1:2 v/v) was added, 
followed by a further 2.5 mL chloroform and 2.5 mL water. The tubes were again 
vortexed for >5 s, and centrifuged, 2,000 rev.min-1 10 min RT. The lower, solvent phase 
was removed to a single 1.5 mL eppendorf for each lipid. The lipids were dried using 
the Savant SpeedVac, and more lipid was added to each tube every 30 min-1 hr.
The dried lipid was re-suspended in 400 µL 0.2 M  sodium acetate pH 5.6, by 2 x 15 s 
sonication bursts, until no lipid could be seen sticking to the inside of the tubes.
Phospholipase D (EC 3.1.4.4), Type III from Peanut (209 units.mg-1 solid, P-0640, 
Sigma-Aldrich): 10.2 mg PLD was dissolved in 850 µL acetate buffer, to give a solution 
of 12 mg.mL-1 or 2,500 units.mL-1.
The total assay volume was 1.3 mL, of which:
 400 µL lipid (PI or PC)
 400 µL PLD (1000 units)
 100 µL CaCl2 (1 M stock)
 400 µL ether (diethyl ether)
The tubes were mixed well, then incubated at RT for 16 hrs. The following day, the caps 
were removed from the eppendorf tubes and the tubes placed into a fume cabinet  to 
allow the ether to evaporate (~10 min). The contents of each eppendorf tube was 
transferred to a 15 mL solvent tube for lipid extraction by  the addition of 3.75 mL 
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chloroform: methanol (1:2 v/v), 1.25 mL chloroform and 1.25 mL water. The tubes were 
vortexed 5 s and centrifuged 2,000 rev.min-1 10 min RT. The lower, organic phase was 
removed to 2 x 1.5 mL eppendorf per lipid, labelled PI-PA and PC-PA, and the lipids 
dried using the Savant SpeedVac. 100 µL fresh chloroform was then added to each 
eppendorf tube, and the tubes vortexed to re-suspend the lipids. 10 µL of each lipid was 
counted using the liquid scintillation counter: PI-PA, 26,480.7 dpm; PC-PA, 25,916.7 
dpm. 100,000 dpm of each lipid was spotted onto a TLC plate alongside 20 µg each of 
PI and PC unlabelled phospholipid standards. The lipids were migrated in the usual 
solvent system, Chloroform: Methanol: Acetic acid: Water (75: 45: 3: 1 v/v).
2.7.12: Permeabilised HL60 cell assay for [14C]-lipid transfer
The lipid binding assay described above monitors a single round of docking and lipid 
exchange by the PITPs. To establish whether the bound lipid was transferred and 
deposited in an acceptor membrane, the permeabilised HL60 cell assay was adapted to 
include unlabelled acceptor liposomes. At the end of the incubation, 0.2 M  sodium 
acetate/0.25 M sucrose pH 5.0 was added to pellet  the HL60 cell membranes. The 
transferred [14C]-acetic acid lipids were extracted from the liposomes (supernatant), and 
analysed by TLC.
50 mL labelled HL60 cells were washed twice in PIPES buffer, then permeabilised with 
0.6 iu.mL-1 SLO in 5 mL PIPES with 2 mM  Mg-ATP at 37°c for 10 min. The 
permeabilised cells were then washed once in PIPES, and re-suspended in 1 mL PIPES 
with 1 mM Mg-ATP.
6 mL PC:PI liposomes (98:2, molar ratio) were prepared in PIPES buffer: 4.7 mg PC 
(47 µL of 100 mg.mL-1 Egg PC stock) and 100 µg PI (4µL of 50 mg.mL-1 stock (50% 
pure, Sigma-Aldrich, P6636, L-α-Phosphatidylinositol from soybean)), were placed into 
a 15 mL falcon tube. The chloroform was evaporated under nitrogen gas. The lipids 
were then re-suspended in 6 mL PIPES buffer using 3 x 15 s sonication bursts. This 
gave 784 µg PC and 16 µg PI per mL assay volume.
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The assay volume was 400 µL, prepared on ice:
  100 µL permeabilised cells.
  200 µL liposomes.
  100 µL recombinant PITP protein (80 µg, 200 µg.mL-1).
The assay was incubated in a water bath at 37°c for 20 min. The tube rack was then 
returned to ice, and the experiment quenched by the addition of 100 µL ice-cold 0.2 M 
sodium acetate/0.25 M sucrose pH 5.0 (total volume now 500 µL). The tubes were 
vortexed and incubated on ice for >10 min. The tubes were then centrifuged at 12,000 
rev.min-1 for 15 min at 4°c to pellet the cell membranes.
400 µL of the supernatant was transferred to a labelled 15 mL solvent tube for lipid 
extraction by the addition of 1.5 mL chloroform: methanol (1:2, v/v), followed by 500 
µL chloroform and 500 µL water. The solvent tubes were vortexed for 5 s, and then 
centrifuged at 2,000 rev.min-1 for separation of the lipid and aqueous phases. The lower, 
solvent phase was removed to a labelled 1.5 mL eppendorf tube, and the lipids dried 
using the Savant SpeedVac.
The dried lipids were re-suspended in 50 µL chloroform per tube, spotted onto two TLC 
plates (one per replicate) and migrated in the solvent system, Chloroform: Methanol: 
Acetic acid: Water (75: 45: 3: 1 v/v).
2.7.13: Lipid binding assay with stimulation of cells by GTPγS or PMA
In order to assess the effect of stimulation of the HL60 cells on lipid binding, the lipid 
binding assay described in Section 2.7.4 was modified. Instead of permeabilising the 
HL60 cells and washing them of cytosol before use in the binding assay, SLO was 
added to the cells at the same time as recombinant PITP, thus combining the 
permeabilisation and lipid-binding incubations.
10 mL confluent HL60 cells labelled with [14C]-acetate were required per assay volume. 
Instead of permeabilisation, labelled cells were washed twice in fresh PIPES buffer, and 
then re-suspended in PIPES buffer with 1 mM Mg-ATP.
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The assay volume was 600 µL, of which the following were added in the order given:
 100 µL recombinant RdgBβ/PITPα (200 µg.mL-1; 120 µg protein per assay vol.).
 400 µL washed HL60 cells + 1 mM Mg-ATP.
 50 µL stimulation: 100 nM PMA or 100 µM GTPγS or buffer for control.
 50 µL 0.4 iu.mL-1 SLO, + 3 mM pCa7 or 3 mM pCa5.
The experiment was otherwise carried out exactly as described above.
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CHAPTER 3: The RdgBβ-sp1 C-terminus and an interaction 
with 14-3-3
3.1: Introduction
Members of the PITP family all carry the defining PITP domain at their N-terminus, yet 
differ in their C-terminal sequences. For some PITPs, it has been reported that this 
region mediates protein-protein interactions and is therefore important in localisation, 
and potentially  function. PITPα interacts with the netrin-1 receptors, DCC and 
neogenin, via its C-terminus (Xie et al., 2005). This association increases 4-fold upon 
netrin-1 stimulation, and likely functions to localise PITPα at the plasma membrane to 
present PI to PI4K. The RdgBα proteins have an FFAT motif which binds VAP proteins, 
targeting RdgBαI to the ER membrane (Amarilio et al., 2005).
The two splice variants of RdgBβ, RdgBβ-sp1 and -sp2, share the same PITP domain, 
yet differ in their C-termini. The RdgBβ PITP domain is encoded by exons 1-8 of the 
PITPNC1 gene; the RdgBβ-sp1 C-terminus is encoded by exon 10, and the RdgBβ-sp2 
C-terminus is encoded by exon 9. I therefore begin my  study of RdgBβ by analysing its 
C-terminus. Bioinformatics tools are used to identify that this region of RdgBβ-sp1 is 
disordered, a finding that  is confirmed by trypsin digestion of the recombinant protein. 
Furthermore, RdgBβ-sp1 is ubiquitinated and undergoes a moderate rate of turnover. A 
database search indicates that the C-terminus is phosphorylated, and that two of the 
phosphorylation sites lie in consensus sites for 14-3-3 binding. I show that RdgBβ-sp1 
binds 14-3-3 via phosphorylated Ser274 and Ser299 in its C-terminus, and that 
phosphorylation is in part mediated by PKC.
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3.2: The C-terminal region of RdgBβ-sp1 lacks secondary structure
The PITPs differ mainly  in their C-termini. RdgBβ-sp1 is ~60 aa longer in sequence 
than PITPα and PITPβ, and I therefore began my study of RdgBβ with the C-terminal 
domain. These regions of RdgBβ-sp1 and -sp2 were analysed using bioinformatics tools 
to establish whether they have any discernible secondary structure or significant 
homology  to other protein domains. The DISOPRED2 server was used to predict 
regions of disorder (lacking secondary structure) within a protein (Ward et al., 2004). 
Analysis of the human sequences, RdgBβ-sp1 (Accession no.: Q9UKF7) and RdgBβ-
sp2 (NP_858057.1), identified several regions of disorder (Figure 3.1 A).
In both splice variants a region of disorder (27-39 aa) is present in the PITP domain, 
which lies in a region of the domain near to the opening of the lipid binding cavity 
between the αA helix and β2 strand. In addition, the C-termini of both splice variants 
are disordered: the disorder for RdgBβ-sp1 begins at residue 251, whereas for RdgBβ-
sp2 it begins at residue 246. For RdgBβ-sp1 this means a long disordered region 
composed of 82 amino acids, broken only by a short α-helix. The helix lies either at 
300-305 (gap predicted by DISOPRED) or 309-313 (α-helix predicted by PSIPRED, the 
secondary structure prediction arm of DISOPRED (Bryson et al., 2005)).
To investigate this prediction experimentally  I reasoned that the unstructured or 
disordered regions of the protein would be more susceptible to digestion with a protease 
than a compact domain. Analysis of the RdgBβ-sp1 and -sp2 sequences revealed 30 
potential trypsin cleavage sites in their common PITP domain sequence, 9 additional 
cleavage sites in the C-terminus of RdgBβ-sp1, but only 2 sites in the C-terminus of 
RdgBβ-sp2 (Figure 3.1 B). In agreement with this, treatment of the recombinant 
proteins with trypsin for 10 minutes saw a prominent size shift for RdgBβ-sp1, but no 
discernible shift  in size for RdgBβ-sp2 (Figure 3.1 C). This indicates that the stable 
protein band reached by 10 minutes is the stable PITP domain. The stable protein unit is 
~37 kDa for RdgBβ-sp1 and 38 kDa for RdgBβ-sp2.
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(Facing page) Figure 3.1: The C-terminus of RdgBβ-sp1 is disordered and 
contains two PEST sequences
(A) DISOPRED2 disordered profile plots for, left panel: RdgBβ-sp1, and, right panel: 
RdgBβ-sp2. (B) Multiple sequence alignment of the human sequences of RdgBβ-sp1 
(Accession no.: Q9UKF7.2) and RdgBβ-sp2 (Accession no.: NP_858057.1). The yellow 
region indicates the sequence identical between the two splice variants, i.e. the region 
encoded by  exons 1-8. The predicted trypsin cleavage sites and PEST sequences are 
also indicated. (C) Trypsin digestion of recombinant RdgBβ-sp1 and -sp2 (0-10 min). 
Left panel: Coomassie-stained SDS-PAGE gel; 2 μg protein loaded per lane. Right 
panel: western blot using anti-RdgBβ antibody, #101; 30 ng loaded per lane. 
(Experiment carried out by Michelle Li.)
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3.3: RdgBβ-sp1 is subject to turnover in mammalian cells
The trypsin protease has been used as a tool here to examine the structure of RdgBβ, but 
this property may also be relevant in vivo. Disordered regions, especially at the N- or C-
terminus of a protein, may spell a more rapid degradation and turnover of a protein in 
cells. The sequence is more accessible to proteases and could permit the protein to 
literally be unravelled from this polypeptide chain. Further analysis of the RdgBβ-sp1 
C-terminus uncovers two PEST sequences (Figure 3.1 B), rich in Proline, glutamate (E), 
Serine and Threonine residues. The PEST sequence was originally identified as being 
common to proteins with a high rate of turnover in cells - the protein concentration is 
reduced by half within 2 hrs (Rogers et al., 1986; Rechsteiner and Rogers, 1996). To test 
whether RdgBβ-sp1 is undergoing rapid turnover, COS-7 cells were transfected with a 
pcDNA3.1 plasmid containing the wild-type RdgBβ-sp1 sequence tagged with a FLAG 
tag. 48 hrs later, the cells were treated with the protein synthesis inhibitor, 
cycloheximide, and the relative quantity of FLAG fusion protein was monitored at 
specific time points by western blotting (Figure 3.2 A). The wild-type FLAG-RdgBβ-
sp1 is reduced by  half by 5 hrs cycloheximide treatment (Figure 3.2 B). This is 
compared to another soluble PITP, PITPβ, which is not seen to degrade at all in the 6 hr 
experiment time.
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Figure 3.2: RdgBβ-sp1 is subject to turnover in mammalian cells
(A) COS-7 cells were transfected with pcDNA3.1-FLAG-RdgBβ-sp1 WT or S299A 
mutant. On the morning of the experiment, the culture media was removed and 
replaced with fresh media containing 100 μg.mL-1 cycloheximide. Cells were harvested 
at 0, 2, 4 and 6 hrs and subjected to western blotting using anti-FLAG antibodies 
(DDK). Membranes were stripped and re-probed for endogenous PITPβ #1C1 (single 
membrane shown). (Experiment carried out by Michelle Li.) (B) Protein bands were 
quantified using densitometry, background intensity  subtracted and protein 
concentration calculated relative to expression at zero time. Error bars are SEM; 
FLAG-RdgBβ-sp1 WT, n=5; PITPβ and FLAG-RdgBβ-sp1 S299A, n=2.
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3.4: RdgBβ-sp1 is ubiquitinated and phosphorylated
The most common signal for intracellular protein degradation is the addition of a 
ubiquitin tag by an E3 ubiquitin ligase. Probing a FLAG-RdgBβ-sp1 immunoprecipitate 
with anti-Ubiquitin antibodies indicated that RdgBβ is ubiquitinated. Cells were 
harvested after treatment with the 26S proteasome inhibitor, MG-132. Without 
treatment, ubiquitin is barely detectable in the FLAG-immunoprecipitate, and increases 
noticeably upon 26S proteasome inhibition (Figure 3.3). A ubiquitin tag is most 
commonly conjugated to an ε-NH2 group of an internal lysine residue. Studies aimed at 
identifying a consensus sequence surrounding the ubiquitinated lysine have reported no 
common sequence (Glickman and Ciechanover, 2002). Since the RdgBβ-sp1 sequence 
contains 27 lysines, it is difficult to narrow down the precise location of the ubiquitin 
signal on RdgBβ.
Alternatively, other post-translational modifications, such as phosphorylation, can 
regulate the recruitment of E3 ubiquitin ligases, or of other proteins that hide or expose 
recognition sequences. High-throughput proteomics screens are increasingly being used 
to identify phosphorylation sites on proteins using mass spectrometry. Such screens 
often have the aim of identifying proteins involved in the progression of a particular 
disease state by looking at its changing regulation. Multiple sites have been identified in 
RdgBβ as being phosphorylated in the human and mouse sequences. Figure 3.4 maps 
the position of these sites and indicates the number of reports concerning each 
phosphorylation. Three sites are associated with >5 reports: Ser274, Thr278 and Ser299. 
The most thorough screen carried out to date is by Huttlin and colleagues, who 
identified phosphorylated peptides from nine organs (brain, brown fat, heart, liver, lung, 
kidney, pancreas, spleen, testis), harvested from 3-week-old Swiss-Webster mice 
(Huttlin et al., 2010). The Ser166 residue, phosphorylated in PITPα (van Tiel et al., 
2000; Morgan et al., 2004), and conserved in almost all PITPs identified, including 
RdgBβ (equivalent residue Ser161), has not been reported as phosphorylated in RdgBβ 
to date.
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Figure 3.3: RdgBβ-sp1 is ubiquitinated
COS-7 cells expressing FLAG-RdgBβ-sp1 fusion protein were treated without or with 
20 μM MG-132 proteasome inhibitor for 4 hrs prior to cell harvest. RdgBβ was 
immunoprecipitated using its FLAG tag and subjected to western blotting with anti-
Ubiquitin (Ub) antibody  (third panel). The PVDF membrane was re-probed to confirm 
presence of FLAG-RdgBβ in the immunoprecipitate (DDK) (fourth panel). 12 μg lysate 
was probed for FLAG-RdgBβ expression on a separate membrane (first panel); this 
membrane was stripped and re-probed for ARF1 loading control (second panel).
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(Facing page) Figure 3.4: Reported mouse and human RdgBβ phosphorylation 
sites
CLUSTAL O (1.0.3) multiple sequence alignment of the human (Hs) RdgBβ-sp1 
(NP_036549) and -sp2 (NP_858057) sequences with mouse (Mm) RdgBβ sequences 
(Q8BTD8 and NP_665822). Residue numbering begins at the human methionine start 
codon. Residues reported as being phosphorylated are indicated on either the human 
or mouse sequence, as appropriate. The frequency  of reports is indicated in brackets 
after the residue name. Residues Ser274, Thr278 and Ser299 have over 5 
observations of being phosphorylated, and are coloured dark orange.
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RdgBβ-sp1 Ser274 was found to be phosphorylated most prominently  in mouse brain 
and heart, with low levels in brown fat, lung, liver and spleen (Huttlin et al., 2010). This 
phosphorylation has also been identified in the developing mouse brain (fore-brain and 
mid-brain from E16.5) by another group (Ballif et al., 2004), and in adult and embryo 
mouse brains, as well as the mouse liver (2008, PhosphoSitePlus database, Cell 
Signalling Technology, (Hornbeck et al., 2004)). In the human sequence this 
phosphorylation has been identified in non-small cell lung carcinoma (H1703 cell line, 
2006, PhosphoSitePlus database, Cell Signalling Technology, (Hornbeck et al., 2004)) 
and in a study that looked at metastasis-associated phosphoproteomic alterations in non-
small cell lung cancer (Wang et al., 2010).
Phosphorylated RdgBβ-sp1 Thr278 was found primarily in mouse heart and brain, with 
low levels in kidney and liver (Huttlin et al., 2010). In separate experiments, this site 
has been identified as being phosphorylated in untreated mouse organs: adult and 
embryo brain, heart and liver (2008, PhosphoSitePlus database, Cell Signalling 
Technology, (Hornbeck et al., 2004)). In the human sequence this phosphorylation has 
been identified in non-small cell lung carcinoma (H1703 cell line, 2006, 
PhosphoSitePlus database, Cell Signalling Technology, (Hornbeck et al., 2004)).
RdgBβ-sp1 Ser299 has been identified as a phosphorylated site following receptor 
tyrosine kinase stimulation of human cancer cell lines (H1703, H3255 and MKN45 
cells) by  EGF, PDGF and c-Met (Moritz et al., 2010), in embryonic stem cells (Brill et 
al., 2009), in a metastasising non-small cell lung cancer (Wang et al., 2010), in HeLa 
(cervical adenocarcinoma) cells and in Jurkat (T cell leukaemia) treated with the 
phosphatase inhibitors, pervanadate and calyculin (2009, PhosphoSitePlus database, 
Cell Signalling Technology, (Hornbeck et al., 2004)). In the mouse, RdgBβ-sp1 S299A 
has been found to be phosphorylated in the brain (Huttlin et al., 2010; Wiśniewski et al., 
2010), after stimulation of signalling by the oncogenic mutant of Flt3 in mouse 32Dcl3 
cells (IL-3-dependent myeloid cell line) (Choudhary et al., 2009), and melanomas from 
TG3 mutant mice (ectopic Grm1 (a glutamate receptor) expression, leading to 
constitutive activation of the Erk signalling pathway) (Zanivan et al., 2008). In addition, 
the Ser299 residue has been identified as a phosphorylated residue in mouse lung 
152
fibroblasts (2009, PhosphoSitePlus database, Cell Signalling Technology, (Hornbeck et 
al., 2004)).
To investigate the role of each of these C-terminal phosphorylations on ubiquitination of 
RdgBβ-sp1, I constructed point mutations of each residue (Ser/Thr to Ala) in the FLAG-
tagged protein, using site-directed mutagenesis. The mutant proteins were each 
immunoprecipitated using their FLAG tags and the immunoprecipitate probed by 
western blotting with anti-Ubiquitin antibodies. No significant difference in the amount 
of ubiquitin detected for the mutants was observed (Figure 3.5). However, protein 
expression did vary  significantly between the wild-type protein and the mutants (Figure 
3.5 B). The FLAG-RdgBβ-sp1 S299A mutant was therefore assessed for protein 
stability, inhibiting protein synthesis using cycloheximide (Figure 3.2). The RdgBβ-sp1 
S299A mutant was more rapidly  degraded than the wild-type protein: the quantity of the 
wild-type protein was reduced by half within 5 hrs cycloheximide treatment; for the 
S299A mutant the quantity of protein in the cell lysate was reduced by  half within 2 hrs 
treatment.
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(Facing page) Figure 3.5: Mutation of C-terminal Ser/Thr phosphorylation sites 
has no effect on RdgBβ-sp1 ubiquitination
COS-7 cells transfected with pcDNA3.1 empty  vector control, FLAG-RdgBβ-sp1 WT, 
S274A, S299A, SS274/299AA or T278A, were treated with 20 μM MG-132 for 4 hrs 
prior to cell harvest. (A) Fusion proteins were immunoprecipitated using their FLAG tag 
and subjected to western blotting with the anti-Ubiquitin antibody  (Ub). The PVDF 
membrane was stripped and re-probed to confirm the presence of the FLAG fusion 
proteins (DDK). 10 μg lysates were also subjected to western blotting with the anti-
FLAG antibody  (DDK). This membrane was stripped and re-probed for ARF1 loading 
control. The western blot protein bands were quantified using AIDA software. (B) 
Quantity of FLAG-RdgBβ-sp1 fusion proteins present in the lysate have first been 
adjusted for ARF1 loading control, and then are expressed relative to WT protein to 
allow multiple experiments to be combined. Error bars are SEM, n=5. * p<0.05, ** 
p<0.01, *** p<0.001. (C) Quantity  of Ubiquitin present in the immunoprecipitate 
adjusted for quantity  of FLAG fusion protein present, relative to WT protein. Error bars 
are SEM, n=2.
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3.5: A search for RdgBβ-sp1-interacting partners uncovers 14-3-3
Although mutation of the C-terminal phosphorylation sites to alanine did not affect the 
ubiquitination of RdgBβ-sp1, mutation of Ser299 did reduce the stability of the protein 
and increase turnover rate. This indicates that  the ability  for this residue to be 
phosphorylated is required for protection of RdgBβ-sp1 from degradation. 
Phosphorylation commonly regulates protein function by altering protein-protein 
interactions. Furthermore, knowledge of a protein’s interaction partners could provide 
an indication of the protein’s function.
I first determined that RdgBβ-sp1 binds neither to itself to form homo-oligomers 
(Figure 3.6), nor to PITPα nor PITPβ (Figure 3.7). The sequence of human RdgBβ-sp1 
(Accession no.: Q9UKF7), was scanned using the cell signalling interaction prediction 
program, Scansite (Obenauer et al., 2003), at high stringency, and was also uploaded to 
the PhosphoMotif Finder tool at the Human Protein Reference database (Amanchy et 
al., 2007). Both indicated that the region surrounding the phosphorylated Ser299 is a 
consensus site for binding of 14-3-3 proteins, specifically  the mode I consensus 14-3-3 
binding sequence, RSXpSXP (where pS is the phosphorylated serine residue) (Yaffe et 
al., 1997); the Ser299 sequence is RKKpSAP (see Figure 3.4). Although not identified 
by either program, the sequence surrounding the phosphorylated Ser274 is 
RSAPSpSAP, also remarkably similar to the mode I consensus sequence for 14-3-3 
binding. 14-3-3 proteins have been shown to bind two tandem sites on a single target 
protein resulting in strong ‘bidentate’ binding (Yaffe et al., 1997; Kostelecky et  al., 
2009). Ser274 and Ser299 could therefore form two such 14-3-3-binding sites on 
RdgBβ-sp1.
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Figure 3.6: RdgBβ-sp1 does not form homo-oligomers
COS-7 cells were transfected with a plasmid containing FLAG-RdgBβ-sp1, HA-RdgBβ-
sp1 or both constructs. The fusion proteins were immunoprecipitated using their FLAG- 
or HA-tag, and subjected to western blotting against the other tag (anti-HA or anti-
FLAG (DDK) antibodies, respectively). Despite low HA-RdgBβ-sp1 expression, this 
fusion protein can be seen in the HA-immunoprecipitate. Membranes were re-probed 
for the immunoprecipitated protein. The HA-RdgBβ-sp1 fusion protein was not present 
in the FLAG-RdgBβ-sp1 immunoprecipitate, and vice versa. The experiment was 
repeated with RdgBβ-sp2 fusion proteins but the protein expression was too low even 
to be seen in the immunoprecipitate.
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Figure 3.7: RdgBβ interacts with neither PITPα nor PITPβ
COS-7 cells were transfected with a plasmid containing FLAG-RdgBβ-sp1 or empty 
control plasmid. FLAG-RdgBβ-sp1 was immunoprecipitated using its FLAG-tag. The 
immunoprecipitate was run on an SDS-PAGE gel and subjected to western blotting 
using anti-PITPα antibody  #674 or anti-PITPβ antibody  #1C1. The membranes were 
stripped and re-probed using anti-FLAG antibody  DDK to confirm the presence of 
FLAG-RdgBβ in the immunoprecipitate. (Only one re-probed membrane shown.)
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To examine whether RdgBβ-sp1 binds endogenous 14-3-3 proteins, COS-7 cells were 
transfected with the pcDNA3.1 empty control vector or pcDNA3.1-FLAG-RdgBβ-sp1 
(Figure 3.8). RdgBβ was immunoprecipitated using its FLAG tag, and the 
immunoprecipitate separated by SDS-PAGE. The proteins were transferred to PVDF 
membrane and subjected to western blotting using the pan 14-3-3 antibody, which 
recognises all isoforms of 14-3-3 (Figure 3.8, fifth panel). Endogenous 14-3-3 is clearly 
present in the FLAG-RdgBβ-immunoprecipitate. An identical membrane was subjected 
to far western blotting by  incubating the membrane with recombinant  14-3-3 protein to 
look for a direct interaction between RdgBβ-sp1 and 14-3-3 (Figure 3.8, fourth panel). 
Recombinant 14-3-3 proteins bound to RdgBβ-sp1 in the far western blot. Both 
membranes were stripped and re-probed to confirm the presence of FLAG-RdgBβ in the 
immunoprecipitate (Figure 3.8, sixth panel). Taken together, this indicates that RdgBβ-
sp1 interacts with 14-3-3, and that  this interaction is direct. In this experiment, the 
amount of serum in the growth media was 0%, 1.5% or 10% FCS, as indicated; 14-3-3 
associated with RdgBβ irrespective of this variation.
Since 14-3-3 ordinarily  binds phosphorylated serine or threonine motifs, I reasoned that 
14-3-3 would be unable to bind to recombinant RdgBβ-sp1, expressed in E. coli. The 
recombinant proteins RdgBβ-sp1, -sp2 and truncated sp1 (1-263 aa), when separated by 
SDS-PAGE and transferred to PVDF membrane, were not found to bind to the 
recombinant 14-3-3 in the far western blot  (Figure 3.9). The recombinant 14-3-3 clearly 
only binds the RdgBβ-sp1 expressed in COS-7 cells which has had the opportunity to be 
phosphorylated, not to recombinant RdgBβ-sp1 lacking the phosphorylation nor 
RdgBβ-sp2 or -sp1 (1-263) which lack the consensus 14-3-3 binding sites.
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(Facing page) Figure 3.8: RdgBβ-sp1 interacts with 14-3-3
COS-7 cells were transfected with empty  vector or a plasmid containing the FLAG-
RdgBβ-sp1 sequence, 42 hrs prior to the experiment. 18 hrs later, the media were 
aspirated from all plates and replaced with fresh DMEM containing 0%, 1.5% or 10% 
FCS (with L-glutamine, penicillin and streptomycin) for 24 hrs as indicated. On the day 
of the experiment the cells were harvested, FLAG-RdgBβ was immunoprecipitated 
using its FLAG tag, and the immunoprecipitates subjected to SDS-PAGE and western 
blotting (fifth panel) and far western blotting using 14-3-3-DIG recombinant proteins 
(fourth panel). Membranes were stripped and re-probed using anti-FLAG antibody 
(DDK) (only  one shown) (sixth panel). 12 μg of each lysate was run together on 
separate western blots (upper three panels); 3 μg lysate run alongside 
immunoprecipitates (lower three panels).
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Figure 3.9: Unmodified recombinant RdgBβ does not interact with 14-3-3
FLAG-RdgBβ-sp1 was immunoprecipitated from cells expressing the FLAG-fusion 
protein, and loaded onto an SDS-PAGE gel alongside recombinant RdgBβ-sp1, -sp2, 
and truncated sp1 (1-263) (50 and 100 ng). The separated proteins were transferred to 
PVDF membrane and subjected to far western blotting using 14-3-3-DIG recombinant 
proteins (upper panel), stripped and re-probed by  western blotting technique using the 
anti-RdgBβ antibody #101 (lower panel) .
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3.6: C-terminal phosphorylation mutants are defective in 14-3-3 binding
Since phosphorylated Ser299 lies in a consensus site for binding to 14-3-3, and since 
phosphorylated Ser274 might lie in a degenerate 14-3-3-binding motif, the FLAG-
RdgBβ-sp1 point mutants S274A, T278A, and S299A, together with the double mutant, 
SS274/299AA, were examined for binding to 14-3-3. Mutation of either Ser274 or 
Ser299 abolished binding to 14-3-3 (Figure 3.10). Although Thr278 is not predicted to 
bind 14-3-3, a considerable loss of 14-3-3-binding is observed for the T278A mutant 
(~90%).
163
(Facing page) Figure 3.10: RdgBβ-sp1 C-terminal phosphorylation mutants are 
defective in 14-3-3 binding
(A) COS-7 cells were transfected with pcDNA3.1 empty  vector control, FLAG-RdgBβ-
sp1 WT, S274A, S299A, SS274/299AA or T278A. Two days later, the lysates were 
harvested, FLAG fusion proteins immunoprecipitated via their FLAG tag and subjected 
to western blotting for 14-3-3. The membrane was stripped and re-probed for FLAG-
RdgBβ in the immunoprecipitate (DDK). (B) Quantification of the amount of 14-3-3 
present in the immunoprecipitate adjusted for the amount of FLAG-RdgBβ 
immunoprecipitated (n=1).
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3.7: The RdgBβ-sp1-14-3-3 interaction is reduced upon PKC inhibition
Since serine phosphorylation of the RdgBβ-sp1 C-terminus is essential for 14-3-3 
binding, the human RdgBβ-sp1 sequence (Q9UKF7) was scanned for kinase 
recognition sequences using the Scansite program (Obenauer et al., 2003). At high 
stringency the program indicated that Ser299 lies in a consensus sequence for 
phosphorylation by PKB, a basophilic Ser/Thr protein kinase. At medium stringency 
this residue may also lie in a consensus sequence for phosphorylation by  PKA. At this 
stringency, the sequence surrounding Thr278 conforms to the glycogen synthase 
kinase-3 (GSK-3) recognition sequence. This kinase is a Ser/Thr protein kinase and 
likely requires prior phosphorylation of Ser274. Thr278 also lies in an ERK1 
recognition sequence (a proline-dependent Ser/Thr kinase). Running the program at low 
stringency indicates Ser274 may  be phosphorylated by PKB, GSK-3 or ERK-1; Thr278 
may be phosphorylated by  p38 MAPK, Cdk5 or Cdc2 (all proline-dependent Ser/Thr 
kinases); and Ser299 may be phosphorylated by  Clk2 kinase (a basophilic Ser/Thr 
kinase). Indeed, when Huttlin and colleagues analysed and displayed their data online 
they  have accompanied it with broad predictions for the kinases that may  be responsible 
for the particular phosphorylations; they reported Ser274 would be phosphorylated by a 
kinase of category ‘other’ (does not fit  comfortably as basophilic, acidophilic, nor 
proline-dependent Ser/Thr kinase), Thr278 would be phosphorylated by a proline-
directed kinase, and Ser299 would be phosphorylated by a basophilic kinase (Huttlin et 
al., 2010). Another group noted that 14-3-3 consensus binding sites show high similarity 
to the consensus sequences for phosphorylation by  the basophilic kinases PKA, PKB 
and PKC (Yaffe et al., 1997), and I therefore began by  looking at  the effect of different 
basophilic kinase inhibitors on 14-3-3 binding by FLAG-RdgBβ-sp1.
PKC was not identified as a potential kinase for Ser274, Thr278, nor Ser299, yet only 
treatment with the inhibitor of PKC, BIM-I, caused a reduction in 14-3-3 binding 
(Figure 3.11). The amount of 14-3-3 present in the immunoprecipitate was adjusted for 
the amount of FLAG-RdgBβ present, therefore the same amount of FLAG-RdgBβ binds 
half the amount of 14-3-3 in the presence of BIM-I, compared with the untreated cells 
(0.55 ±0.11 SEM (n=3) p<0.05). In addition, cells treated with BIM-I exhibited a 
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significantly lower expression of FLAG-RdgBβ-sp1 in the lysates (0.49 ±0.06 SEM 
(n=4) p<0.001) (Figure 3.11 B, left panel).
PKB is activated by PI(3,4,5)P3 produced by PI3K, and therefore the activity of PKB 
can be blocked by  the PI3K inhibitor, LY294002. The use of this compound, however, 
did not have a significant effect on FLAG-RdgBβ-sp1 protein expression or 14-3-3 
binding (Figure 3.11 B). Inhibition of PKA with H89 resulted in an increase in both 
FLAG-RdgBβ-sp1 expression (1.48 ±0.16 SEM (n=4) p<0.05) and 14-3-3 binding (1.60 
±0.17 SEM (n=3) p<0.05) (Figure 3.11 B).
Phorbol esters, such as phorbol 12-myristate 13-acetate (PMA), are analogues of DAG 
and potent activators of PKC. PMA and DAG stimulate PKC activity by increasing the 
affinity of the enzyme for Ca2+ and phospholipids, promoting translocation of the 
enzyme to the membrane. Ultimately, PKC activity is terminated by dephosphorylation, 
which the active conformation is more sensitive to than the inactive form, and 
degradation (‘down-regulation’). Different PKC isozymes appear to be subject to 
different rates of down-regulation: >90% of the type II conventional PKC isozyme 
(PKCβ) was found to be lost from RBL-2H3 cells after only  5 min treatment with 20 
nM PMA, whereas degradation of the type III isozyme (PKCα) is slower - a significant 
degradation was only observed after 10-30 min PMA treatment (Huang et al., 1989). 
PKC activity was reduced by  >96% in neonatal rat cardiac ventricular myocytes which 
had been treated with 1 µM  PMA (Rogers et  al., 1990). I therefore reasoned that 16 hrs 
100 nM  PMA treatment would remove PKC isozymes and mimic the effect of PKC 
inhibition on 14-3-3 binding by RdgBβ.
However, PMA more than doubled the expression of FLAG-RdgBβ in the lysate (2.27 
±0.40 SEM (n=4) p<0.05), and mildly increased binding to 14-3-3 (1.30 ± 0.03 SEM 
(n=3) p<0.001) (Figure 3.11). A time course of the effect of PMA treatment on FLAG-
RdgBβ-sp1 protein expression indicates that maximal protein expression is reached by 4 
hrs PMA treatment (Figure 3.12).
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(Facing page) Figure 3.11: PKC inhibition suppresses the RdgBβ-14-3-3 
interaction
(A) COS-7 cells transfected with pcDNA3.1-FLAG-RdgBβ-sp1 were treated with 10 μM 
H89, 10 μM LY294002 (LY), 5 μM BIM-I or 100 nM PMA, for 16 hrs prior to cell harvest. 
FLAG-RdgBβ was immunoprecipitated via its FLAG tag and subjected to western 
blotting for 14-3-3. The membrane was then stripped and re-probed using anti-FLAG 
antibody  (DDK). Similarly, lysate was subjected to western blotting for FLAG, and the 
membrane stripped and re-probed for ARF1 loading control. (B) Protein bands were 
quantified using densitometry. Error bars are SEM. P values are calculated relative to 
unstimulated FLAG-RdgBβ-sp1: * p<0.05, *** p<0.001. Left panel: Amount of FLAG-
RdgBβ present in the lysate adjusted for ARF1 loading control, n=4. Right panel: 
Amount of 14-3-3 present in the immunoprecipitate adjusted for the amount of FLAG-
RdgBβ immunoprecipitated, n=3.
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Figure 3.12: Time course of FLAG-RdgBβ stabilisation by PMA
COS-7 cells were seeded into 35 mm cell culture dishes at a concentration of 2.0 x 105 
cells.mL-1, and transfected with control empty  vector or pcDNA3.1-FLAG-RdgBβ-sp1 6 
hrs later. 40 hrs after transfection, cells were treated with or without 100 nM PMA and 
harvested in RIPA buffer on ice at the end of the appropriate time period. 50 μg of each 
lysate was subjected to western blotting using anti-FLAG antibody (DDK) for FLAG-
RdgBβ-sp1 expression. Western blot protein bands were quantified using AIDA 
software. A single background value for each blot was subtracted from the intensity 
value for each band, and the protein concentration at each time point expressed 
relative to its zero time control. The data depicted in the graph are concentration of 
FLAG-RdgBβ-sp1 expression treated with PMA minus untreated control samples at 
each time point.
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3.8: Towards reconstitution of the RdgBβ-14-3-3 interaction in vitro
To begin to understand the significance of the RdgBβ-14-3-3 interaction, reconstitution 
of the complex was attempted in vitro. Firstly, recombinant RdgBβ-sp1 required 
phosphorylation. Since PKC is the only kinase that I have identified as being required 
for the serine phosphorylation and 14-3-3 interaction, I set up  an in vitro assay  for 
phosphorylation of RdgBβ-sp1 by PKC. Since RdgBβ-sp2 doesn’t contain the Ser274 
and Ser299 sites, I used this protein as a negative control. Recombinant proteins were 
incubated without or with PKC purified from rat brain (predominantly the conventional 
PKC isoforms, α, β1, β2 and γ), alongside PS, DAG (for full activation of PKC) and 
Mg-ATP (phosphate donor). I used a 14-3-3 far western blot as a read-out for 
phosphorylation of RdgBβ-sp1. However, no 14-3-3 binding to RdgBβ-sp1 (or -sp2) 
was observed after incubation of RdgBβ with PKC (Figure 3.13, top  panel). RdgBβ-sp1 
and -sp2 appeared no different in terms of molecular weight when the far western blot 
was re-probed using the anti-RdgBβ antibody #101 (Figure 3.13, middle panel), or on a 
Coomassie-stained gel (Figure 3.13, bottom panel).
Since phosphorylation by PKC was insufficient  to promote 14-3-3-binding, I exposed 
the RdgBβ-sp1 recombinant protein to HL60 cells with their full complement of Ser/Thr 
protein kinases to see whether this would promote phosphorylation of RdgBβ. I 
incubated 120 µg His-RdgBβ-sp1 or His-PITPα as a negative control, with washed 
HL60 cells and 0.4 iu.mL-1 SLO to acutely  permeabilise the cells and allow entry  of the 
recombinant PITPs. I buffered the calcium in the experiment at either physiological 
Ca2+ (100 nM, pCa7) or high (10 µM, pCa5), and added 100 nM PMA to one each of 
the pCa5 tubes. The assay  was incubated at  37°c for 20 min prior to incubation with 
nickel beads for re-capture of the recombinant proteins via their His tags. The nickel 
beads were next either crudely washed and proteins eluted in SDS-PAGE sample buffer 
(Figure 3.14 A), or washed in increasing concentrations of salt to purify the re-captured 
proteins, before elution from the beads in imidazole and buffer exchange to PIPES/salts 
buffer (Figure 3.14 B).
Both sets of samples were subjected to western blotting using the pan 14-3-3 antibody. 
In the unpurified samples, a clear band is seen in both the RdgBβ and PITPα lanes at 28 
171
kDa, likely to be binding of non-specific proteins. Above this, at ~30 kDa, is a band 
faintly present in the pCa7 RdgBβ lane and stronger in both pCa5 RdgBβ lanes, likely 
to correspond to 14-3-3 (Figure 3.14 A). This 30 kDa band is absent  from the PITPα 
lanes and is no longer detectable after protein purification (Figure 3.14 B), whereas the 
28 kDa nonspecific protein band is. The pan 14-3-3 antibody detects a protein at 48 kDa 
in all three RdgBβ lanes, which survives purification but is absent from the PITPα 
lanes. Crude staining of the membrane with indian ink is shown in the lower panels of 
Figure 3.14: RdgBβ and PITPα can clearly  be identified and the bands indicate 
approximately equal loading.
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Figure 3.13: Phosphorylation of RdgBβ by PKC in vitro
Recombinant RdgBβ-sp1 or -sp2 (10 μg per reaction) was incubated -/+ rat brain PKC 
for 1 hr at 30°c. The reaction was quenched with SDS-PAGE sample buffer, and 15 & 
30 ng or 1.5 & 3.0 μg protein were subjected to SDS-PAGE for far western blotting 
with recombinant 14-3-3 proteins (top panel) or Coomassie-staining (bottom panel), 
respectively. The far western blot was stripped and re-probed using the anti-RdgBβ 
antibody #101 by western blotting (middle panel).
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Figure 3.14: Reconstitution of the RdgBβ-14-3-3 complex in vitro
Unlabelled HL60 cells were incubated for 20 min at 37°c with recombinant His-RdgBβ-
sp1 or His-PITPα, at pCa7 (100 nM Ca2+) or pCa5 (10 μM Ca2+), with 100 nM PMA, 
where indicated, and 0.4 iu.mL-1 SLO to permeabilise the cells and allow PITP entry. 
Supernatants were then incubated with nickel beads for re-capture of the His-tagged 
proteins. (A) Captured proteins eluted directly  from the nickel beads in SDS-PAGE 
sample buffer. (B) Nickel beads (in mini-spin columns) washed twice in low, then high, 
salt buffer, prior to elution of captured proteins in imidazole. The buffer was exchanged 
to PIPES/salts pH 6.8 before SDS-PAGE sample buffer addition. All samples (A & B) 
were boiled 10 min at 95°c before SDS-PAGE and transfer to PVDF membrane. Top 
panels: membranes subjected to western blotting using the pan 14-3-3 antibody. 
Bottom panels: membranes stained with indian ink.
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3.9: Discussion
I have demonstrated that the long, unique C-terminus of RdgBβ-sp1 is disordered and 
contains two PEST sequences, often found in proteins subject to rapid turnover in cells. 
RdgBβ is ubiquitinated, phosphorylated and directly interacts with 14-3-3 via two 
phosphorylated serine residues in its C-terminus. I have shown that RdgBβ-sp1 is 
rapidly degraded in cells, more so when the protein is mutated at Ser299. Lastly, I have 
presented evidence suggesting that protein kinase C phosphorylates RdgBβ-sp1 at one 
or both of the serine residues to facilitate 14-3-3 binding: PKC is necessary but not 
sufficient to promote 14-3-3 binding.
3.9.1: Phosphorylation of RdgBβ-sp1 by PKC
Two phosphorylated residues in the RdgBβ-sp1 C-terminus, Ser274 and Ser299, 
mediate the interaction between RdgBβ and 14-3-3. Treatment of COS-7 cells 
expressing FLAG-RdgBβ-sp1 with the PKC inhibitor, BIM-I, resulted in reduced 
14-3-3 binding: the amount of 14-3-3 found in the FLAG-RdgBβ-immunoprecipitate 
from cells treated with BIM-I was approximately half that seen in untreated cells, 
relative to the same amount of FLAG-RdgBβ-sp1 immunoprecipitated. This implies that 
PKC is responsible for one or both of the phosphorylations enabling 14-3-3-binding. 
The fact that some 14-3-3-binding remains implicates at least one other kinase in 
facilitating 14-3-3-binding; indeed, in the in vitro assay, phosphorylation of RdgBβ-sp1 
by PKC alone failed to promote an interaction between RdgBβ and 14-3-3.
In addition to reduced 14-3-3 binding, the amount of FLAG-RdgBβ-sp1 present in the 
COS-7 lysate is reduced by half upon PKC inhibition, compared to the untreated 
control. As the C-terminus of RdgBβ-sp1 is disordered and susceptible to protease 
digestion, binding of 14-3-3 to the C-terminus could protect the protein from 
degradation. This is supported by the observation that the RdgBβ-sp1 S299A mutant, 
unable to bind 14-3-3, is degraded more rapidly than the wild-type protein: the 
concentration of the wild-type protein was observed to half within 5 hrs, whereas for the 
S299A mutant, this time was reduced to 2 hrs. The reduced FLAG-RdgBβ-sp1 
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expression upon PKC inhibition therefore reflects a reduced protein stability  in the 
absence of 14-3-3-binding.
There are ten PKC isozymes, which can be grouped into the categories, conventional, 
novel and atypical, based on their sequence and activation profile. BIM-I has been 
reported to inhibit the conventional isozymes, α and β1 (but not β2 or γ), the novel 
isozymes, δ and ε (but not η or θ), and the atypical isozyme, ζ (but not ι (human) or λ 
(mouse) (Martiny-Baron et al., 1993). By contrast, rat brain PKC, which failed to 
promote an interaction between RdgBβ-sp1 and 14-3-3, is predominantly the 
conventional isoforms, α, β1, β2, and γ. This could imply that the 14-3-3-binding site is 
alone mediated by either of the novel isozymes, δ or ε, or the atypical isozyme, ζ.
The use of a single inhibitor for PKC makes it difficult to draw conclusions. In addition 
to using several different inhibitors for each kinase, it would have been more 
appropriate to use each inhibitor at multiple concentrations. Chemical inhibitors are 
rarely specific for one target protein and instead may inhibit other proteins at  different 
concentrations. For example, BIM-I has many reported off-target effects: the 
manufacturer’s documentation warns that it  will also inhibit GSK-3 in primary 
adipocyte lysates (IC50=360 nM) and GSK-3β in immunoprecipitates (IC50=170 nM). In 
addition it may inhibit PKA at high concentrations (Ki=2 µM), although in my 
experiments the potential for PKA to be the kinase responsible for facilitating the 
RdgBβ-sp1-14-3-3 interaction can be excluded due to the use of the PKA inhibitor, 
H89. BIM-I could also inhibit MAPKAP kinase 1β (IC50=50 nM) and p70 S6 kinase 
(IC50=100nM) (Alessi, 1997).
3.9.2: The effect of PKA on FLAG-RdgBβ-sp1 expression and the 
RdgBβ-14-3-3 interaction
Whereas indirect inhibition of PKB had no significant effect on FLAG-RdgBβ-sp1 
expression or 14-3-3-binding, use of the PKA inhibitor, H89, increased both FLAG-
RdgBβ-sp1 and 14-3-3 presence in the FLAG-RdgBβ-sp1-immunoprecipitate by 48% 
and 60%, respectively. It  would have been interesting to assess the effect of forskolin, 
which activates adenylyl cyclase to produce cAMP and so activate PKA, on FLAG-
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RdgBβ-sp1 expression and the RdgBβ-sp1-14-3-3 - likely it would have reduced both 
FLAG-RdgBβ-sp1 expression and the interaction between RdgBβ-sp1 and 14-3-3. One 
explanation for the effect of PKA on FLAG-RdgBβ-sp1 and RdgBβ-sp1-14-3-3 is that 
PKA phosphorylates 14-3-3 proteins, inhibiting their ability to dimerise and interact 
with target proteins (Gu et al., 2006). Inhibition of PKA would then provide more 
14-3-3 for binding to RdgBβ-sp1, stabilising more of the protein against  degradation. 
The fact that binding to 14-3-3 can be increased by this treatment indicates that not all 
RdgBβ-sp1 protein molecules are bound to 14-3-3 under basal conditions.
3.9.3: The effect of PMA on FLAG-RdgBβ-sp1 expression and the 
RdgBβ-14-3-3 interaction
Inhibition of PKC reduces FLAG-RdgBβ-sp1 expression by  half, and this reduced 
amount of RdgBβ protein binds half of the amount of 14-3-3 as the untreated FLAG-
RdgBβ-sp1 population. This indicates that PKC activity  is required for formation of the 
RdgBβ-14-3-3 complex, and that binding of 14-3-3 stabilises expression of the RdgBβ-
sp1 protein. Prolonged treatment with phorbol esters, such as PMA, promotes PKC 
down-regulation, and therefore chronic treatment with PMA would be expected to 
mimic the effect of PKC inhibition. However, the reverse effect was observed: the 
expression of FLAG-RdgBβ in the lysate more than doubled after 100 nM PMA 
treatment for 16 hrs, yet the amount of 14-3-3 in the FLAG-RdgBβ-sp1-
immunoprecipitate was mildly  increased (1.3-fold). As discussed for PKA above, this 
latter result, though only a small increase, indicates that not all of the RdgBβ-sp1 
molecules are bound to 14-3-3.
Whereas BIM-I inhibits PKC consistently throughout the 16 hrs treatment, PMA 
strongly activates PKC at first and only down-regulates it later. Early in the treatment, 
PKC might phosphorylate RdgBβ-sp1 in its C-terminus, promoting 14-3-3 binding and 
stabilisation of the protein. At later time points, the down-regulation of PKC is 
irrelevant, since a large pool of stable RdgBβ-sp1 bound to 14-3-3 has accumulated. 
Only new RdgBβ-sp1 made at the later time points will be affected, as this protein will 
not be phosphorylated by PKC, and therefore not bound to 14-3-3 and stabilised. 
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Consistent with this hypothesis, FLAG-RdgBβ-sp1 protein expression reaches a 
maximal concentration by 4 hrs PMA treatment.
3.9.4: The RdgBβ-sp1 Thr278 residue
The Thr278 residue does not lie in a consensus site for 14-3-3-binding, yet mutation of 
Thr278 to an alanine residue reduced 14-3-3 binding to RdgBβ-sp1 by ~90%. It may be 
that phosphorylation of either Ser274 or Ser299 is dependent on prior phosphorylation 
of Thr278. Alternatively, removal of the Thr278 phosphorylation could affect the local 
protein structure, making it  unfavourable for binding of 14-3-3. Phosphorylated Thr278 
might make additional contacts with 14-3-3, or permit the binding of other protein 
partners, required for the full, stable binding of 14-3-3. Thr278 lies adjacent to a proline 
residue, a common recognition motif in protein-protein interactions, and phospho-T278 
lies in a consensus site for binding the BRCT domain (Rodriguez et al., 2003), PBD 
domain (Elia et al., 2003a; 2003b), and WW domain (Lu et al., 1999b). It is notable that 
expression of RdgBβ-sp1 T278A was lower than that observed for S299A, indicative of 
its instability.
3.9.5: Reconstitution of the RdgBβ-14-3-3 complex in vitro
Experiments using recombinant proteins could aid in our understanding of the 
significance of the RdgBβ-14-3-3 complex in vivo. Phosphorylation of recombinant 
RdgBβ-sp1 by rat  brain PKC failed to promote 14-3-3 binding to RdgBβ in a 14-3-3 far 
western blot. However, exposure of recombinant RdgBβ-sp1 to the intracellular 
environment of HL60 cells led to endogenous 14-3-3-binding, which was most notable 
at high Ca2+ (10 µM). The addition of PMA to the assay had no effect on 14-3-3-
binding. The RdgBβ-14-3-3 association was disrupted by washing with a high salt 
buffer (525 mM  NaCl). High salt disrupts electrostatic, and therefore protein-protein, 
interactions. Since purified, phosphorylated RdgBβ would be required for analysis of 
the RdgBβ-14-3-3 complex in vitro, recombinant (GST-tagged) 14-3-3 needs to be used 
along with the HL60 cell-phosphorylated RdgBβ. This will also give a much higher 
yield of 14-3-3 than would be possible in mammalian cells.
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The presence of a 48 kDa band in the pan 14-3-3 blots is peculiar (Figure 3.14, upper 
panels). Since this band is not observed in FLAG-RdgBβ-sp1-immunoprecipitates from 
COS-7 cells, and since the band is not present in the PITPα lanes, this protein must  be 
contamination derived from the recombinant His-RdgBβ-sp1 protein preparation.
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CHAPTER 4: An interaction between RdgBβ and ATRAP
4.1: Introduction
Two yeast two-hybrid screens have reported an interaction between RdgBβ and the 
Angiotensin II receptor-associated protein, ATRAP (Rual et al., 2005; Venkatesan et  al., 
2009). ATRAP interacts with the AT1R (Daviet et al., 1999; Wang et al., 2002; Lopez-
Ilasaca et al., 2003), an association that increases more than 2-fold upon Angiotensin II 
stimulation (Tanaka et al., 2005; Azuma et al., 2007). Over-expression of ATRAP 
suppresses inositol phosphate production by PLC in response to Angiotensin II 
stimulation (Daviet et al., 1999; Lopez-Ilasaca et al., 2003), likely  by promoting 
uncoupling from Gq protein and receptor internalisation (Lopez-Ilasaca et al., 2003; 
Tanaka et al., 2005; Azuma et al., 2007). CAML has also been identified as a binding 
partner of ATRAP (Guo et al., 2005), and it  appears that this interaction has a distinct, 
yet related, function to the ability of ATRAP to down-regulate Angiotensin II signalling 
(Min et al., 2009).
The biochemical property uniting PITPs is their ability to bind and transfer PI, and a 
role for these proteins in PLC activity has been established (Thomas et al., 1993; Xie et 
al., 2005; Adachi et al., 2010). PITPs deliver PI to the agonist-sensitive pool at the 
plasma membrane, making the PI delivered by  this protein a more favourable substrate 
for PI kinases and subsequently PLC (Cunningham et al., 1995). Furthermore, PITPs 
have also been shown to exert a stimulatory activity on PI kinases (Kauffmann-Zeh et 
al., 1995; Kular et al., 1997; Panaretou et al., 1997).
Both RdgBβ and ATRAP are highly  expressed in the heart and kidney (Daviet et al., 
1999; Fullwood et al., 1999; Wang et al., 2002; Takano et al., 2003; Tanaka et al., 2005; 
Tsurumi et  al., 2006; Oppermann et al., 2010). Since ATRAP reduces Angiotensin II-
stimulated inositol phosphate production by PLC, and other PITPs have a role in 
providing the substrate for PLC activity, it seems possible that an interaction between 
RdgBβ and ATRAP is functionally  significant. I therefore begin this part of my study by 
assessing whether an interaction can be observed between RdgBβ and ATRAP using co-
immunoprecipitation experiments. I find that an RdgBβ-ATRAP association is only 
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observed after stimulation of cells with PMA for 4-16 hrs and can be blocked by 
inhibition of PKC or protein synthesis. I deduce that RdgBβ interacts with ATRAP via 
its PITP domain, and despite sharing ~40% identity  with the class I PITPs, PITPα and 
PITPβ, the interaction between ATRAP and the PITP domain is specific to RdgBβ. 
Candidate ATRAP-binding residues on the RdgBβ PITP domain are proposed. The 
relationship  between Angiotensin II, PLC activity  and the RdgBβ-ATRAP interaction is 
explored.
4.2: RdgBβ does not interact with ATRAP under basal conditions
I first sought to demonstrate an interaction between FLAG-RdgBβ and HA-ATRAP 
proteins expressed in COS-7 cells. However, initial co-immunoprecipitation 
experiments failed to confirm an interaction between the two proteins. Some protein-
protein interactions are very  transient and as a consequence the interacting partners may 
dissociate during immunoprecipitation. One method that may  be used to stabilise 
protein-protein interactions is to treat cells with cell-permeable cross-linkers prior to 
cell harvest. In the experiment shown in Figure 4.1 A I have treated the cells with 0.5 
mM disuccinimidyl suberate (DSS) before harvesting and immunoprecipitation of HA-
ATRAP. HA-ATRAP is clearly  seen in the immunoprecipitate, yet no additional protein 
bands are present in the far right-hand lane of the anti-FLAG blot, indicating an absence 
of FLAG-RdgBβ-sp1.
The second yeast-two hybrid screen that reported an interaction between RdgBβ and 
ATRAP, recorded the RdgBβ nucleotide (mRNA) accession number as BC007905 
(Venkatesan et al., 2009), which translates to protein AAH07905 and is the sequence of 
the short splice variant, RdgBβ-sp2. Both splice variants receive coding sequence from 
exons 1-8 of the PITPNC1 gene. In addition, a short C-terminus for sp2 is encoded by 
exon 9. RdgBβ-sp1 receives the sequence for its long C-terminus from exon 10. It is 
therefore possible that ATRAP interacts with RdgBβ-sp2, not sp1, via the 32 residues 
coded for by  exon 9. To test this hypothesis I used COS-7 cells transiently transfected 
with empty control vector or pcDNA3-HA-ATRAP, immunoprecipitated HA-ATRAP 
from the cell lysates using its HA tag and subjected the immunoprecipitate to western 
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blotting using the anti-RdgBβ polyclonal antibody, #101, which recognises both 
RdgBβ-sp1 and sp2 (Garner et al., 2011). Neither RdgBβ-sp1 nor -sp2 were found to be 
present in the HA-ATRAP immunoprecipitate (Figure 4.1 B). However, although the 
101 antibody clearly detects the recombinant RdgBβ-sp1 (10-30 ng), endogenous 
RdgBβ is not detected in the lysates.
4.3: RdgBβ interacts with ATRAP when cells are stimulated with PMA
The 101 antibody recognises the recombinant RdgBβ proteins at quantities of >5 ng 
(Garner et al., 2011) but not the endogenous proteins in COS-7 cells (Figure 2.3, p. 87; 
Figure 2.4, p. 105), implies that the protein is expressed at  very low amounts. This can 
be compared to another PITP, PITPβ: the 1C1 antibody used in Figure 3.2 clearly 
detects the endogenous PITPβ, and detects recombinant protein above 6.2 ng (Morgan 
et al., 2006). I have demonstrated that FLAG-RdgBβ-sp1 is subject to rapid turnover in 
COS-7 cells (Figure 3.2), and therefore hypothesised that there may simply not be 
enough RdgBβ protein present, even with over-expression, to enable an interaction 
between RdgBβ and ATRAP to be seen. I observed that 16 hr treatment with the phorbol 
ester PMA more than doubled the expression of FLAG-RdgBβ-sp1 (Figure 3.11) and I 
therefore questioned whether an interaction between RdgBβ and ATRAP could be 
observed under these conditions. COS-7 cells were transfected with plasmids encoding 
FLAG-RdgBβ-sp1 and HA-ATRAP, and half of the plates were treated with 100 nM 
PMA for 16 hrs prior to cell harvest. HA-ATRAP co-immunoprecipitated with FLAG-
RdgBβ-sp1, and vice versa, when cells were treated with PMA (Figure 4.2).
The PMA treatment was performed in normal COS-7 cell culture medium (DMEM 
containing 10% FCS). Since FCS contains growth factors and is used to promote cell 
division in culture, I assessed whether the presence of serum affected the RdgBβ-
ATRAP interaction. The presence or absence of FCS had no effect: the RdgBβ-ATRAP 
interaction was still only observed when cells were treated with PMA (Figure 4.3).
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(Facing page) Figure 4.1: An RdgBβ-ATRAP interaction is not observed under 
basal conditions
(A) COS-7 cells were transfected with pcDNA3 empty  control vector, pEFPLink-FLAG-
RdgBβ-sp1 or pcDNA3-HA-ATRAP plasmids as indicated. Two days after transfection 
the cells were treated with DSS cross-linker prior to harvest. HA-ATRAP was 
immunoprecipitated using its HA tag. Eluted proteins were run alongside 9 μg whole 
cell lysate on an SDS-PAGE gel. Separated proteins were transferred to PVDF 
membrane and probed with anti-FLAG (polyclonal, OctA) antibody, and re-probed with 
anti-HA (HA-probe) antibody. The position of the antibody heavy (Ab HC) and light (Ab 
LC) chains in the immunoprecipitate are indicated. (B) COS-7 cells were transfected 
with either pcDNA3 empty  control vector or pcDNA3-HA-ATRAP plasmid, as indicated. 
HA-ATRAP was immunoprecipitated using its HA tag, and the eluted proteins run 
alongside 10 μg whole cell lysate and His-RdgBβ-sp1 recombinant proteins (quantities 
indicated) on an SDS-PAGE gel. The separated proteins were transferred to PVDF 
membrane and probed with anti-RdgBβ polyclonal antibody  #101, then re-probed with 
HA-probe antibody.
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(Facing page) Figure 4.2: RdgBβ interacts with ATRAP when cells are stimulated 
with PMA
COS-7 cells were transfected with pcDNA3.1-FLAG-RdgBβ-sp1 with or without 
pcDNA3-HA-ATRAP co-transfection. Cells were then unstimulated or stimulated with 
100 nM PMA for 16 hrs prior to cell harvest and FLAG-immunoprecipitation. Lysates 
were run on SDS-PAGE gels for western blotting with anti-FLAG (DDK) and anti-HA 
antibodies (18 μg and 3 μg, respectively). FLAG- and HA-immunoprecipitates were 
separated by SDS-PAGE and subjected to western blotting using anti-HA and anti-
FLAG (DDK) antibodies, respectively. The IP: FLAG membrane was stripped and re-
probed for the presence of FLAG in the IP.
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Figure 4.3: The RdgBβ-ATRAP interaction is unaffected by serum in the cell 
culture medium
COS-7 cells were transfected with pcDNA3.1-FLAG-RdgBβ-sp1 and pcDNA3-HA-
ATRAP, or pcDNA3.1 empty control vector. Cells then were treated with or without 100 
nM PMA and 10% FCS in the cell culture medium, for 16 hrs prior to cell harvest. 
RdgBβ was immunoprecipitated using its FLAG tag, and the immunoprecipitates 
probed by  western blotting using anti-HA antibodies. The membrane was stripped and 
re-probed for the presence of FLAG-RdgBβ in the immunoprecipitate.
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4.4: PKC activity and protein synthesis are required for the PMA-induced 
RdgBβ-ATRAP interaction
Since PMA is an analogue of DAG, PKC is a direct target of PMA. I therefore wanted 
to find out whether the interaction between RdgBβ and ATRAP was mediated by this 
kinase by using an inhibitor of PKC, BIM-I. I also reasoned that since maximal FLAG-
RdgBβ-sp1 expression is reached by 4 hrs PMA treatment (Figure 3.12), the RdgBβ-
ATRAP interaction would also be observed at 4 hrs. Only  trace amounts of HA-ATRAP 
were present in the FLAG-RdgBβ-sp1 immunoprecipitate when cells were treated with 
both 100 nM  PMA and 5 µM BIM-I for 4 hrs prior to harvest, in contrast to 4 hr PMA 
treatment alone, at which time the interaction between RdgBβ and ATRAP was very 
clear (Figure 4.4).
I have demonstrated that  FLAG-RdgBβ-sp1 expression is reduced by  half within 5 hrs 
of inhibition of protein synthesis using cycloheximide (Figure 3.2). To determine 
whether the stabilisation of nascent RdgBβ is required before the RdgBβ-ATRAP 
interaction is observed, I treated cells with 100 µg.mL-1 cyclohexmide in combination 
with 100 nM PMA for 4 hrs prior to cell harvest. CHX abolished the PMA-induced 
RdgBβ-ATRAP interaction, despite the presence of FLAG-RdgBβ in the FLAG-
immunoprecipitate (Figure 4.4).
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Figure 4.4: PKC and protein synthesis inhibition block the RdgBβ-ATRAP 
interaction
COS-7 cells were transfected with pcDNA3.1-FLAG-RdgBβ-sp1 and pcDNA3-HA-
ATRAP, or pcDNA3.1 empty  control vector. Cells were then either untreated, or treated 
with 100 nM PMA, with or without 5μM BIM-I or 100 μg.mL-1 CHX for 4 hr prior to cell 
harvest as indicated. FLAG-immunoprecipitates were subjected to western blotting 
using anti-HA antibodies, and the membrane was re-probed to confirm the presence of 
FLAG-RdgBβ-sp1.
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4.5: The PMA-induced RdgBβ-ATRAP interaction and a calcium ionophore
PMA is an analogue of DAG, yet for full activity PKC requires the presence of 
phosphatidylserine (PS), DAG and Ca2+. High intracellular Ca2+ can be recapitulated in 
a number of ways, one of which is by treatment of cells with a calcium ionophore, such 
as ionomycin. Ionomycin raises the intracellular Ca2+ level by  transporting it across the 
plasma membrane of the cell from the extracellular medium. Although treatment of cells 
expressing FLAG-RdgBβ-sp1 and HA-ATRAP with ionomycin alone did not induce an 
interaction between RdgBβ-sp1 and ATRAP, dual treatment with both PMA and 
ionomycin doubled the amount of HA-ATRAP observed in the FLAG-
immunoprecipitate (Figure 4.5). PMA and ionomycin, neither alone nor in conjunction, 
induced an interaction between RdgBβ-sp1 and ATRAP at 1 hr treatment.
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(Facing page) Figure 4.5: The PMA-induced RdgBβ-ATRAP interaction and a Ca2+ 
ionophore
(A) COS-7 cells were transfected with pcDNA3.1-FLAG-RdgBβ-sp1 and pcDNA3-HA-
ATRAP, or pcDNA3.1 empty  control vector. Cells were treated with 100 nM PMA and/or 
5 μM ionomycin (ʻionoʼ) for 1 or 4 hrs prior to cell harvest. 20μg lysate was loaded in 
each well of the lysate gels. FLAG-immunoprecipitates were separated by  SDS-PAGE 
and subjected to western blotting using anti-HA antibodies. The membrane was 
stripped and re-probed using anti-FLAG (DDK) antibodies to confirm the presence of 
FLAG-RdgBβ in the immunoprecipitate. (B) Protein bands were quantified using AIDA 
software. The amount of HA-ATRAP in the immunoprecipitate was adjusted for the 
amount of FLAG-RdgBβ present for each data point. Across each experiment, values 
were adjusted relative to HA-ATRAP present at 4 hr PMA treatment to enable 
independent experiments to be combined. Error bars are SEM; n=2. Significance 
values are calculated relative to untreated control using an unpaired t test:  * p<0.05, 
*** p<0.001.
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4.6: ATRAP interacts with the PITP domain of RdgBβ-sp1, a domain 
distinct from the 14-3-3-binding site
Whereas ATRAP only binds to RdgBβ-sp1 when cells are stimulated with PMA for 4-16 
hrs, 14-3-3 interacts with RdgBβ-sp1 under both basal and PMA-stimulated conditions. 
The C-terminus of RdgBβ-sp1 is the region of the protein most likely to serve as a 
protein-protein interaction domain, since it lacks secondary structure and is therefore 
flexible. To assess whether ATRAP also binds to the C-terminus of RdgBβ-sp1, a 
mutation was made in the pcDNA3.1-FLAG-RdgBβ-sp1 plasmid to convert Ile251 into 
a stop  codon so that only residues 1-250 of RdgBβ-sp1 would be translated - in essence 
completely removing the disordered C-terminus. This mutant  was investigated for 
binding to ATRAP alongside the RdgBβ-sp1 S299A mutant, which is unable to bind 
14-3-3.
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Figure 4.6: ATRAP interacts with the PITP domain of RdgBβ
COS-7 cells were transfected with pcDNA3-HA-ATRAP and either pcDNA3.1-FLAG-
RdgBβ-sp1 WT, the truncated 1-250 or S299A mutants. Cells were then treated with or 
without 100 nM PMA in the cell culture medium for 16 hrs prior to cell harvest. FLAG-
immunoprecipitates were subjected to western blotting using anti-HA antibodies 
alongside cell lysates, and re-probed for FLAG (DDK).
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Surprisingly, HA-ATRAP was found in the FLAG-immunoprecipitates of both RdgBβ-
sp1 1-251 and S299A mutants (Figure 4.6), indicating that ATRAP binds to the PITP 
domain of RdgBβ-sp1 rather than to its C-terminus. Like the wild-type protein, the 
expression of both FLAG-RdgBβ-sp1 1-250 and the S299A mutant appears to increase 
upon treatment with PMA.
Since ATRAP binds to the PITP domain of RdgBβ-sp1 and 14-3-3 binds to the extended 
C-terminus, it is possible that both proteins bind simultaneously upon PMA treatment. 
To investigate this possibility, COS-7 cells were transfected with both pcDNA3.1-
FLAG-RdgBβ-sp1 and pcDNA3-HA-ATRAP plasmids and stimulated with PMA prior 
to cell harvest. HA-ATRAP was immunoprecipitated using its HA tag, and the 
immunoprecipitate probed using the pan 14-3-3 antibody by  western blotting to see 
whether the FLAG-RdgBβ-sp1 bound to HA-ATRAP came along with 14-3-3. FLAG-
RdgBβ-sp1 and HA-ATRAP are clearly present in the right-hand lane of the western 
blot, where both proteins together with PMA stimulation are present (Figure 4.7 A). The 
30 kDa 14-3-3 band is not present, however, but there does seem to be a particularly 
large quantity  of non-specific proteins in the immunoprecipitate. This can be seen more 
clearly  when FLAG-RdgBβ-sp1-immunoprecipitates are run alongside HA-ATRAP 
immunoprecipitates on a gradient gel and subjected to western blotting using pan 14-3-3 
antibody (Figure 4.7 B). The HA-immunoprecipitates have very dark non-specific 
bands where 14-3-3 would ordinarily be seen in the FLAG-RdgBβ-sp1-
immunoprecipitate.
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(Facing page) Figure 4.7: Investigating the relationship between RdgBβ-ATRAP 
and RdgBβ-14-3-3
(A) COS-7 cells expressing either FLAG-RdgBβ-sp1 alone or with HA-ATRAP were 
treated with 5 μM BIM-I or 100 nM PMA, as indicated, for 16 hrs prior to cell harvest. 
HA-ATRAP was immunoprecipitated using its HA tag (1.5 μg HA-probe, 20 μL Protein 
A/G PLUS Agarose), the eluted proteins separated by  SDS-PAGE and transferred to 
PVDF membrane. The HA-immunoprecipitate was probed by  western blotting using 
anti-FLAG monoclonal antibody (DDK), pan 14-3-3 and re-probed with anti-HA 
monoclonal antibody. (B) FLAG-RdgBβ-sp1-immunoprecipitate (FL) and HA-ATRAP-
immunoprecipitate (using one third the amount of antibody for IP, 0.5 μg) from control 
COS-7 cells (left two lanes) and cells expressing both FLAG-RdgBβ-sp1 and HA-
ATRAP, treated with 100 nM PMA prior to cell harvest (right two lanes), have been run 
alongside one another on a NuPAGE 4-12% gradient gel. The separated proteins were 
transferred to PVDF membrane and probed by western blotting using the pan 14-3-3 
antibody.
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4.7: Binding of ATRAP to the PITP domain is specific to RdgBβ
Since the human RdgBβ sequence is ~40% identical to PITPα and PITPβ in its PITP 
domain, and ATRAP binds to the PITP domain of RdgBβ, it is important to question 
whether ATRAP binds to either PITPα or PITPβ. The available PITPα and PITPβ 
antibodies exhibit  good recognition of the endogenous proteins, and so HA-ATRAP 
alone was expressed in COS-7 cells and immunoprecipitated using its HA tag following 
16 hrs PMA treatment. The HA-immunoprecipitates were separated using SDS-PAGE, 
transferred to PVDF membrane and probed using anti-PITPα or anti-PITPβ antibodies 
(Figure 4.8). Neither PITPα nor PITPβ was present in the HA-ATRAP-
immunoprecipitate.
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Figure 4.8: Binding of ATRAP to the PITP domain is specific to RdgBβ
HA-ATRAP was expressed in COS-7 cells and immunoprecipitated using its HA tag 
from lysates following 16 hrs 100 nM PMA treatment. HA-immunoprecipitates were 
separated by  SDS-PAGE, the proteins transferred to PVDF membrane and subject to 
western blotting using anti-PITPα antibody #674 or anti-PITPβ antibody #1C1.
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4.8: Determination of candidate RdgBβ ATRAP-binding residues
ATRAP binds to the PITP domain of human RdgBβ (1-250 aa), and binding is specific 
to RdgBβ despite ~40% identity shared between RdgBβ and the class I PITPs. This 
information can be used to determine candidate residues for binding of ATRAP. A 
multiple sequence alignment of the human PITPα, PITPβ and RdgBβ (1-250) indicated 
that 91 residues in the RdgBβ sequence are identical to those in PITPα and PITPβ (red 
amino acids; highly conserved residues), 102 residues have similar physicochemical 
properties (magenta amino acids; conserved residues), and 57 residues differ from the 
PITPα and PITPβ sequences (black residues; unconserved) (Figure 4.9 A). As ATRAP 
binds to RdgBβ but not to PITPα or PITPβ, the identical and conserved residues were 
excluded as candidate ATRAP-binding residues, leaving 57 potential ATRAP-binding 
residues.
An X-ray crystal structure of the RdgBβ protein has not been reported. The 
MODELLER program (Eswar et al., 2006), was therefore used to produce a 
comparative model of the RdgBβ PITP domain based on the structure of rat PITPα 
(PDB: 1t27; (Yoder et al., 2001)), which shares the highest number of identical residues 
with human RdgBβ of all of the class I PITP structures reported. The location of the 
lipid-binding cavity  (‘void’) was determined using AVP (Cuff and Martin, 2004), and a 
list of the residues lining the cavity generated (Figure 2.1). These too were excluded as 
candidate ATRAP-binding residues, as the ATRAP-binding site most likely lies on the 
surface of the RdgBβ PITP domain. This removed 17 potential ATRAP-binding 
residues, leaving 40 candidates remaining.
The candidate ATRAP-binding residues were then mapped onto the RdgBβ model, 
grouping them into patches of residues. A further 3 residues were excluded as candidate 
ATRAP-binding residues as they are not, or are only  barely, exposed on the surface of 
the protein (L12, I138, A221). Remaining candidate residues were grouped into 10 
patches (Figure 4.9 B). One residue, Q43, is largely exposed on the surface of the 
protein, but does not appear to form part of a cluster of residues. Notably, 19 out of the 
37 remaining residues lie in the regulatory loop: 8 residues lie in the β6-αC loop, and 11 
residues lie in the β7-β8 loop.
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(Facing page) Figure 4.9: Candidate ATRAP-binding residues on the RdgBβ PITP 
domain
(A) Multiple sequence alignment of the human sequences RdgBβ-sp1 1-250 aa 
(NP_036549.2), PITPα  (NP_006215.1) and PITPβ (NP_036531.1), using the MATLAB 
multialign function. Red=highly  conserved (identical) residues, magenta=conserved 
(similar) residues, black=non-conserved residues. x=non-conserved residues 
previously  identified as cavity-lining residues, o=candidate ATRAP-binding residues in 
the RdgBβ sequence. (B) Candidate ATRAP-binding residues were mapped onto the 
comparative model of the RdgBβ PITP domain. For each patch of amino acids, their 
location is first given in terms of secondary  structure, followed by  the residues making 
up the patch using single letter amino acid code. (For naming of α-helices or β-strands, 
see Figure 1.3 C for the tertiary structure, and Figure 2.1 A for the primary sequence.) 
For patches comprised of residues from more than one location, details are as follows: 
D115/H177/Q178/I180 patch: D115 lies in the β6-αC loop, whereas the other residues 
lie in the β7-αE loop. H51/G53/Y89 patch: H51 and G53 lie in the β2-β3 loop, whereas 
Y89 is contributed from the β4-β5 loop. Hydrophobic patch: W71 lies on αB helix, V193 
lies in the β8-αF loop. Cysteine patch: C136 is located on the β7 strand, whereas C142 
lies in the β7-αE loop. E162/Y227 patch: E162 lies in the β7-αE loop, whereas Y227 is 
located in the αF helix.
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4.9: Determination of a potential ATRAP RdgBβ-binding site
Lopez-Ilasaca and colleagues reported that ATRAP has three transmembrane domains 
and that  the protein is oriented with its N-terminus outside of the cell (Lopez-Ilasaca et 
al., 2003). The class I PITPs, PITPα and PITPβ, are cytosolic proteins, and fluorescence 
microscopy has been used to show that the same is true for RdgBβ (Fullwood et al., 
1999; Takano et al., 2003). In addition, the RdgBβ protein sequence does not contain 
any organelle import sequences; the default address for proteins leaving the Golgi 
apparatus is the cytosol. Therefore, RdgBβ would be expected to interact with ATRAP 
through its cytosolic domains, the intracellular loop and protein C-terminus. The 
ATRAP protein sequence I have used in my immunoprecipitation experiments is the 
mouse sequence, and the yeast  two-hybrid screens from which the interaction was first 
identified was with human proteins (Rual et al., 2005; Venkatesan et al., 2009). 
Therefore, candidate RdgBβ-binding residues on the ATRAP protein are residues 
common to both the human and mouse sequences in the intracellular loop and C-
terminal residues. The human and mouse sequences share 76% identity, however, 
making it difficult to narrow down the binding site further without further experiments.
4.10: The RdgBβ-ATRAP interaction and Angiotensin II
Thus far, the interaction between RdgBβ and ATRAP has only been observed when cells 
are stimulated with PMA. Unlike DAG, the phorbol ester PMA is not metabolised by 
mammalian cells and so promotes a much more potent, sustained activation of PKC 
than would be instigated in a physiological setting. The interaction between RdgBβ and 
ATRAP is also not seen at short periods of PMA, only at >4 hrs, making the conditions 
under which the RdgBβ-ATRAP interaction might occur in vivo difficult to predict. 
ATRAP interacts with the AT1R, and binding is increased upon Angiotensin II 
stimulation. Angiotensin II was therefore tested for its ability to stimulate the RdgBβ-
ATRAP interaction. COS-7 cells were co-transfected with FLAG-RdgBβ-sp1, HA-
ATRAP and HA-AT1R plasmids and stimulated with Angiotensin II for differing time 
periods (Figure 4.10).
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In Figure 4.10 A, COS-7 cells transfected with the HA-AT1R have been stimulated with 
100 nM Angiotensin II for 10 mins following 16 hrs serum starvation. In the FLAG-
immunoprecipitate, FLAG-RdgBβ-sp1 is clearly  seen in all but the first, control-
transfected lane. In the lysate, HA-ATRAP is well-expressed in the final two lanes. 
However, when the FLAG-immunoprecipitate is probed with the anti-HA antibody, no 
clear HA-ATRAP band is seen. In this experiment, as in the next three, Figure 4.10 B-D, 
HA-AT1R is not seen when the lysate is probed with anti-HA antibody.
The experiment shown in Figure 4.10 B is slightly more complex. The third lane from 
the left is intended to be the positive control: cells expressing FLAG-RdgBβ-sp1 and 
HA-ATRAP have been treated for 16 hrs with 100 nM PMA (in DMEM  containing 0% 
FCS, as in Figure 4.3), yet the band corresponding in size to HA-ATRAP in the FLAG-
RdgBβ-immunoprecipitate is faint compared to other experiments. Lanes 6, 7, 8 have 
been treated for 30 min (following 16 hr serum starvation) with EGF, insulin and 100 
nM Angiotensin II, respectively, with only  the cells in the final lane co-transfected with 
HA-AT1R. The cells in lanes 4 and 5 have been transfected with the plasmid encoding 
FLAG-RdgBβ-sp2 rather than -sp1, together with HA-ATRAP, and treated either 
without (lane 4) or with (lane 5) 100 nM PMA for 16 hr. Despite FLAG-RdgBβ-sp2 
expression being almost completely absent, it  is enriched in the FLAG-
immunoprecipitate. In both the lysate and FLAG-immunoprecipitate, more FLAG-
RdgBβ-sp2 is observed in the cells treated with PMA than those without, indicating a 
similar stabilising effect  of PMA on RdgBβ-sp2. Unusual in this experiment is the 
variability in HA-ATRAP expression in the lysate - HA-ATRAP is normally  expressed 
at a similar level throughout. If RdgBβ expression must be stabilised so that the protein 
is allowed to accumulate before ATRAP-binding is observed, then it  is important also to 
quantify FLAG-RdgBβ in the lysate, re-probed and adjusted for ARF loading control. 
Compared to untreated control (lane 2) (1.0), the quantity of FLAG-RdgBβ-sp1 in 
PMA-treated cells was 1.66, in EGF-treated cells it was 1.33, following insulin 
treatment it was 1.04, and in Angiotensin II-treated cells it was 1.37.
Plasmids encoding FLAG-RdgBβ-sp1 and HA-AT1R were transfected into all cells in 
the experiment  shown in Figure 4.10 C; the HA-ATRAP plasmid was transfected into 
cells in lanes 2, 4 and 6. Cells with and without HA-ATRAP expression were then either 
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untreated, or treated with 1 µM  PMA or 1 µM  Angiotensin II for 90 mins, without prior 
serum starvation. Again, no clear HA-ATRAP bands are observed in the FLAG-
immunoprecipitate, and the ARF bands in the re-probe of the lysate membrane and 
surprisingly variable in this experiment, making any  comment about stabilisation of 
FLAG-RdgBβ difficult to substantiate. Looking at the FLAG-immunoprecipitate alone, 
the most believable HA-ATRAP band is in the lane treated with 1 µM Angiotensin II, 
with the second most likely  being in the final lane, the cells treated with 1 µM PMA. 
Similarly, the FLAG-RdgBβ-sp1 in the immunoprecipitate appears to be higher in the 
Angiotensin II-treated lane, although one could argue that all of the (non-specific) 
protein bands in that lane are darker, which would indicate a higher amount of total 
protein loaded onto the gel.
In Figure 4.10 D, 16 hr treatment of Angiotensin II (1 µM) and PMA (1, 10, 100 nM) 
have been administered prior to cell harvest and immunoprecipitation. The positive 
control band for HA-ATRAP in the immunoprecipitate is clearly seen for 100 nM PMA, 
and also for 10 nM PMA. The band may also be present, although very faint, for 1 nM 
PMA, and by extension a band of the same molecular weight might be present in the 
immunoprecipitate of the Angiotensin II-treated cells, but even fainter. As in the 
previous experiment (Figure 4.10 C), the FLAG-RdgBβ-sp1 expression in the whole 
cell lysates seems misleading - the protein bands have an increased intensity towards the 
centre of the western blot as though there was inadequate mixing during antibody 
incubation, development with ECL or imaging.
205
(Facing page, and subsequent three pages) Figure 4.10: The RdgBβ-ATRAP 
interaction and Angiotensin II stimulation
All experiments were carried out in COS-7 cells transiently  transfected with HA-AT1R 
and with FLAG-RdgBβ-sp1 and HA-ATRAP, as indicated. RdgBβ was 
immunoprecipitated using its FLAG tag, the immunoprecipitate subjected to western 
blotting using the anti-HA antibody, HA-probe, followed by  re-probing of the membrane 
to confirm the presence of FLAG-RdgBβ-sp1 in the immunoprecipitate. Whole cell 
lysates were also probed to confirm protein expression: HA-AT1R was not seen in any 
of the HA lysate blots. (A) Cell culture medium containing 10% FCS was removed and 
replaced with fresh DMEM containing 0% FCS for serum starvation of the cells, 16hrs 
prior to 100 nM Angiotensin II treatment for 10 mins in HEPES buffer. (B) Serum-
starved cells were treated with 100 nM Angiotensin II, 50 ng.mL-1 EGF or 100 nM 
insulin for 30 mins prior to harvest. In addition, cells transiently  expressing FLAG-
RdgBβ-sp1 or -sp2 and HA-ATRAP were treated with 100 nM PMA prior to harvest. (C) 
Cells in this experiment were not serum-starved prior to treatment; cells were treated 
with 1 μM PMA or angiotensin II in HEPES buffer prior to cell harvest and 
immunoprecipitation of FLAG-RdgBβ. (D) Cells were treated with 1 μM angiotensin II in 
DMEM + 10% FCS for 16 hrs prior to cell harvest, alongside 1, 10 and 100 nM PMA.
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4.11: RdgBβ and the stimulation of PLC activity
PITP is required for the reconstitution of PLC activity (Thomas et al., 1993; 
Kauffmann-Zeh et al., 1995; Cunningham et al., 1996), and ATRAP suppresses 
Angiotensin II-stimulated inositol phosphate production (Daviet et al., 1999; Lopez-
Ilasaca et al., 2003). I therefore wondered whether there was a function for the RdgBβ-
ATRAP interaction in PLC signalling.
I first  tested whether RdgBβ is involved in Angiotensin II-stimulated PLC activity. 
HEK-293 cells were transfected with a plasmid encoding HA-AT1R, with or without 
RdgBβ-sp1 co-transfection. Cells were labelled for 24 hrs with [3H]-inositol prior to 
Angiotensin II stimulation. The [3H]-inositol phosphates were separated from the [3H]-
inositol lipids by Chloroform-Methanol extraction, and from other water soluble 
components by isolation using Dowex columns. RdgBβ over-expression was observed 
to increase inositol phosphate production by PLC (Figure 4.11 A).
By contrast, the reverse was seen upon ATRAP co-expression with the AT1R (Figure 
4.11 A). Inositol phosphate production was reduced to ~40% of that observed upon 
AT1R expression alone (0.41 ±0.02 SD, n=2, mean fold difference across both 
Angiotensin II concentrations). With ATRAP over-expression, inositol phosphates are 
produced in an Angiotensin II dose-dependent manner. This is in contrast with the 
results for RdgBβ over-expression: for RdgBβ, no significant difference is observed 
between 10 nM and 1 µM Angiotensin II.
Since an interaction is only  observed between RdgBβ and ATRAP following 4-16 hrs 
PMA treatment, I assessed the effect of this treatment on PLC activity. For this 
experiment I used COS-7 cells transiently transfected with the HA-AT1R plasmid and a 
HEK-293 cell line stably expressing AT1R (HEK-293-AT1R). Angiotensin II treatment 
time was reduced to 5 min, at 100 nM.
Notably, RdgBβ and ATRAP over-expression do not produce the same response in the 
absence of PMA as seen in the previous graph. Here, RdgBβ has no effect on 
Angiotensin II-stimulated inositol phosphate production, and the effect of ATRAP is to 
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increase inositol phosphates rather than reduce them, although the error bars are very 
large (Figure 4.11 B & C). The over-expression of RdgBβ and ATRAP together reduces 
Angiotensin II-stimulated inositol phosphate production in COS-7 cells.
In general, PMA pre-treatment caused a reduction in inositol phosphate production in 
response to Angiotensin II. An exception is seen for control HEK-293-AT1, where the 
reverse is observed (Figure 4.11 C).
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(Facing page) Figure 4.11: PLC activity in intact cells with RdgBβ and ATRAP 
over-expression
(A) [3H]-inositol-labelled HEK-293 cells transiently expressing HA-AT1R, and co-
expressing RdgBβ-sp1 and/or HA-ATRAP, were treated with Angiotensin II (AngII) at 
the concentrations indicated for 20 min prior to quenching and isolation of inositol 
phosphates. [3H]-Inositol phosphates produced are expressed relative to unstimulated 
cells. nd, not done. Error bars are absent where n=1, SD where n=2 or SEM where 
n≥3. 10 nM AngII, Control n=2, RdgBβ n=2; 100 nM AngII, Control n=6, RdgBβ n=4, 
ATRAP n=2; 1 μM AngII, Control n=3, RdgBβ n=2, ATRAP n=1. (B) [3H]-inositol-
labelled COS-7 cells transiently  expressing HA-AT1R, and co-expressing RdgBβ-sp1 
and/or HA-ATRAP, were treated with 100 nM Angiotensin II for 5 mins, following 16 hrs 
pre-treatment with 100 nM PMA, where indicated. [3H]-Inositol phosphates produced 
are expressed relative to unstimulated cells. AngII - PMA, n=2; AngII + PMA, n=1. (C) 
[3H]-inositol-labelled HEK-293 cells stably  expressing AT1R (HEK-293-AT1 cells), and 
transiently  expressing RdgBβ-sp1 and/or HA-ATRAP, were pre-treated 100 nM PMA for 
16 hr as indicated prior to stimulation with 100 nM Angiotensin II for 5 mins. nd, not 
done. Data expressed as in (B). Control, n=3; RdgBβ, n=1; ATRAP, n=1; RdgBβ + 
ATRAP, n=1.
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4.12: Discussion
I have demonstrated that RdgBβ binds to the Angiotensin II receptor-associated protein, 
ATRAP, when cells are stimulated for 4-16 hr with PMA. This interaction was blocked 
by inhibition of PKC or protein synthesis. ATRAP interacts with the PITP domain of 
RdgBβ, a region distinct from the 14-3-3-binding site.
4.12.1: Conditions of the RdgBβ-ATRAP interaction
RdgBβ and ATRAP are not observed to interact  with one another in unstimulated cells 
in co-immunoprecipitation experiments. However, an RdgBβ-ATRAP interaction is 
observed following stimulation of cells with PMA for 4-16 hrs, conditions which 
increase FLAG-RdgBβ expression. The PMA-induced interaction is blocked by 4 hrs 
treatment with the protein synthesis inhibitor, cycloheximide, indicating that a certain 
threshold concentration of RdgBβ must  be reached before the RdgBβ-ATRAP 
interaction is observed.
The RdgBβ-ATRAP association is not seen when cells are co-transfected with the AT1R 
and stimulated with Angiotensin II. This is either a result of PMA and Angiotensin II 
not activating the same downstream effectors, or because Angiotensin II is not as potent 
at increasing FLAG-RdgBβ concentration as PMA, at the Angiotensin II doses tested. 
The PMA-induced RdgBβ-ATRAP interaction was also blocked by inhibition of PKC 
with BIM-I, indicating that the direct target of PMA in this instance might be PKC. 
Activation of PKC also requires Ca2+, and treatment of cells with the Ca2+ ionophore, 
ionomycin, increased the PMA-induced RdgBβ-ATRAP interaction two-fold. The effect 
of PKC on FLAG-RdgBβ-sp1 stability is distinct from its ability to promote the 
interaction between RdgBβ and 14-3-3, since both the RdgBβ-sp1 1-250 mutant, 
lacking the disordered C-terminus, the RdgBβ-sp1 S299A mutant, unable to bind 
14-3-3, and RdgBβ-sp2, with its distinct C-terminus, all experience a PMA-induced 
increase in protein expression. It is likely that PMA acts on the cell’s protein synthesis 
machinery  to effect a global upregulation of protein synthesis, and here this effect is 
indistinguishable from the targeted stabilisation of protein expression by PMA.
215
The observation that RdgBβ-sp2 expression is increased in response to PMA, and that 
ATRAP interacts with RdgBβ-sp1 via its PITP domain, indicates that  RdgBβ-sp2 will 
also participate in an interaction with ATRAP. Indeed, the second yeast two-hybrid 
study to identify the RdgBβ-ATRAP interaction reported the nucleotide sequence for 
RdgBβ as BC007905 (Venkatesan et al., 2009), which corresponds to the RdgBβ-sp2 
sequence, rather than RdgBβ-sp1.
4.12.2: The relationship between RdgBβ-14-3-3 and RdgBβ-ATRAP
14-3-3 interacts with RdgBβ-sp1 via its long, disordered C-terminus, yet ATRAP 
interacts with RdgBβ via its PITP domain. Both proteins interact with RdgBβ when 
cells are stimulated with PMA, but whether both proteins bind to the same RdgBβ 
molecule simultaneously has not been clear from my experiments. 
FLAG-(RdgBβ)-immunoprecipitates and HA-(ATRAP)-immunoprecipitates were 
prepared from the COS-7 cells using two distinct methods, which may explain why 
blotting the HA-immunoprecipitate with anti-14-3-3 antibody produced such a large 
amount of non-specific protein bands. Immunoprecipitation of FLAG-RdgBβ used anti-
FLAG M2 antibody covalently attached to agarose beads, enabling a single capturing 
step consisting of 2 hr incubation of 300 µg lysate with anti-FLAG M2 affinity gel on 
the rotating wheel.  HA-immunoprecipitation, by contrast, utilised a two-step  method: 
firstly  300 µg lysate was incubated with 1.5 µg anti-HA monoclonal antibody for 1 hr, 
to enable the antibody to bind the HA tag of ATRAP, and secondly this mixture was 
incubated with 20 µL Protein A/G PLUS Agarose to enable capture of the Fc region of 
the HA antibody by  Protein A/G. Perhaps an anti-HA antibody conjugated to agarose 
beads for a one-step capture would have yielded cleaner 14-3-3 western blots. An 
alternative would have been to change the HA tag on ATRAP to a FLAG tag, transfect 
this alongside HA- or Myc-RdgBβ-sp1, and use the anti-FLAG M2 affinity gel, as for 
immunoprecipitation of FLAG-RdgBβ.
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4.12.3: RdgBβ candidate ATRAP-binding residues
RdgBβ interacts with ATRAP via its PITP domain. The ATRAP interaction is specific to 
RdgBβ: neither PITPα nor PITPβ bind to ATRAP upon PMA stimulation. These 
observations led to the identification of 37 residues organised into 10 patches on the 
RdgBβ PITP domain surface as potential ATRAP-binding residues. Of the 37 residues, 
19 lie in the regulatory loop, proposed as a site of protein interactions (Yoder et al., 
2001). Specifically, 8 residues lie in the β6-αC loop and 11 residues lie in the β7-β8 
loop. Notably, the loop β6-αC also contains the Ser119 and Thr122 residues, which have 
been reported to be phosphorylated in the mouse brain (Huttlin et al., 2010; Wiśniewski 
et al., 2010), imparting on this loop a means by which to regulate protein-protein 
interactions. A scan of the human RdgBβ sequence (Q9UKF7), with the PhosphoMotif 
Finder tool at the Human Protein Reference Database (http://www.hprd.org/
PhosphoMotif_finder/) indicates that Ser119 lies in a consensus site for phosphorylation 
by PKA, PKC, and Casein kinase I and II, whereas Thr122 could be phosphorylated by 
Casein kinase II.
4.12.4: RdgBβ and Angiotensin II signalling
An obvious concern for the experiments to assess whether Angiotensin II could promote 
the RdgBβ-ATRAP interaction in transiently transfected COS-7 cells was that the HA-
AT1R was not observed in any of the anti-HA western blots of the whole cell lysates. 
This was not properly explored. It is possible that not enough lysate was loaded onto the 
gel, since a clear HA-ATRAP band was consistently observed in merely 3-5 µg lysate. 
Other researchers have found the AT1R difficult to resolve through western blotting of 
whole cell lysates due to the presence of post-translational modifications including 
phosphorylation and glycosylation. AT1R has a typical molecular weight of 41-58 kDa 
(although a value as high as 75 kDa has been recorded) (Cook et al., 2006), due to these 
modifications. Others see several diffuse bands over the range 70-200 kDa, representing 
extensive glycosylation of the receptor. These can be reduced to ~40 kDa upon 
treatment with peptide N-glycosidase F (PNGase F) to deglycosylate the AT1R 
(Hunyady et al., 2002). Several studies immunoprecipitate the receptor from membrane 
fractions before western blotting (Smith et al., 1998; Tanaka et al., 2005; Azuma et al., 
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2007). It seems unlikely, therefore, that I would have seen HA-AT1R in whole cell 
lysates in my experiments. COS-7 cells transiently transfected with the pcDNA3.1-HA-
AT1R plasmid using the same transfection protocol as used prior to co-
immunoprecipitation (Figure 4.10), did respond to Angiotensin II in the form of PIP2 
hydrolysis by PLC (Figure 4.11), indicating the presence of a functional AT1R in the co-
immunoprecipitation experiments.
RdgBβ over-expression increases inositol phosphate production by PLC when cells are 
stimulated by Angiotensin II for 20 mins. 10 nM, 100 nM and 1 µM Angiotensin II all 
produce ~3.8 times the amount of inositol phosphates compared to unstimulated cells 
expressing both the AT1R and RdgBβ-sp1. Inositol phosphate production appears 
relatively unaffected by Angiotensin II dose, indicating that PIP2 hydrolysis has reached 
near-maximum by 20 min treatment with either of the three Angiotensin II 
concentrations. The Angiotensin II dose response curve has shifted to the left with 
respect to cells transfected with the receptor only; a larger inositol phosphate response is 
produced by a reduced Angiotensin II dose. This could reflect either an increase in PIP2 
substrate availability or an increase in the rate of PIP2 hydrolysis by PLC.
In contrast, over-expression of ATRAP was observed to reduce inositol phosphate 
production in response to Angiotensin II stimulation. This trend is in agreement with a 
previous study, in which a significant reduction (p<0.05) in inositol phosphate 
production was observed upon ATRAP over-expression following treatment  with 10 
nM, 100 nM  and 1 µM  Angiotensin II for 60 mins (Daviet et al., 1999) (transient 
transfection of COS-7 cells with HA-ATRAP and FLAG-AT1R plasmids). In a different 
study, CHO-K1 cells stably  expressing the AT1R were transiently  transfected with an 
ATRAP expression plasmid. Maximal suppression of inositol phosphate production in 
response to 1 µM Angiotensin II was observed at 5 min, and the difference between 
ATRAP-expressing cells and control cells was indistinguishable by 20 min Angiotensin 
II treatment (Lopez-Ilasaca et al., 2003). These differences clearly reflect differences in 
the concentrations of receptor, PLC enzyme and PIP2 substrate in different cell types. 
The latter study  indicates that ATRAP has no effect  on substrate availability, since 
inositol phosphate production ‘caught up’ by 20 min, rather it either tempers substrate 
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availability or has a direct effect on PLC activity by reducing the rate of PIP2 hydrolysis 
by PLC.
In COS-7 cells transiently transfected with the AT1R and HEK-293-AT1 cells, ATRAP 
over-expression was observed to increase inositol phosphate production in response to 5 
min 100 nM Angiotensin II stimulation, rather than decrease it. There were few 
replicates carried out, but this variation could reflect a difference in ATRAP function 
depending on cell type. Perhaps a different complement of ATRAP-interacting proteins 
are present here, tipping the effect of ATRAP over-expression towards a stimulatory, 
rather than a suppressor, function.
Li+ in the HEPES buffer used for the PLC assays inhibits inositol monophosphatase, 
promoting inositol phosphate accumulation and preventing PI re-synthesis. Li+ is 
present throughout the experiment, and therefore longer stimulation time points would 
be expected to produce a more accurate picture of the effect of over-expression of 
particular proteins on PLC activity, and likely explains the variability of the results 
gained after 5 min stimulation. However, if the effect of a particular protein is to reduce 
or increase the rate of PLC activity, this may not be observed at longer time points since 
maximal inositol phosphate production may have been reached.
In general, PMA pre-treatment reduced Angiotensin II-stimulated inositol phosphate 
production. This is in accordance with previous studies which have shown that  PKC 
phosphorylates the AT1R to promote heterologous desensitisation, uncoupling it  from 
Gq protein and attenuating PLC activity (Tang et al., 1998). In this way, PKC provides 
negative feedback to limit the magnitude and duration of Angiotensin II signalling.
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CHAPTER 5: RdgBβ binds PI and PA
5.1: Introduction
Resolution of X-ray crystal structures of PI- and PC-bound class I PITPs has revealed 
that the PITP domain is composed of eight β-strands that form a large, concave sheet, 
together with seven α-helices. The PI or PC cargo occupies the same space in the 
ligand-binding cavity, formed between the β-sheet and two of the long α-helices, αA and 
αF. PITPα has a 16-fold higher affinity  for PI than it does for PC (van Paridon et al., 
1987a): the inositol head group  of PI is secured by direct hydrogen bonds with residues 
Q22, T59, K61, E86 and N90, whereas the choline head group of PC is not observed to 
form any direct bonds. C95 forms a hydrogen bond with PC indirectly via a water 
molecule, and the presence of F225 has also been reported to be important for PC 
transfer (Vordtriede et al., 2005). In contrast to binding of the lipid head group, the 
phosphate group of either PI or PC is secured by hydrogen bonds to T97 and K195, and 
the acyl chains form bonds with Y63 and E218.
The structure of the PITP domain of RdgBβ has not been reported, however. RdgBβ-sp1 
has been observed to exhibit robust PI transfer activity, comparable to that of PITPα, 
and this activity  was unaffected by removal of its C-terminal tail (Fullwood et al., 
1999). RdgBβ shares ~40% sequence identity  with PITPα and PITPβ, yet a protein-lipid 
overlay assay indicated that RdgBβ-sp2 binds only PI, not  to any of the other 
phospholipids, including PC and phosphorylated PI derivatives (Takano et al., 2003). 
Whether RdgBβ actually  differs from the class I PITPs in its lipid binding properties is 
of significance.
I therefore begin this part of my study by establishing whether the residues shown to be 
important for PI- or PC-binding in the class I PITPs are also present  in RdgBβ. Using a 
permeabilised HL60 cell assay for lipid binding, I observe that PC binding by RdgBβ is 
negligible. RdgBβ binds PI, together with a mystery lipid, in approximately equal 
proportions. The mystery lipid is not labelled with [3H]-sphingosine, and 
monomethylamine treatment of the isolated lipid indicates that the mystery  lipid is a 
glycerol phospholipid, with ester linkages connecting the fatty acids to the backbone. 
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[3H]-ethanolamine appears to label the mystery lipid, yet I rule out its identity as either 
PMME or lyso-PE. Finally, the mystery  lipid is identified as PA by  mass spectrometry. 
RdgBβ selects for short-chain monounsaturated or saturated PA species, yet is non-
selective in its preference of PI species. The addition of GTPγS to the lipid binding 
assay at high calcium increases PA binding by RdgBβ.
5.2: The RdgBβ lipid-binding cavity: sequence and structural analysis
A sequence alignment of both splice variants of RdgBβ (sp1 and sp2) with PITPα and 
PITPβ, indicates that the residues responsible for binding the inositol head group of PI 
(Q22, T59, K61, E86, N90) and the phosphate group (T97 and K195) are all conserved 
in human RdgBβ (Figure 5.1 A). However, the residues co-ordinating the phospholipid 
acyl chains are not conserved: Y63 and E218 in PITPα and PITPβ are present as valine 
residues in RdgBβ.
Since an X-ray crystal structure of RdgBβ has not been reported, modelling of the 
RdgBβ PITP domain was undertaken. The PDB: 1t27 structure was used as the template 
since it shares the highest sequence identity with the RdgBβ sequence. Pairwise 
comparisons were made between the RdgBβ model and each reported PITP crystal 
structure in turn using the ‘Align’ command in Pymol. This allowed the PI and PC 
ligands from the published PDB files to be modelled in the RdgBβ structure, and the 
proximity of particular residues to the ligand to be analysed. The consequences of the 
Y63V and E218V substitutions in the RdgBβ sequence are visualised in Figure 5.1 B, 
and clearly indicate that a phospholipid in the RdgBβ lipid-binding cavity is unlikely to 
be positioned as securely or tightly as it would in the class I structures.
In the PC-bound PITPα and PITPβ structures, no residues in the lipid-binding cavity 
directly  contact the choline head group. C95 contacts the PC (not PI) phosphate group 
indirectly via a molecule of water, yet the residue at position 95 in RdgBβ is a threonine 
residue (Figure 5.1 A). F225, also relevant for PC transfer, is present in RdgBβ as a 
glycine residue. The two tryptophan residues, W203 and W204, important for 
membrane interaction in the class I PITPs, are V203 and W204 in the RdgBβ sequence.
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(Facing page) Figure 5.1: Bioinformatic analysis of the RdgBβ lipid-binding 
cavity
(A) Sequence alignment of human sequences: PITPα Q00169.2, PITPβ P48739.2, 
RdgBβ-sp1 Q9UKF7.2, RdgBβ-sp2 NP_858057.1. Residues that contact the inositol 
head-group of PI in PITPα and PITPβ (Q22, T59, K61, E86, N90) are indicated in blue; 
those that make hydrogen bonds with the phosphate group of PI (T97 and K195) are 
indicated in red; and those that contact the acyl chains (Y63 and E218) are indicated in 
brown. C95/T95 are indicated in lime green, and the WW residues (W203 and W204) 
are indicated in green. The F225/G225 residue is also indicated. (B) RdgBβ lacks two 
residues that make stabilising hydrogen bond contacts to the PC (or PI) acyl chains. 
Left and middle panels: PC acyl chains are stabilised by hydrogen contacts with E218 
and Y63 residues in PITPβ (and PITPα; PITPβ (PDB: 2a1l) shown here). Right panel: 
RdgBβ lacks these stabilising hydrogen bonds; in RdgBβ, these residues are valine 
residues (RdgBβ comparative model with PC ligand from 2a1l overlay).
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5.3: RdgBβ binds PI and a mystery lipid, rather than PI and PC
The lipid binding properties of RdgBβ-sp1 were assessed by exposing the recombinant 
protein to HL60 cells which had been metabolically labelled with [14C]-acetic acid and 
permeabilised with SLO to allow PITP entry. Lipid binding by PITPα was assessed 
alongside RdgBβ as a positive control.
As previously reported, it  is clear that PITPα binds PI and PC in approximately equal 
quantities (Figure 5.2 A, B). RdgBβ, by  contrast, binds only trace amounts of PC, and in 
addition to PI, binds another lipid, which runs faster than PI on the TLC plate (Figure 
5.2 A).  RdgBβ binds PI and the mystery  lipid in equal amounts (Figure 5.2 B). When 
the values are adjusted to account for the relative amount of PITP protein recovered, it 
is clear that RdgBβ binds only one tenth of the amount of phospholipid that PITPα does 
under these conditions (PITPα, 100 ± 0; RdgBβ 9.9 ± 3.4 SEM, n=3).
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(Facing page) Figure 5.2: RdgBβ binds PI and a mystery lipid
(A) Assessment of the lipids bound by  RdgBβ-sp1 and PITPα after exposure to 
permeabilised [14C]-HL60 cell membranes. Left: TLC plate phosphor image. ʻTotalʼ 
indicates total [14C]-acetic acid-labelled HL60 lipids, 50,000 dpm. Right: Coomassie-
stained SDS-PAGE gel showing input and output protein quantity. 1, Control (No PITP); 
2, PITPα; 3, RdgBβ. (B) Phospholipids bound are expressed as a percentage of the 
total PC+PI+mystery  lipid. Error bars are SEM (PITPα (n=6), RdgBβ (n=5)). (C) 
Phospholipids bound are adjusted for the amount of protein recovered, where PI bound 
by  PITPα is set at 100 to enable comparison of multiple datasets. Error bars are SEM; 
PITPα, n=5, RdgBβ, n=3.
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5.4: The hunt for the identity of the mystery lipid
RdgBβ binds PI and the mystery lipid in comparable amounts, yet binds little PC. I 
therefore sought to determine the identity of this mystery lipid.
Figure 5.3 A shows a tracing of unlabelled phospholipid standards which have been run 
on a TLC plate and stained with iodine. The mystery  lipid runs between PI and 
phosphatidylethanolamine (PE); only a trace contaminant of cardiolipin (CL) is present 
at this position on the standard phospholipids plate. CL itself is almost exclusively 
found in mammalian cells in the inner mitochondrial membrane and, since it is 
composed of two phosphatidic acid (PA) molecules (i.e. a total of four fatty acid chains) 
connected by a glycerol molecule (Figure 5.3 B), CL would be too large to fit  into the 
lipid-binding cavity of RdgBβ. PA and phosphatidylglycerol (PG) are intermediates in 
CL synthesis: PA runs to the same place as PE, or slightly  higher (Figure 5.3 A), and PG 
runs between PE and CL (Figure 5.3 C).
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(Facing page) Figure 5.3: TLC analysis of unlabelled phospholipids
(A, C) Unlabelled lipids were spotted onto a TLC  plate (20μg, as indicated), which was 
migrated in the solvent system, Chloroform: Methanol: Acetic acid: Water (75: 45: 3: 1). 
Once dry, the plate was stained with iodine to visualise the lipids. The lipid spots were 
traced in pencil and the image scanned using a flatbed scanner. The darkest spots 
have been shaded. CL, cardiolipin; PA, phosphatidic acid (Sigma-Aldrich, P9511); PE, 
phosphatidylethanolamine; PG, phosphatidylglycerol; PS, phosphatidylserine; PI, 
phosphatidylinositol (~50% purity  reported - contains PE and possibly PA 
contamination; Sigma-Aldrich, P6636); PC, phosphatidylcholine; SM, sphingomyelin. 
(B) The molecular structure of CL.
228
!"##$%"&'()
*+,-#."/%/'0'()1
23
45
46
47
48
42
89
23 45 46 4748 42 89 :3;<%#=#"/
&,//-/".%/'0'()
!
"
46 4> 23
46
4>
23
*23
&=?#"@'?"?#1
#
A
A
A
A
A
4A
A
A B
A
A
A
A
OH
A
4A
A
A B
23
>/$&,.=/
4>
45
229
To further advance the search for the mystery  lipid, 20 mL volumes of HL60 cells were 
labelled with different radionucleotides: [3H]-sphingosine, [3H]-choline chloride, [3H]-
inositol, [3H]-ethanolamine, [3H]-palmitate, [14C]-acetic acid. The lipids were extracted 
and appropriate quantities run side-by-side on a TLC plate (Figure 5.4). Some [3H]-
sphingosine-labelled lipids appear to run between PI and PE. I therefore carried out a 
lipid binding assay exactly as for [14C]-acetate labelling, only labelling cells with [3H]-
sphingosine for 24 hrs prior to the experiment. No [3H]-sphingosine-labelled lipids were 
enriched in the RdgBβ-bound material (Figure 5.5). Only sphingomyelin (SM) and 
sphingosine were observed in the ‘Total’ lipids lane.
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Figure 5.4: Labelling HL60 cells with different radionucleotides
HL60 cells were labelled with different radionucleotides and the lipids extracted. 
75,000-200,000 dpm of each lipid was spotted per lane of the TLC plate (detailed in 
Table 2.9).
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Figure 5.5: RdgBβ does not bind [3H] sphingosine-labelled lipids
120 μg recombinant RdgB proteins were exposed to permeabilised [3H]-sphingosine 
HL60 cells prior to re-capture and lipid extraction. Upper panel: Coomassie-stained 
SDS-PAGE gel showing input and output proteins. Lower panel: TLC plate. 50,000 
dpm [3H]-sphingosine-labelled HL60 cell lipids were spotted into the ʻTotalʼ lipid lane.
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Sphingolipids are built from sphingosine, an amino alcohol with a long, unsaturated 
hydrocarbon chain, rather than glycerol. To this, a single fatty  acid is attached by an 
amide bond; in glycerol phospholipids two fatty acids are attached to the glycerol 
backbone using ester bonds (Figure 5.6). This property can be used to deduce whether a 
given lipid is a sphingolipid or a glycerol phospholipid using the chemical, 
monomethylamine. Monomethylamine is a primary amine (strong nucleophile), which 
reacts with esters to form amides. The reaction is an O→N-transacylation, with the 
formation of fatty acid amides or N-methyl fatty acids. RdgBβ-bound [14C]-acetate-
labelled lipids were first subjected to two-dimensional TLC to purify the lipids (Figure 
5.7 A). The PI and mystery lipid spots were identified by  comparison with 2D plates run 
using the same solvent system by  other members of the laboratory, the silica scraped 
and the lipids re-extracted. The extracted lipids were divided into two eppendorf tubes 
and treated without or with monomethylamine reagent for 30 min at 53°c. Both PI and 
mystery  lipid spots migrated to the top of the plate after treatment (Figure 5.7 B), 
indicating that both phospholipids contain two ester linages.
Figure 5.6: The structures of glycerol phospholipids and sphingolipids
Both PC and SM have a phosphate group and a choline group, yet their fatty  acid 
groups are attached in different ways: two fatty  acid groups are attached to the glycerol 
backbone in glycerol phospholipids via ester bonds; a single fatty  acid connects to 
sphingosine in sphingolipids via an amide bond.
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(Facing page) Figure 5.7: The mystery lipid is a glycerol phospholipid
(A) Two-dimensional TLC analysis using the solvent systems indicated. Left panel: 
Total [14C]-acetate HL60 cellular lipids (10 μL, 2,400,000 dpm, equivalent to 4 mL 
cells). Right panel: RdgBβ-bound lipids (300 μg recombinant protein), spiked with lipids 
extracted from 4 mL unlabelled HL60 cells, so that approximately the same amount of 
lipid was run on both 2D plates. (B) The PI and mystery  lipid spots were excised and 
the lipids re-extracted from the silica. The PI and mystery  lipid were treated with 
monomethylamine reagent for 30 min at 53°c. The lipids were then re-extracted and 
run on a TLC plate adjacent to untreated samples. (Solvent system: Chloroform: 
Methanol: Acetic Acid: Water (75: 45: 3: 1 (v/v)).
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5.5: Could the mystery lipid be a PE derivative?
Whereas the major route of PC synthesis is through the Kennedy  (CDP-choline) 
pathway, a minor route comprises the step-wise methylation of PE to PC by two PE N-
methyltransferase (PEMT) enzymes. The methylated intermediates, phosphatidyl-N-
monomethyl-ethanolamine (PMME) and phosphatidyl-N,N-dimethylethanolamine 
(PDME), would therefore migrate between PE and PC on a TLC plate. I therefore 
wondered whether the mystery lipid would label with [3H]-ethanolamine.
I carried out a lipid binding assay, this time using HL60 cells labelled with [3H]-
ethanolamine. An [3H]-ethanolamine-labelled lipid was observed in material bound by 
RdgBβ (Figure 5.8), and I hypothesised that this lipid was PMME. The Kennedy 
pathway can synthesise PC or PE, and involves the activity of three enzymes, whose 
substrate specificity overlaps between ethanolamine and choline (Gibellini and Smith, 
2010). In addition, monomethyl- and dimethyl-ethanolamine can be used as substrates 
in the Kennedy pathway  (Ishidate, 1997), to yield PMME and PDME, respectively. To 
increase the concentration of [14C]-PMME in the HL60 cells, I labelled cells with [14C]-
acetic acid in two flasks, and supplemented one of the cultures with 400 µM 2-
(methylamino)ethanol (monomethyl-ethanolamine). The lipid binding assay was 
performed using these cells, and the bound lipids separated by TLC alongside an 
unlabelled PMME standard (Figure 5.9).
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Figure 5.8: RdgBβ binds a [3H]-ethanolamine-labelled lipid
HL60 cells were labelled with [3H]-ethanolamine for 72 hrs, permeabilised, and then 
incubated with 120 μg recombinant RdgBβ-sp1 for 20 mins. The recombinant protein 
was re-captured using its His-tag, and the lipids bound extracted and separated by 
TLC. Upper panel: Coomassie-stained SDS-PAGE gel showing input and output 
protein. Lower panel: TLC plate.
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Figure 5.9: The mystery lipid is not PMME
HL60 cells were labelled with 1 μCi.mL-1 [14C]-acetic acid +/- 400 μM 2-(methylamino)
ethanol (ʻMMEʼ) for 72 hrs, prior to permeabilisation and use in the lipid binding assay. 
Recombinant proteins, PITPα, RdgBβ-sp1, RdgBβ-sp2, were exposed to the 
permeabilised cells before being re-captured using their His tags. The bound lipids 
were extracted and separated by  TLC. The unlabelled lipid, PMME, was run alongside 
the radioactive lipids. 100,000 dpm total HL60 lipids were spotted into the ʻTotalʼ lanes. 
TLC plate shown.
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A clear enrichment of PMME in the Total lipids lane was observed just below PE 
(Figure 5.9). The unlabelled PMME standard partially overlaps with both the 
radioactive PMME and the mystery lipid. Crucially, however, no enrichment in the 
mystery  lipid was observed when RdgBβ was exposed to the cells with the PMME 
enrichment, indicating that the mystery lipid is not  PMME. By contrast, PITPα does 
bind a small amount of radioactive PMME.
RdgBβ-sp2 was omitted from the lipid binding assays on the whole, since recombinant 
RdgBβ-sp2 protein preparations were less pure than those of RdgBβ-sp1, and 
consequently produced a lower yield. In Figure 5.9, RdgBβ-sp2 was observed to bind 
the same lipids as RdgBβ-sp1, in the same proportions.
Lyso-PE is another lipid that would label with [3H]-ethanolamine and as it only has a 
single fatty  acid chain, would migrate less far than PE on a TLC plate. Purified HL60 
cell lipids labelled with [3H]-ethanolamine from previous experiments were combined 
and treated with phospholipase A2 (PLA2) from bee venom. PLA2 removes the fatty 
acid from the sn2 position of the glycerol backbone of phospholipids to yield the lyso-
phospholipid and free fatty acid. PLA2-treated PE was resolved on a TLC plate 
alongside unlabelled PE, PMME and PI standards (Figure 5.10). The solvent-soluble 
product (lyso-PE) migrates less far than PI, indicating that the mystery lipid is not lyso-
PE.
The PI standard used was that from Sigma-Aldrich (P6636). The manufacturers report 
that this phospholipid sample is ~50% pure, with PE and possibly PA contaminants. In 
Figure 5.3, a lipid corresponding to PE only  was observed. In Figure 5.10, an additional 
lipid migrating to between PI and PE is observed. In Figure 5.3, I also noted that PA 
migrates slightly further than PE, and therefore the identity of the additional PI 
contaminant in Figure 5.10 is unclear.
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Figure 5.10: The mystery lipid is not lyso-PE
[3H]-ethanolamine-labelled liposomes were treated with PLA2 for the time periods 
indicated. The solvent-soluble product (lyso-PE) was resolved using TLC (100,000 
dpm) alongside 20 μg of each unlabelled phospholipid standard (PE, PMME, PI). TLC 
plate shown.
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Meanwhile, lipid binding experiments were carried out using [3H]-choline- and [3H]-
inositol-labelled HL60 cells. The cells were labelled exactly as for the experiment using 
[3H]-ethanolamine-labelled HL60 cells, i.e. for 72 hrs. RdgBβ bound some PI, as 
expected, which was less than the PITPα-bound PI (Figure 5.11). RdgBβ was not 
observed to bind PC, whereas PITPα clearly bound PC. In addition, in the lipids 
extracted from PITPα, a [3H]-choline-labelled lipid was observed above PC, 
approximately in line with the PI labelled with [3H]-inositol, and a [3H]-inositol-labelled 
lipid was seen below PI, in line with PC labelled with [3H]-choline.
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Figure 5.11: Binding of [3H]-choline and [3H]-inositol-labelled lipids by PITPα
HL60 cells labelled with either [3H]-choline chloride (1 μCi.mL-1, 72 hrs) or [3H]-inositol 
(2 μCi.mL-1 M199 medium, 72 hrs), were permeabilised and used in the lipid binding 
assay. Lipids bound by PITPα and RdgBβ-sp1 were resolved by  TLC alongside 50,000 
dpm total labelled lipids. TLC plate shown.
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5.6: RdgBβ binds PA
The mystery  lipid did not co-migrate with any known lipid standards, and although it 
was observed to label with [3H]-ethanolamine, further experiments ruled out PE 
derivatives, PMME and lyso-PE, as possible mystery lipid candidates. I therefore 
sought the assistance of our collaborators, Dr. Alan Hunt and Grielof Koster at  the 
University  of Southampton. The lipid binding assay  was scaled up  to 600 µg 
recombinant protein and 50 mL (unlabelled) HL60 cells, and the lipids extracted from 
RdgBβ-sp1 for analysis by  mass spectrometry. The molecular species of PI and PC have 
previously  been identified using the same method for PITPα (Hunt et al., 2004), and 
therefore PITPα was used here as a control. Mass spectrometric analysis revealed that 
the mystery lipid picked up by RdgBβ was phosphatidic acid (PA).
The acyl chains of PI and PA vary according to the source of the phospholipid: the 
dominant species of PI in mammalian cells is long chain, polyunsaturated, C18:0/20:4 
(sn-1-stearoyl-2-arachidonyl), whereas the dominant PC is short-chain, mono-
unsaturated or saturated species. PA can be produced either by the hydrolysis of PI(4,5)
P2 by PLC, yielding DAG, which is subsequently  phosphorylated to PA by DGK, or by 
the hydrolysis of PC by  PLD, to PA and choline. Analysis of the molecular species of 
PA bound by RdgBβ using precursor scans of the m/z -153 fragment revealed that 
RdgBβ-bound lipids were enriched in short-chain monounsaturated or saturated PA 
species, specifically  C16:0/16:1 (m/z 645, ~27%) and C16:1/18:1 (m/z 671, ~23%) 
species. These species made up ~15% and ~10% of the cellular PA pool, respectively 
(Figure 5.12 and Table 5.1). By contrast, cellular PA contained a higher proportion of 
the C16:0/16:0 species (m/z 647, ~17%), than the RdgBβ-bound PA (~7%). PA 
molecular species were not observed in the lipid sample extracted from PITPα by mass 
spectrometry.
Whereas RdgBβ bound short-chain, saturated or monounsaturated PA species 
(C16:0/16:1 and C16:1/18:1), the PI molecular species bound were long-chain, 
polyunsaturated species. These are also the most common PI species in mammalian 
cells. A representative trace of PI species bound by RdgBβ looks remarkably similar to 
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the profile of PI molecular species in mammalian cells (Figure 5.13, Upper panel and 
inset).
By comparison, the PI species bound by PITPα were enriched in short-chain, saturated 
or monounsaturated species, C16:0/16:1 and C16:1/18:1, as previously  reported (Hunt 
et al., 2004).
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(Facing page) Figure 5.12: Analysis of PA species bound by RdgBβ and in HL60 
cell extracts
(A) Recombinant RdgBβ protein (600 μg) was exposed to permeabilised HL60 cell 
membranes for 20 mins at 37°c, then recaptured using its His-tag. The lipids bound 
were extracted and analysed by  mass spectrometry. A representative ESI-MS/MS 
precursor scan of the m/z -153 fragment in negative ionisation is shown. (B) A second 
example of a precursor scan of m/z -153 fragment of the PA species bound by  RdgBβ 
(upper panel), together with a scan showing the total PA species present in HL60 cells. 
Dashed ellipses indicate enriched PA species. (Mass spectrometry  and data analysis 
carried out by Dr. Alan Hunt and Grielof Koster at the University of Southampton.)
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Mass (m/z)
Total Carbon:
double bonds
Dominant 
molecular 
species
Total HL60 
PA (%)
PA bound by 
RdgBβ
619 C30:0 14:0/16:0 10.00 ± 1.47 5.02 ± 0.63 *
643 C32:2 16:1/16:1 4.74 ± 0.70 6.14 ± 0.93
645 C32:1 16:0/16:1 14.59 ± 1.59 26.90 ± 5.27 *
647 C32:0 16:0/16:0 16.77 ± 4.18 7.09 ± 0.58 *
671 C34:2 16:1/18:1 9.94 ± 0.97 23.09 ± 2.80 **
673 C34:1 16:0/18:1 10.82 ± 0.57 7.32 ± 0.59 **
699 C36:2 18:1/18:1 11.52 ± 2.20 6.09 ± 1.14 *
701 C36:1 18:0/18:1 7.56 ± 0.65 6.02 ± 1.61
Table 5.1: PA species bound by RdgBβ
Comparison of the molecular species of PA present in whole HL60 cells with PA bound 
by  RdgBβ. The species identified represent the dominant species from ESI-MS/MS 
fragmentation analysis. Errors are SEM, n=6. The significance of the fraction of 
individual PA species bound by  RdgBβ compared with the fraction of that species 
present in whole HL60 cells has been assessed, and p values are indicated: * p<0.05, 
** p<0.005. (Mass spectrometry  and data analysis carried out by  Dr. Alan Hunt and 
Grielof Koster at the University of Southampton.)
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(Facing page) Figure 5.13: Molecular PI species bound by RdgBβ and PITPα
Recombinant RdgBβ or PITPα protein (600 μg) was exposed to permeabilised HL60 
cell membranes for 20 mins at 37°c, then recaptured using its His-tag. The lipids bound 
were extracted and analysed by  mass spectrometry. Representative ESI-MS/MS 
precursor scans of m/z -241 precursor in negative ionisation showing PI species bound 
by  RdgBβ (upper panel) and PITPα (lower panel). Inset: Relative quantities of total PI 
species present in HL60 cells (taken from Hunt et al., 2004 (Fig. 2)). (Mass 
spectrometry  and data analysis carried out by  Dr. Alan Hunt and Grielof Koster at the 
University of Southampton.)
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PA was previously  rejected as a candidate for the mystery lipid as the standard did not 
co-migrate with the lipid bound by  RdgBβ, but instead migrated past PE. It now seemed 
possible that PA species with different acyl chains might migrate differently during 
TLC. To explore this notion further I sourced additional PA samples and spotted them 
side-by-side on a TLC plate. A wide difference was observed: the long chain, 
polyunsaturated C18:0/20:4 PA species migrated noticeably further than the short-chain, 
saturated C16:0 PA species (Figure 5.14). PA derived from hydrolysis of [14C]-PC by 
peanut PLD migrated just  above PI on another TLC plate (Figure 5.15). ([14C]-PI is not 
a substrate of PLD, but instead appears to be contaminated here with PA and PC.)
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Figure 5.14: Long-chain and short-chain PA standards
C18:0/20:4 PA (P1293, Sigma-Aldrich), egg PA (P9511), dipalmitoyl PA (C16:0) 
(P9388) samples were spotted onto a TLC  plate alongside PI. The lipids were migrated 
in the solvent system, Chloroform: Methanol: Acetic acid: Water (75: 45: 3: 1, v/v), then 
stained in an iodine tank for visualisation of the lipid spots. The edges of the lipids were 
traced in pencil, and the plate scanned using a flat-bed scanner.
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Figure 5.15: Treatment of [14C]-PI and [14C]-PC with PLD
Total HL60 [14C] lipids from previous experiments were combined and separated by 
TLC. The [14C] PI and [14C] PC lipids were identified and silica scraped. The lipids were 
re-extracted and treated with PLD for 16 hrs. The lipids were again purified and 
100,000 dpm of each run on a TLC plate (shown) alongside 20 μg of PI and PC 
unlabelled standards.
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5.7: PA transfer
The lipid binding assay monitors a single round of lipid exchange. The next step is to 
ask whether the PITP is able to pick up  a radioactive lipid from a donor membrane and 
deposit it into an unlabelled, acceptor membrane. In a lipid transfer assay, multiple 
rounds of docking and lipid exchange have taken place. To assess whether RdgBβ is 
able to transfer PI, I included unlabelled PC:PI (98:2, molar ratio) liposomes in a lipid 
binding assay. Rather than re-capturing the PITP, the HL60 cell membranes and proteins 
were denatured and precipitated using 0.2 M  sodium acetate/0.25 M sucrose pH 5.0, and 
the radioactive lipids transferred to the unlabelled liposomes assessed by TLC.
A high background transfer of lipids was observed in the control lane (no PITP) (Figure 
5.16). However, this was subtracted from the quantities of particular [14C]-lipids 
transferred in the presence of PITPα or RdgBβ-sp1. The data are expressed as a 
percentage of the total PC+PI+PA transferred to the liposomes. PC transfer by RdgBβ is 
absent, as is PA transfer by PITPα. RdgBβ clearly transfers PA, although considerably 
less than PI by proportion (20.4 ±0.9% SD PA, compared with 79.6 ±0.9% SD PI). In 
this assay, PITPα transfers more PC than PI (61.0 ±0.3% SD PC, compared with 38.7 
±0.4% SD PI).
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(Facing page) Figure 5.16: RdgBβ transfers [14C]-PA to unlabelled liposomes
Recombinant PITPα or RdgBβ-sp1 proteins were incubated with permeabilised [14C]-
HL60 cells and unlabelled PC:PI (98:2, molar ratio) liposomes for 20 min at 37°c (in 
duplicate). The cells were precipitated using 0.2 M sodium acetate/0.25 M sucrose pH 
5.0, and transferred lipids extracted from the liposomes (supernatant). The lipids were 
spotted onto two TLC plates (one per replicate) and migrated in the solvent system, 
Chloroform: Methanol: Acetic acid: Water (75: 45: 3: 1 (v/v)). (A) Single TLC plate 
shown. (B) Lipids transferred (PC, PI, PA) quantified using densitometry, and 
background transfer subtracted (control lane). Lipid transfer is expressed as a 
percentage of the total PC+PI+PA transferred. Error bars are SD (single experiment 
shown).
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5.8: Lipid binding by RdgBβ in stimulated cells
The availability of PA can be increased by stimulation of cells with GTPγS, PMA or by 
increasing the Ca2+ concentration to 10 µM. I next assessed whether PA binding by 
RdgBβ was enhanced by  these treatments by  adapting the lipid binding assay so that the 
permeabilisation of the cells with SLO was combined with the addition of PITP. This 
retained the cytosol yet permeabilisation still enabled the recombinant PITPs to enter 
the cells.
Most notably, PA binding by RdgBβ increased three-fold when cells were stimulated by 
GTPγS at pCa5 (10 µM  Ca2+) (1.1 ±0.6 SD at pCa7 (100 nM  Ca2+), rising to 3.3 ±0.2 
SD at  pCa5, GTPγS), and total lipid binding doubled compared with unstimulated 
conditions at  100 nM Ca2+ (Figure 5.17 A & B). In comparison to PI bound by PITPα at 
pCa7, PA binding increased considerably, from 12.6 ±3.7% SD at pCa7 to 41.3 ±9.1% 
SD at pCa5, GTPγS (Table 5.2). A moderate increase in PA binding by RdgBβ was 
observed when the calcium Ca2+ was raised from 100 nM (pCa7) to 10 µM (pCa5), 
without the addition of stimulus, and PMA treatment did not modify this response 
further. By contrast, lipid binding by PITPα did not  vary greatly upon increase in Ca2+ 
or by treatment of the cells with GTPγS or PMA (Figure 5.17 A & C).
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(Facing page) Figure 5.17: RdgBβ PA binding increases upon stimulation with 
GTPγS
(A) The lipid binding assay  was adapted so that SLO was added to permeabilise the 
[14C]-acetate-labelled HL60 cells during the 20 min incubation with recombinant 
proteins, RdgBβ or PITPα, calcium buffer (pCa7 (100 nM Ca2+) or pCa5 (10 μM Ca2+)), 
and 100 μM GTPγS or 100 nM PMA to stimulate the cells, as appropriate. Single 
representative experiment shown. A-H throughout correspond to the lanes on the TLC 
plate (right panel). Left panel: Coomassie-stained SDS-PAGE gel loaded with ʻInputʼ 
and ʻOutputʼ recombinant protein. Rβ=RdgBβ; Pα=PITPα. (B) Quantification of 
phospholipids bound by  RdgBβ under the different assay  conditions indicated on the 
TLC image in (A). The amount of lipid bound has been adjusted relative to the amount 
of recombinant protein recovered in the assay. To compare two independent 
experiments, the quantity  of lipid bound has been adjusted relative to the amount of PI 
bound at 100 nM Ca2+. * indicates significance of quantity  of PA bound by RdgBβ at 
pCa5 with GTPγS compared to pCa7, p<0.05. Inset: Total lipid bound (PC+PI+PA) 
adjusted relative to the total lipid bound at 100 nM Ca2+. (C) As (B) but for PITPα. Error 
bars are SD, n=2.
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PITP Condition PC PI PA
RdgBβ pCa7 0.6 ± 0.3 12.5 ± 3.4 12.6 ± 3.7
pCa5 0.7 ± 0.1 11.1 ± 0.1 19.0 ± 2.6
GTPγS, pCa5 0.9 ± 0.5 9.2 ± 0.9 41.3 ± 9.1
PMA, pCa5 0.5 ± 0.0 9.6 ± 0.7 18.7 ± 1.1
PITPα pCa7 73.7 ± 10.8 100.0 ± 0.0 0.2 ± 0.3
pCa5 73.3 ± 35.2 94.4 ± 29.0 0.1 ± 0.1
GTPγS, pCa5 73.4 ± 45.5 119.1 ± 52.7 0.2 ± 0.2
PMA, pCa5 64.4 ± 29.4 90.99678198 0.1 ± 0.1
Table 5.2: Lipid binding under stimulated conditions
Data represented in Figure 5.20 expressed as a percentage of PI binding at pCa7 by 
PITPα. Errors are SD, n=2.
259
5.9: Discussion
I have demonstrated that RdgBβ binds PI and a second lipid in approximately equal 
proportions; PC binding by  RdgBβ is negligible. I analysed the migration patterns of 
common phospholipids by  TLC, employing lipid binding assays with HL60 lipids 
labelled with a variety  of [3H]-radionucleotides, and eventually, upon collaboration with 
Dr. Alan Hunt at the University  of Southampton, the mystery lipid was identified as PA 
by mass spectrometry. Furthermore, it was revealed that RdgBβ selects for short-chain 
monounsaturated or saturated PA species, yet is non-selective in its preference of PI 
species. Modification of the lipid binding assay to manipulate calcium levels with the 
addition of GTPγS vastly increased PA binding by RdgBβ.
5.9.1: RdgBβ binds PA
The most striking result to emerge from the analysis of the lipid binding properties of 
RdgBβ was the observation that RdgBβ binds PA. The class I PITPs, PITPα and PITPβ, 
share ~41% identical residues with RdgBβ, yet PA binding and transfer is specific to 
RdgBβ.
In the lipid binding assay, where a single round of lipid exchange is assessed by 
analysing the lipid picked up by PITP proteins, the amount of PI and PA bound across 
the RdgBβ population was approximately 50:50. When the same assay was used to 
monitor lipid transfer, with the addition of unlabelled PC:PI liposomes, the proportion 
of PA transferred relative to PI was 20:80. This latter observation may be due to the 
amount of PA actually available, rather than the willingness of RdgBβ to transfer the 
lipid. This notion is consolidated by the observation that  PA binding by RdgBβ is 
increased 3-fold by stimulation (10 µM Ca2+, GTPγS), since under these conditions the 
availability of PA will be increased by  the action of PLC and PLD. It has previously 
been shown that high intracellular calcium (10 µM) stimulates both PLC and PLD 
activity to some extent, but the addition of GTPγS causes a robust  activation of both 
phospholipases (Stutchfield and Cockcroft, 1988; Geny and Cockcroft, 1992). In the 
presence of 10 µM Ca2+, a small increase in PA binding by  RdgBβ was observed, which 
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increased substantially  upon addition of GTPγS. Under these conditions PI re-synthesis 
does not take place since inositol is diluted out of the permeabilised cells.
In retrospect, much of the evidence pointed to the identification of PA as the mystery 
lipid, but the fact that the PA standard ran higher than PE on the TLC plate led me to 
disregard PA (Figure 5.5). In Figure 5.5, the CL ‘contaminant’ that ran in the right place 
was clearly PA, since PA is one of the intermediates in CL biosynthesis. The PI standard 
used was ~50% pure, with PE and PA contaminants reported by  the manufacturer (seen 
in Figure 5.10).
The observation that  the mystery lipid labelled with [3H]-ethanolamine, with hindsight, 
was clearly a red herring. A binding assay with [3H]-inositol- and [3H]-choline-labelled 
revealed that, for either radionucleotide, PITPα bound lipids corresponding in migration 
distance to PI and PC. The labelling time was the same in this experiment as it was for 
[3H]-ethanolamine-labelling (72 hrs). This indicates that metabolism of the [3H]-
radionucleotide has occurred in this time period, and therefore indicates that the [3H]-
ethanolamine lipid bound by RdgBβ in the experiment shown in Figure 5.10 was likely 
to be PI.
5.9.2: RdgBβ-bound PA and PI acyl chain selectivity
Mass spectrometric analysis indicated that RdgBβ selects short-chain saturated or 
monounsaturated PA species, particularly  C16:0/16:1 and C16:1/18:1. These molecular 
species were enriched in the RdgBβ-bound material relative to the total cellular lipids. 
By contrast, RdgBβ was non-selective in its binding of PI, as its profile of bound PI 
species reflected that present in the total cellular lipids. PA can be produced in cells 
from PLC hydrolysis of PI(4,5)P2 to DAG and the subsequent phosphorylation of DAG 
to PA by DGK. The common PI species in cells is C18:0/20:4 (Figure 5.13, inset), and 
therefore the PA species produced by  this pathway is long-chain, polyunsaturated. An 
alternative pathway to PA is through the hydrolysis of PC by PLD. The most common 
PC species in cells is short-chain, saturated or monounsaturated (C16:0/16:1, 
C16:0/18:1 and C18:1/18:1 (Hunt et al., 2004)), and likewise the PA derived from this 
261
route is short-chain, unsaturated or monounsaturated. Therefore, the PA preferred by 
RdgBβ is most likely the PLD-derived PA, rather than the PLC-derived species.
The PI and PC molecular species picked by PITPα are identical (in the order, 16:1 > 
16:0 > 18:1 > 18:0 (Hunt et al., 2004)), and in the X-ray crystal structure, PI and PC 
acyl chains occupy the same positions (Yoder et al., 2001; Tilley  et al., 2004). 
Therefore, it is curious that RdgBβ selects short-chain, unsaturated or monounsaturated 
PA species, yet is non-selective in its PI-binding, binding the most common PI species, 
long-chain polyunsaturated species. This might indicate that the PI and PA acyl chains 
occupy  different binding sites in RdgBβ, and therefore could indicate the possibility that 
RdgBβ mutants could be created to differentiate between the PI-bound and PA-bound 
forms.
5.9.3: Can RdgBβ exist without a lipid bound?
In the unstimulated lipid binding assays, RdgBβ binds only one tenth of the amount of 
lipid bound. The two tryptophan residues, WW203/204 in PITPα and PITPβ, have been 
shown to be essential for membrane docking (Shadan et al., 2008), and mutation of 
these residues to alanines, WW203/204AA, leads to a loss of lipid transfer activity 
(Tilley et  al., 2004). In RdgBβ these residues are a valine and a tryptophan, 
VW203/204. This may indicate that RdgBβ interacts with membranes less well than 
PITPα and PITPβ, or that  it employs different  residues for membrane interaction. 
During the binding assay only  one tenth of the RdgBβ population might successfully 
exchange their bound lipid.
However, during synthesis in E. coli, PITPα is loaded with bacterial lipid, PG and PE in 
the ratio 8:2 (Hara et  al., 1997), and mass spectrometry  of the lipids bound by RdgBβ 
found no trace of un-exchanged, bacterial lipid, indicating that the whole RdgBβ 
population has exchanged its bound lipid. The lipid binding assay for TLC analysis 
differs from that for mass spectrometric analysis in that, (1) in the former the cells are 
metabolically labelled with [14C]-acetic acid, whereas in the latter experiment the cells 
are unlabelled, (2) the former uses 120 µg recombinant protein per incubation, whereas 
the latter uses 600 µg, and (3) the former uses 10 mL cells per incubation, whereas the 
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latter uses 50 mL. None of these three differences can explain why only one tenth of the 
amount of lipid binding is seen for RdgBβ compared with PITPα. Neither PITPα nor 
PITPβ have been observed without ligand bound - during X-ray crystallography only 
the apo-form is devoid of ligand, and this structure is proposed to exist  when the protein 
is docked onto a membrane in the process of lipid exchange.
Two residues are observed to bind the PI or PC acyl chains in the crystal structures of 
PITPα and PITPβ, Y63 and E218 (Yoder et  al., 2001; Tilley  et al., 2004; Vordtriede et 
al., 2005). In RdgBβ, these residues are both valines, and might indicate that the lipid 
bound in RdgBβ is not nestled so tightly as it is in PITPα and PITPβ: perhaps some lipid 
is lost during the experimental procedure.
Relevant here also is the observation that PA-binding by RdgBβ was increased by 
stimulation of PA production by raising the calcium concentration to 10 µM, together 
with the addition of GTPγS. If lipid is lost during the process of protein capture and 
lipid extraction, then PA must be more tightly  bound in the RdgBβ lipid-binding pocket 
than PI.
5.9.4: RdgBβ does not bind PC
In contrast to the class I PITPs, I have demonstrated that PC binding by RdgBβ is 
largely absent. Residues important for PC binding are much harder to predict than for 
PI, since no residues directly contact the PC head group in the PC-bound X-ray crystal 
structure of PITP (Yoder et al., 2001). It  has been reported that mutation of C95 in 
PITPβ to either an alanine or a threonine residue causes a loss of PC transfer, leaving PI 
transfer unaffected (Carvou et al., 2010). In addition, F225 has also been shown to be 
important for PC transfer (Vordtriede et al., 2005). RdgBβ has a threonine residue at 
position 95 and a glycine residue at position 225 (Figure 5.1 A), and it  is therefore not 
surprising that RdgBβ does not bind PC.
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CHAPTER 6: Discussion
6.1: Summary of results
RdgBβ is the third soluble PITP to be discovered, and is a member of the class II PITPs, 
also known as the RdgB proteins. Like the other PITPs, RdgBβ-sp1 carries the defining 
PITP domain at its N-terminus, yet has a unique ~80 aa C-terminal domain. Using 
bioinformatics tools and protease digestion I have demonstrated that this domain is 
disordered or unstructured.
The RdgBβ-sp1 C-terminus contains two PEST sequences, and when expressed in 
COS-7 cells, RdgBβ-sp1 is ubiquitinated and undergoes a moderate rate of turnover. 
Furthermore, RdgBβ-sp1 interacts with 14-3-3 via two phosphorylated serine residues, 
Ser274 and Ser299, in its C-terminal domain. Mutation of Ser299 to alanine destabilised 
RdgBβ-sp1, increasing its rate of turnover, indicating that  binding to 14-3-3 might 
protect RdgBβ from protease digestion. RdgBβ-sp1 interacts with 14-3-3 under basal 
conditions, and the amount of 14-3-3 present in the FLAG-RdgBβ-immunoprecipitate 
was reduced by ~50% following 16 hrs treatment with the PKC inhibitor, BIM-I. In 
addition, PKC inhibition reduced the expression of RdgBβ-sp1 protein in the lysate, 
and together these observations support a role for 14-3-3 in protecting RdgBβ-sp1 from 
degradation. This also indicates that PKC is responsible for one or both of the serine 
phosphorylations mediating the RdgBβ-14-3-3 interaction. However, treatment of the 
recombinant protein with rat brain PKC was insufficient to promote 14-3-3 binding in 
the far western assay, indicating that at least one other kinase is required to facilitate the 
RdgBβ-14-3-3 interaction.
Chronic PMA treatment has been shown to down-regulate PKC, and therefore would be 
expected to mimic the effect of PKC inhibition. However, the reverse effect was 
observed: PMA promoted an increase in RdgBβ-sp1 protein expression, which reached 
a maximal level at  4 hr treatment. Furthermore, PMA treatment increased the amount of 
14-3-3 present in the FLAG-RdgBβ-immunoprecipitate relative to the amount of 
RdgBβ, indicating that, under basal conditions, a small portion of the RdgBβ-sp1 is not 
bound to 14-3-3. It was reasoned that PMA stimulates PKC at early time points to 
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phosphorylate RdgBβ-sp1 and promote 14-3-3 binding. As new RdgBβ-sp1 is 
synthesised, protein expression is stabilised, increasing the size of the RdgBβ pool. That 
the PMA-induced increase in RdgBβ-sp1 protein expression reached a plateau after 4 
hrs likely reflects the eventual down-regulation of PKC.
Two yeast two-hybrid screens reported that RdgBβ interacts with ATRAP (Rual et al., 
2005; Venkatesan et al., 2009), and using co-immunoprecipitation experiments I 
confirmed that  this interaction occurs in COS-7 cells between over-expressed, tagged 
proteins. Surprisingly, this association was not observed under basal conditions, but 
required 4-16 hrs PMA treatment before HA-ATRAP was resolved in the FLAG-
RdgBβ-immunoprecipitate. The combined treatment of cells with PMA and the Ca2+ 
ionophore, ionomycin, for 4 hrs had an additive effect on the RdgBβ-ATRAP 
interaction. Conversely, the PMA-induced association was blocked by  inhibition of 
PKC or protein synthesis. Since maximal RdgBβ-sp1 concentration was reached by  4 
hrs PMA treatment, and the PMA-induced RdgBβ-ATRAP interaction was blocked by 
inhibition of protein synthesis, I suggested that a certain threshold quantity of RdgBβ 
was required before interaction with ATRAP was observed. The RdgBβ-ATRAP 
interaction was not observed when AT1R-expressing cells were stimulated with 
Angiotensin II, likely because the Angiotensin II dose used did not optimally  increase 
RdgBβ protein expression.
RdgBβ interacts with ATRAP via its PITP domain, and despite RdgBβ sharing ~40% 
identical residues with the class I PITPs, neither PITPα nor PITPβ interact with ATRAP 
when cells are stimulated with PMA. From this information I was able to pinpoint 37 
candidate residues, organised into 10 distinct patches on the RdgBβ surface. Notably, 19 
candidate residues lie in the regulatory loop, proposed to be a site of protein 
interactions. Ser119, in the β6-αC section of the regulatory  loop, has been reported to be 
phosphorylated in the mouse brain (Huttlin et  al., 2010; Wiśniewski et al., 2010), and 
lies in a consensus site for phosphorylation by PKC. I therefore suggested that the β6-
αC loop mediates the RdgBβ-ATRAP interaction, regulated by PKC.
A role for other members of the PITP family  has been established in PLC signalling 
(Thomas et al., 1993; Xie et al., 2005; Adachi et al., 2010), and by  over-expression of 
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RdgBβ in HEK-293 cells along with the AT1R, I observed a ~3.8-fold increase in 
Angiotensin II-stimulated inositol phosphate production by PLC. 10 nM, 100 nM or 1 
µM Angiotensin II for 20 min produced little difference in inositol phosphates, 
indicating maximal activity  at  all three doses. Consistent with previous reports, ATRAP 
reduced Angiotensin II-induced inositol phosphate production by PLC, as did PMA pre-
treatment.
Lastly, an analysis of the lipids bound by RdgBβ by TLC indicated that whereas the 
class I proteins bind PI and PC in approximately equal quantities, RdgBβ binds PI and a 
second lipid in similar amounts, and PC binding by RdgBβ is almost negligible. Further 
biochemical analysis of the unknown lipid, and finally mass spectrometry, revealed its 
identity  to be PA. Whereas RdgBβ displayed non-selective binding of PI, the PA 
molecular species bound were enriched in short-chain saturated and mono-unsaturated 
species. The most common species of PC are short-chain, monounsaturated and 
saturated species, whereas the most common species of PI are long-chain, 
polyunsaturated species. Since RdgBβ preferentially binds short-chain, 
monounsaturated or saturated species, I reasoned that the PA selected by RdgBβ is 
derived from PLD hydrolysis of PC, rather that the hydrolysis of PI(4,5)P2 by  PLC and 
subsequent phosphorylation by  DGK. Unlike the PI and PC species selected by PITPα, 
the PI and PA bound by  RdgBβ differ in their acyl chain composition. I therefore 
proposed that these two phospholipids occupy distinct  sites within RdgBβ, and that the 
PA-binding site is more secure than that for PI.
In a modification of the lipid-binding assay, RdgBβ was observed to transfer [14C]-PA to 
unlabelled liposomes. PA binding by RdgBβ was significantly increased by the addition 
of GTPγS to the lipid binding assay, likely due to the increased availability of PA under 
these conditions.
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6.2: RdgBβ ubiquitination and protein turnover
Inhibition of protein synthesis with cycloheximide and immunoprecipitation 
experiments with proteasome inhibition indicated that unphosphorylated RdgBβ is 
rapidly degraded in cells, targeted to the proteasome by the addition of ubiquitin.
Disordered regions of a protein are highly  susceptible to proteolytic degradation, 
particularly if they occur at one of the termini of the protein sequence. Such regions are 
flexible, permitting interaction with proteases, and give a point for the proteasome to 
unravel the protein from. The transplantation of a disordered region from one protein to 
another can increase the rate of degradation of a protein (Prakash et  al., 2008), however 
the disordered region itself is not sufficient for proteasomal degradation, ubiquitination 
is also required. Ubiquitin may  be used as a tag for functions other than degradation, for 
example regulation of DNA repair, enzyme recruitment or vesicular trafficking (Liu and 
Walters, 2010). In the absence of MG-132 treatment to inhibit  the proteasome, RdgBβ-
sp1 ubiquitination is only weakly detectable, indicating that the protein is rapidly 
degraded as soon as ubiquitin is attached. The ubiquitin smear associated with RdgBβ in 
untreated cells closely resembles the pattern seen in the MG-132-treated cells, and 
together these observations indicate an exclusively  degradative function for ubiquitin 
tagging of RdgBβ-sp1.
Three enzymes are necessary  for the ubiquitination of a substrate protein: an E1 
activating enzyme to activate ubiquitin, an E2 conjugating or ubiquitin carrier enzyme, 
and an E3 ubiquitin ligase. It is the E3 enzyme that binds to the target protein and thus 
confers substrate specificity. Phosphorylation of the substrate protein may promote E3 
ubiquitin ligase recruitment or displace it. Alternatively, phosphorylation may affect  the 
binding of other proteins to the substrate protein which stabilise the protein or promote 
its degradation. p53 is bound by Mdm2 which exports it from the nucleus and targets it 
for ubiquitin-dependent  proteolysis in the cytoplasm. However, in response to DNA 
damage, p53 is phosphorylated preventing its association with Mdm2 and promoting its 
accumulation in the nucleus to promote gene transcription (Böttger et al., 1999; Chehab 
et al., 1999). For RhoA GTPase the reverse is true: phosphorylation of the GTP-bound 
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form of RhoA increases its interaction with its binding partner RhoGDI, preventing its 
degradation (Rolli-Derkinderen et al., 2005).
For RdgBβ-sp1, mutation of any  of its C-terminal phosphorylation sites, Ser274, 
Thr278 or Ser299, had no effect on the ubiquitination of RdgBβ-sp1. Several other sites 
had been reported as phosphorylated in the RdgBβ protein, but were omitted from my 
investigation as they had <5 reports associated with them (Figure 3.4), and it is possible 
that there are other RdgBβ phosphorylation sites that have not been reported. Any of 
these sites may be relevant for the ubiquitination of RdgBβ-sp1.
6.3: The RdgBβ-sp1 C-terminal protein-interaction domain
In addition to providing access to proteases, unstructured regions of a protein are 
commonly used as protein-protein interaction domains for similar reasons: they  are 
flexible, provide a large surface area for interaction and are readily accessible.
6.3.1: PEST sequences
The RdgBβ-sp1 C-terminus contains two PEST sequences, rich in proline, glutamate, 
serine and threonine residues. PEST sequences were originally  identified as degradation 
signals due to their abundance in rapidly degraded proteins (Rogers et al., 1986; 
Rechsteiner and Rogers, 1996), yet  some researchers have found that the PEST 
sequence can be deleted from their protein of interest without (or with minimal) 
stabilising effect, as has been demonstrated for the c-Fos transcription factor (Carillo et 
al., 1996; Acquaviva et al., 2001). A wider use of this region appears to be in mediating 
protein-protein interactions. This is indeed a more all-encompassing model. It  has been 
known for a long time that components of large protein complexes are more susceptible 
to degradation when dissociated from their binding partners (Goldberg and Dice, 1974). 
PEST sequences may therefore lie in the region mediating binding and will therefore be 
exposed when the subunits dissociate. The presence of serine and threonine residues 
amenable to phosphorylation provides a means by which such protein-protein 
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interactions can be regulated. All three of the RdgBβ-sp1 C-terminal phosphorylation 
sites (Ser274, Thr278 and Ser299) lie within its PEST sequences.
6.3.2: The RdgBβ-sp1 C-terminus is a proline-rich domain
The PEST sequence itself is a proline-rich domain, as is the rest of the C-terminus of 
RdgBβ-sp1. Proline-rich domains make common protein-protein interaction domains, 
for example WW and SH3 domains bind to proline-rich domains and have been 
hypothesised to compete for binding partners (Sudol, 1996; Macias et al., 2002). The 
identification of the C-terminal region of RdgBβ-sp1 as a disordered region and a 
proline-rich domain therefore indicates a high propensity towards multiple binding 
partners for RdgBβ-sp1.
6.4: The RdgBβ-sp1-14-3-3 interaction
6.4.1: 14-3-3
I have identified one binding partner of the disordered C-terminus of RdgBβ-sp1, 
14-3-3. 14-3-3 proteins are 28-33 kDa cytosolic proteins present in all eukaryotes, 
originally  described by Moore and Perez in 1967. The name ‘14-3-3’ refers to their 
elution position on DEAE-cellulose chromatography and gel electrophoresis during a 
systematic attempt at classifying bovine brain proteins. There are seven isoforms in the 
mammalian genome, β, γ, ε, σ, ζ, τ and η, which homo- or heterodimerise, depending on 
the isoform. Each monomer in a 14-3-3 dimer recognises and binds a single phospho-
serine or phospho-threonine motif; together the two monomers making up a 14-3-3 
dimer may bind two phosphorylated motifs on the same protein, or on different proteins, 
bringing two proteins together into a protein complex. The phosphorylated motif 
generally  conforms to the sequence RSXpSXP (mode 1) or RX(Y/F)XpSXP (mode 2) 
(Yaffe et al., 1997), where ‘X’ is any  amino acid and ‘pS’ represents the phosphorylated 
serine (or threonine) residue, although there are exceptions and the interaction is not 
always phosphorylation-dependent. Where the two 14-3-3-binding sites appear on the 
same protein, it has been postulated that one binding site might act as a ‘gatekeeper’, 
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whose phosphorylation is necessary for 14-3-3 binding, but not necessarily sufficient 
for the full binding of 14-3-3 and hence for the full biological activity of the interaction 
(Yaffe, 2002).
Each 14-3-3 subunit consists of nine anti-parallel α-helices that form a ‘palisade’ around 
a large, negatively charged ligand-binding groove (Liu et al., 1995; Xiao et al., 1995). 
Although once believed to be a rigid cup-shaped structure, referred to as a ‘molecular 
anvil’ which deformed its bound ligands to induce a conformational change and 
alteration in protein function (Yaffe, 2002), later work indicated that the 14-3-3 dimer is 
in fact a flexible structure, enabling 14-3-3 proteins to bind to diverse peptides and a 
wide variety of proteins of different size and sequence (Yang et al., 2006).
More than two hundred 14-3-3 target proteins have been identified, and analysis of 
target protein structures indicated that  the majority  of 14-3-3 binding partners contain 
regions of disorder, like the RdgBβ-sp1 C-terminal domain. Indeed, ~70-94% of the 
target proteins contained unstructured regions, depending on the disorder prediction 
program used (Bustos and Iglesias, 2006). This again indicates a propensity for 
unstructured regions of a protein to form protein-interaction domains, due to their 
intrinsic flexibility, and it  has been proposed that 14-3-3-binding induces a disorder-to-
order transition in the target protein (Bustos and Iglesias, 2006).
Binding partners of 14-3-3 include transcription factors, biosynthetic enzymes, 
cytoskeletal proteins, signalling molecules, apoptosis factors and tumour suppressors. 
The precise function of the 14-3-3 interaction varies depending on the protein and site 
of interaction. There is much discussion as to whether 14-3-3 is an adaptor protein with 
a passive function or phospho-dependent chaperone protein with an active function in 
intracellular signalling. Functions of 14-3-3 binding have been classified into three 
categories, one or more of which may be used at any  one time: (i) directed 
conformational changes of the target protein; (ii) physical occlusion of sequence-
specific or structural features (which may alter intracellular localisation, for example); 
and (iii) scaffolding (Bridges, 2004). 14-3-3 proteins have been described as more than 
just adaptor proteins, able to ‘finish the job’ started by phosphorylation to effect changes 
in the activities of intracellular proteins (MacKintosh, 2004).
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6.4.2: The function of the RdgBβ-sp1-14-3-3 interaction
I have demonstrated that  14-3-3 binds directly to RdgBβ-sp1, via phosphorylated 
residues Ser274 and Ser299, which lie in consensus sites for 14-3-3 recognition. 
Mutation of either one of these residues abolishes 14-3-3 binding, which was 
unexpected. As the sequence surrounding Ser274 would be considered to be a low 
affinity, or degenerate 14-3-3 recognition sequence, one might expect mutation of this 
residue to have less effect on 14-3-3-binding. I would have expected that Ser299 would 
be the ‘gatekeeper’ binding site, whose phosphorylation is necessary for 14-3-3 binding 
but not sufficient for the full binding of 14-3-3 (Yaffe, 2002). Therefore mutation of 
Ser299 would abrogate 14-3-3 binding, whereas mutation of Ser274 would only 
partially reduce binding. This was not the case, however. This discrepancy can be 
explained if the two phosphorylation events (for Ser274 and for Ser299) are not 
independent but are in some way  linked: if prior phosphorylation of Ser274 is required 
for phosphorylation of Ser299 (directly  or indirectly), the fact that mutation of Ser274 
also abolishes 14-3-3 binding rather than merely reducing it, can be accounted for.
The disordered C-terminus of RdgBβ-sp1 permits the access of proteases and gives the 
proteasome a point from which to unravel the protein from. Recombinant RdgBβ-sp1 is 
susceptible to digestion by  trypsin, and RdgBβ-sp1 expressed in COS-7 cells is subject 
to a moderate rate of turnover. The majority  of the protein in COS-7 cells is bound to 
14-3-3 under basal conditions via its C-terminal disordered region. The RdgBβ-sp1 
S299A mutant, unable to bind 14-3-3, is more rapidly degraded, with a half-life of ~2 
hrs. It  is therefore plausible that 14-3-3 masks this unstructured region from access by 
proteases by physically masking the C-terminus, and possibly promoting a disorder-to-
order transition in the structure. The interaction of 14-3-3 with RdgBβ-sp1 therefore can 
be classified as the physical occlusion of sequence-specific or structural features 
(Bridges, 2004). It is clear that 14-3-3 does not  prevent ubiquitination, however, since 
mutation of Ser274 or Ser299, the residues responsible for binding 14-3-3, has no effect 
on the ubiquitination of RdgBβ-sp1.
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Biochemical and structural analyses of PITPα indicate that the protein is in a closed 
conformation, resistant to proteases (Tremblay et al., 1996; Prosser et al., 1997), when 
in the process of lipid transport. Upon membrane interaction, the αG helix swings out 
from the main structure and the C-terminal residues become disordered, exposing the 
lipid-binding cavity  to the membrane interface for lipid exchange (Schouten et al., 
2002). Unlike PITPα, the longer RdgBβ-sp1 C-terminus is susceptible to protease 
digestion in the absence of membranes. If 14-3-3-binding does promote a disorder-to-
order transition in the RdgBβ-sp1 C-terminus, perhaps 14-3-3 is a co-factor for lipid 
transport. Binding of 14-3-3 might be required for compaction of RdgBβ to enable its 
transit through the cytosol. If 14-3-3-binding is required for efficient lipid transport, this 
could provide another reason for RdgBβ performing less well than PITPα in the lipid 
transfer assays, where neither RdgBβ phosphorylation, nor 14-3-3, is present.
Upon membrane-binding the C-terminus of PITPα becomes disordered, required so that 
it doesn’t interfere with lipid exchange. Likewise, with 14-3-3 bound, the ordered 
RdgBβ-sp1 C-terminus would prevent lipid exchange by  forming a rigid lid. Therefore 
it is plausible that as RdgBβ approaches the membrane, 14-3-3 receives a signal to 
dissociate and the C-terminus of RdgBβ-sp1 resumes its disordered state. RdgBβ would 
then be able to interact with the membrane for lipid exchange, and its long C-terminus, 
now flexible, would now not occlude the lipid-binding cavity. 
6.5: RdgBβ basal activity: non-selective PI transfer
In the PLC assay, co-expression of RdgBβ and the AT1R in HEK-293 cells increased 
inositol phosphate production by PLC stimulated by Angiotensin I for 20 min, 3.8-fold. 
There was little difference in response between the three Angiotensin II concentrations 
used, 10 nM, 100 nM and 1 µM, indicating that PLC was operating maximally at all 
three, limited only by substrate availability. It is possible that RdgBβ prepares the 
substrate by  transporting PI to the agonist-sensitive pool in the absence of stimulation. 
RdgBβ binds PI without selecting for PI with particular acyl chains, supporting a model 
in which, under basal conditions, RdgBβ transfers PI from regions of high concentration 
(the ER, the site of PI synthesis), down its concentration gradient to distal intracellular 
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membranes. Since the majority of RdgBβ-sp1 is bound to 14-3-3 under basal 
conditions, this supports the hypothesis that 14-3-3 acts as a co-factor for lipid transport 
by RdgBβ.
6.6: RdgBβ stimulated activity: membrane localisation and PA binding
6.6.1: The possibility of a distinct RdgBβ function in stimulated cells
For PITPα, several lines of evidence support a model in which activity in stimulated 
cells differs from its activity in unstimulated cells. A reduced mobility of PITPα at the 
plasma membrane was observed in response to EGF stimulation in COS-7 cells 
(Larijani et al., 2003). In A431 cells, PITP was detected in an endogenous signalling 
complex with the EGF receptor, PI4K and PLCγ, and this association increased 
following stimulation with 100 nM EGF for 5 mins (Kauffmann-Zeh et al., 1995). In the 
developing nervous system, PITPα interacts with the DCC and neogenin 
transmembrane cell surface receptors, and this association increased 4-fold by addition 
of the agonist, netrin-1 (Xie et al., 2005). These studies indicate that upon cellular 
stimulation, PITPα is re-localised to membranes through protein-protein interactions.
6.6.2: The PMA-stimulated RdgBβ-ATRAP interaction
RdgBβ interacts with ATRAP when cells are stimulated by PMA. Since ATRAP is a 
three-pass transmembrane protein, this association would function to localise RdgBβ to 
the membrane. I found that  the PMA-induced RdgBβ-ATRAP interaction could be 
blocked by treatment with BIM-I, indicating that  the direct target of PMA could be 
PKC. PKC may then directly  phosphorylate either RdgBβ or ATRAP to permit the 
interaction. A candidate residue is Ser119 on the RdgBβ regulatory loop, which has 
been identified as being phosphorylated in the mouse brain (Huttlin et al., 2010; 
Wiśniewski et al., 2010), and lies in a consensus site for phosphorylation by PKC.
However, PKC is activated rapidly upon PMA addition (within minutes), yet the 
RdgBβ-ATRAP interaction is not observed until 4 hrs PMA treatment. This could 
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indicate that direct phosphorylation of RdgBβ or ATRAP is insufficient for mediating 
the interaction. In addition to PKC inhibition, I observed that the PMA-induced RdgBβ-
ATRAP complex could be blocked by inhibition of protein synthesis. This might imply 
that a certain threshold concentration of RdgBβ must be synthesised and stabilised prior 
to interaction with ATRAP. This mechanism of stabilisation of protein expression now 
appears to be distinct from 14-3-3-binding, since RdgBβ-sp1 1-250 and S299A and 
RdgBβ-sp2, all unable to bind 14-3-3, undergo a similar increase in protein expression 
in response to PMA as the wild-type RdgBβ-sp1 (Figure 4.6). In this experiment, 
ATRAP expression is also observed to increase upon PMA treatment, in fact indicating 
a global upregulation of protein expression in response to PMA. Whether RdgBβ-sp1 
expression needs to be stabilised by post-translational modification or binding a co-
factor, or whether merely  increased RdgBβ protein synthesis is required for the RdgBβ-
ATRAP interaction to take place is therefore unclear.
Perhaps RdgBβ binding to ATRAP only occurs when all of the available 14-3-3 proteins 
are bound to target proteins. This possibility could be assessed by manipulating 14-3-3 
levels by  over-expression or RNAi, and monitoring the effect on the RdgBβ-ATRAP 
interaction. As over two hundred binding partners of 14-3-3 have been identified, the 
relative state of each of these would determine whether RdgBβ interacts with ATRAP, 
and therefore represent a very  complex form of regulation of the RdgBβ-ATRAP 
interaction.
6.6.3: Binding of PA under stimulated conditions
RdgBβ binds short-chain, monounsaturated or saturated PA species, and using a 
modified lipid binding assay, I demonstrated that PA-binding by RdgBβ was increased 
to some extent by 10 µM Ca2+, but was profoundly increased by stimulation with 
GTPγS. It has previously been shown that high intracellular calcium (10 µM) stimulates 
both PLC and PLD activity  to some extent, but the addition of GTPγS causes a robust 
activation of both phospholipases (Stutchfield and Cockcroft, 1988; Geny and 
Cockcroft, 1992). The PA selected by  RdgBβ is more similar to the common PC species 
than the common PI species, which are enriched in long-chain, polyunsaturated 
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molecular species, and therefore RdgBβ-PA is likely  to be derived from the hydrolysis 
of PC by PLD.
PLD is also activated by PMA, and it is therefore unclear why the addition of PMA 
appeared to have no effect on PA-binding by RdgBβ. Since the target of PMA is PKC, it 
is possible that the high Ca2+ conditions have already stimulated PKC, and that the rate-
limiting step is therefore activation of PLD by PKC. GTPγS, however, produces an 
additive effect on top of increased Ca2+. PLD is also directly, activated by  the small 
GTPase ARF, and it is likely  to be activation of ARF as well as PLD that produces the 
additive effect on PA production, and therefore PA-binding by RdgBβ.
6.6.4: PA binding as a signal regulating protein interactions
PITPα binds short-chain, monounsaturated or saturated PI and PC molecular species, 
and X-ray  crystal structures of PI- and PC-bound PITPα indicate that  PI and PC acyl 
chains occupy  the same space in the PITPα lipid-binding cavity. Since the PI and PA 
acyl chains are different, this may imply that PI and PA occupy slightly  different sites in 
the RdgBβ cavity. RdgBβ lacks the Y63 and E218 residues, that in PITPα, make 
hydrogen bond contact with the acyl chains. Therefore the sites of the phospholipid 
chains in RdgBβ are difficult to predict. Perhaps the binding of one of these 
phospholipids deforms the lipid in a particular way, in contrast to the other, making it 
possible to ‘sense’ whether RdgBβ has bound PI or PA from interaction with the protein 
surface.
Alternatively, PI and PA carry different amounts of negative charge. The original 
purification of PITP from bovine brain yielded two subforms that  could be distinguished 
on the basis of their isoelectric points (Helmkamp et al., 1974). Subsequent analysis 
revealed that these two subforms were the PI- and PC-loaded forms of PITP (van 
Paridon et al., 1987b), due to the different charges on the phospholipid molecules: PI is 
negatively charged due to the phospholipid phosphate group, whereas in PC this 
negative charge is cancelled out by a single positive charge in the choline head group. 
Likewise, PI and PA could impart different charges on the RdgBβ protein, which could 
be sensed by a protein interacting with the RdgBβ surface: PI carries a single negative 
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charge on its phosphate, whereas PA carries two (in PI the second negative charge is 
removed through covalent interaction with the inositol head group).
It is possible that both PKC phosphorylation of the regulatory  loop  at  Ser119, which 
occurs constitutively, and the binding of PA, which only  occurs when PLD activity  is 
stimulated sufficiently to increase PA production, could promote ATRAP-binding and 
targeting of RdgBβ to the membrane. If PA-binding is the signal for ATRAP-binding 
then the conditions under which Angiotensin II promotes an increase in PA will be the 
true determinant of the RdgBβ-ATRAP interaction.
6.7: Function of the RdgBβ-ATRAP interaction
6.7.1: ATRAP down-regulates Angiotensin II signalling
ATRAP has been reported to have a negative effect on Angiotensin II signalling. Over-
expression of ATRAP suppresses inositol phosphate production by PLC in response to 
Angiotensin II stimulation (Daviet et al., 1999; Lopez-Ilasaca et al., 2003), and GTP 
binding experiments indicated a reduction in GTP binding following Angiotensin II 
stimulation of membranes prepared from cells over-expressing ATRAP (Lopez-Ilasaca 
et al., 2003). Together, these observations suggested that  ATRAP uncouples the AT1R 
from Gq protein, resulting in a reduced G protein activation and therefore GTP binding, 
and a consequent reduced stimulation of PLC. The possibility that ATRAP affects 
activation of other membrane-associated GTPases, such as the small GTPase Rho, was 
not assessed. ARF GTPase would have dissociated from the membranes under the 
conditions used (Fensome et al., 1996).
ATRAP also interacts with CAML (Guo et al., 2005), and the function of this interaction 
appears to be related to, but distinct from, the role of ATRAP in suppression of 
Angiotensin II signalling (Min et al., 2009). Since other PITPs have been implicated in 
PLC signalling (Thomas et al., 1993; Xie et al., 2005; Adachi et al., 2010), and one of 
the effects of the ATRAP-AT1R interaction is the reduction in Angiotensin II-stimulated 
inositol phosphate production by PLC (Daviet et al., 1999; Lopez-Ilasaca et al., 2003), it 
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seemed plausible that the RdgBβ-ATRAP interaction functioned to prevent the delivery 
of PI by  RdgBβ to the signalling membrane. Significantly, the conditions under which 
the RdgBβ-ATRAP interaction was observed, 4-16 hrs PMA, inhibited PLC activity, 
consistent with negative feedback by PKC on the AT1R through heterologous 
desensitisation (Tang et al., 1998). Therefore, it  seems unlikely  that RdgBβ binding to 
ATRAP at this time would have a significant effect on PLC activity and the supply of 
substrate.
In addition to uncoupling the AT1R from G proteins, ATRAP promotes internalisation of 
the receptor (Cui et  al., 2000; Lopez-Ilasaca et al., 2003). ATRAP appears to perform 
this function even in unstimulated cells, and has been observed to maintain the AT1R in 
internal compartments, even after the removal of Angiotensin II (Tanaka et al., 2005; 
Azuma et al., 2007). The mechanism by which it  promotes receptor internalisation has 
not been reported, yet the action of ATRAP, to uncouple the receptor from G proteins 
and promote its internalisation, is comparable to the function of arrestin.
6.7.2: RdgBβ and AT1R endocytosis
Roles for PITPs have been reported in membrane trafficking (Hay and Martin, 1993; 
Ohashi et al., 1995; Fensome et al., 1996; Peretti et al., 2008; Carvou et al., 2010), 
specifically through the formation, fission and fusion of vesicles at membranes, due to 
the requirement for phosphoinositides in these processes for the assembly of protein 
effector molecules at the membrane.
PA is small, and since it lacks a head group, promotes negative membrane curvature. In 
this way, PA is important at the neck of a developing membrane vesicle. PLD itself is 
activated by Gβγ subunits in response to Angiotensin II stimulation (Ushio-Fukai et al., 
1999). PLD2 localises to the plasma membrane and has been observed to facilitate 
endocytosis of the EGF receptor by acting as a GTPase-activating protein for dynamin 
(Lee et al., 2006), which is responsible for scission of the newly-formed endocytosing 
vesicle from the plasma membrane. PLD2 has also been shown to be important in AT1R 
endocytosis: in PLD2-knockdown HEK-293 cells, or cells transfected with the inactive 
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PLD2-K758A mutant, the stably expressed AT1R did not endocytose in response to 
Angiotensin II (Du et al., 2004).
A role for RdgBβ in AT1R endocytosis seems possible. In unstimulated cells, RdgBβ re-
distributes PI from the ER to other intracellular membranes, down its concentration 
gradient. This ensures that a certain quantity of PI is present at the membranes when a 
stimulus is received. PI(4,5)P2 is required for the full activation of PLD, and re-
localisation of RdgBβ binding to ATRAP upon stimulation could focus RdgBβ activity 
to the membrane, close to PLD. Here, RdgBβ might be required for the local re-
organisation of PI and PA into distinct patches for vesicle formation and the assembly of 
coat proteins. PA has been shown to activate type 1 PI4P-5-K (Jenkins et al., 1994), 
producing positive feedback to concentrate the formation of PI(4,5)P2 at the membrane.
6.8: RdgBβ-sp2
The short splice variant, RdgBβ-sp2, was largely omitted from my study as it had a low 
yield when expressed in COS-7 cells, or in E. coli for synthesis of the recombinant 
protein. In an analysis of the localisation of PITPNC1 transcripts in the mouse brain, 
mRNA encoding RdgBβ-sp2 was seen mainly in the embryonic brain (weak expression 
in the ventricular and mantle zones of the cerebral cortex), which declined after birth 
(Takano et al., 2003). RdgBβ-sp2 expression was also observed in the P49 heart and 
small intestine, indicating that this protein has a very restricted expression, and probably 
a specific function in those cells. Since RdgBβ-sp2 is unable to bind to 14-3-3 and due 
to its instability, it seems likely that RdgBβ-sp2 has its own co-factor, required to 
stabilise its expression. This factor could be specific to a restricted number of cell types, 
where RdgBβ-sp2 is expressed.
Despite not carrying the 14-3-3-binding site, RdgBβ-sp2 does share the ATRAP-binding 
site with RdgBβ-sp1, and may be ubiquitinated by the same method, targeting it for 
degradation. Therefore, unwelcome RdgBβ-sp2 might be degraded unless co-expressed 
with its own stabilising partner.
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6.9: Conclusion
Unmodified RdgBβ (-sp1 or -sp2) is susceptible to ubiquitination and targeting to the 
proteasome. Unmasked, the protein C-terminus is unstructured and therefore accessible 
to proteases, giving the proteasome a point from which to unravel the protein from.
Alternatively, RdgBβ-sp1 is phosphorylated at Ser274 and Ser299 in its C-terminus by 
the concerted activity of PKC and at least one other kinase. These serine 
phosphorylations mediate interaction with 14-3-3, which masks and orders the protein 
C-terminus, protecting it from degradation by the proteasome. RdgBβ-sp1 is not 
protected from ubiquitination, however. 14-3-3 acts as a co-factor for lipid transport, 
making the RdgBβ-sp1 protein into a compact heterodimer. Interaction between RdgBβ 
and the membrane encourages 14-3-3 to dissociate from RdgBβ, removing the order 
from the C-terminus and permitting lipid exchange.
In addition, PKC might phosphorylate RdgBβ-sp1 and -sp2 on residue Ser119 in the 
regulatory loop. Phosphorylation of RdgBβ occurs under basal conditions and is 
increased by activation of PKC, for example with PMA and/or ionomycin and/or 10 µM 
Ca2+.
PMA also activates PLD, which hydrolyses PC and increases the concentration of PA at 
the membrane. PA binding targets RdgBβ to the membrane and permits its interaction 
with ATRAP, mediated by the phosphorylated Ser119 residue in its regulatory  loop. In 
this way, ATRAP localises RdgBβ to the membrane to enrich it  in the negatively 
charged phospholipid, PA, required for endocytosis of the AT1R. Alternatively, RdgBβ 
might enhance the activity of PI4P-5-K for production of PI(4,5)P2 for assembly of 
endocytic vesicle coat proteins at the membrane (Figure 6.1).
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6.10: Future work
• The production of the RdgBβ-14-3-3 in vitro complex will aid in establishing whether 
14-3-3 is a co-factor for lipid transport by RdgBβ-sp1, and whether association with 
14-3-3 protects RdgBβ-sp1 from protease digestion.
• PITPs are clearly involved in the delivery  of PI, but whether they have an active role 
in stimulation of PI4K or PI3K activity is not always clear. My  experiments indicate 
that RdgBβ enhances the basal incorporation of [3H]-inositol, probably  due to the 
removal of PI from the ER, promoting flux through the PI cycle. Whether RdgBβ is 
able to stimulate the PI4K activity  in vitro should therefore be assessed. Since PA has 
been shown to activate type 1 PI4P-5-K, the ability of RdgBβ to stimulate the activity 
of this lipid kinase should also be examined. Each of these experiments should be 
performed in the presence and absence of PI and PA vesicles, with and without 
recombinant RdgBβ.
• PLD requires PI(4,5)P2 for its activity, and therefore the ability of RdgBβ to promote 
PLD activity in the presence and absence of PI vesicles in vitro should be assessed to 
further understand the function of RdgBβ.
• The interaction between RdgBβ and ATRAP was only observed when cells were 
stimulated with PMA for 4-16 hr, which may  be due to its ability to promote an 
increase in RdgBβ protein expression or to promote an increase in PA production by 
PLD. By contrast, an interaction was not observed when cells were stimulated by 
Angiotensin II, either because Angiotensin II is unable to activate the same 
downstream effectors as PMA, or the incorrect dose was administered. If the latter is 
correct, the effect  of a variety of different Angiotensin II concentrations and times 
could be administered to HEK-293-AT1 cells, and assessed for their ability to increase 
RdgBβ protein concentration by  western blotting or PA concentration using TLC. The 
Angiotensin II doses promoting the highest  increase in RdgBβ expression and PA 
concentration should then be assessed to establish whether they  promote the RdgBβ-
ATRAP interaction. Assessment of whether the RdgBβ-ATRAP interaction occurs 
under chronic Angiotensin II stimulation (>72 hrs) will require methods to analyse 
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either the endogenous interaction or a stable cell line expressing the tagged proteins. It 
should be borne in mind that ATRAP expression is down-regulated by chronic 
Angiotensin II treatment (14 days) (Wakui et al., 2010a; 2010b), and so an interaction 
between RdgBβ and ATRAP is unlikely at this time point.
• The existing anti-RdgBβ polyclonal antibody #101 is unable to recognise endogenous 
RdgBβ, probably because the concentration of RdgBβ is low in unstimulated cells, but 
also because the antibody is not  very sensitive. In addition, monoclonal antibodies 
seem to work much better for immunoprecipitation since they  recognise a single 
epitope and so give a sharper signal. For analysis of RdgBβ-sp1 alone, a monoclonal 
antibody could be raised against part of the protein C-terminus. Although an antibody 
could be designed that would avoid the 14-3-3-binding site, the RdgBβ-sp1 C-
terminus demonstrates a high propensity towards protein-protein interactions, some 
amount of trial-and-error might be required to make an antibody that recognises the 
endogenous, native protein by immunofluorescence microscopy and 
immunoprecipitation. The availability of a good antibody able to recognise 
endogenous RdgBβ would permit analysis of the RdgBβ-ATRAP interaction in 
specialised cell lines or primary cells, such as those derived from the heart or kidney.
• Confocal immunofluorescence microscopy should be employed to establish where in 
cells the RdgBβ-ATRAP interaction occurs, and how the association reacts to 
stimulation in real time. Moreover, this method will be required to analyse whether 
RdgBβ is required for endocytosis of the AT1R, and how the membrane trafficking 
events unfold in real time.
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(Facing page) Figure 6.1: Model of RdgBβ regulation
Nascent RdgBβ may  either be ubiquitinated, targeting the protein for degradation, or 
phosphorylated. Phosphorylation at Ser274 and Ser299 by  PKC and one or more other 
kinases permits 14-3-3 binding to the RdgBβ-sp1 C-terminus. This interaction orders 
the C-terminus and protects the protein from proteasomal degradation, irrespective of 
ubiquitin modification. In this state, under basal conditions, RdgBβ participates in the 
non-selective re-distribution of PI from the ER, using 14-3-3 as a co-factor for transport. 
Meanwhile, PKC also phosphorylates the regulatory loop of RdgBβ at Ser119. When 
PLD is stimulated, PA concentration at the membrane is increased, targeting RdgBβ to 
the membrane for binding to ATRAP via the phosphorylated regulatory  loop. Membrane 
interaction signals the dissociation of 14-3-3, removing order from the C-terminus and 
permitting lipid exchange. (The RdgBβ PITP domain structure used is the comparative 
model, with PI from PDB: 1uw5. The atoms of the inositol head group were removed 
for visualisation of PA. C-terminus manually  added in dark blue. Regulatory  loop 
coloured brown. Ub, ubiquitin.)
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